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Chapter 1. General introduction
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Inflammatory joint diseases (IJD) comprise a broad range of related disorders 
of which rheumatoid arthritis (RA) and spondyloarthropathies (e.g. ankylosing 
spondylitis (AS) and psoriatic arthritis (PsA)) are the most common. IJD are 
characterized by chronic inflammation of the joints and related tissues. Alongside 
joint involvement other organs including the bowels, eyes, skin, lungs, kidneys, 
nervous system, and also the heart and blood vessels can be affected, leading to 
an increased morbidity and mortality in comparison to the general population. (1-4) 
Notably, a large excess of the reported deaths in these patients is attributable to 
cardiovascular disease (CVD), predominantly of atherosclerotic origin. (4, 5)  This 
introduction provides a general overview of the context in which this thesis should 
be placed and read. The in-dept discussion of the current state-of-the-art with 
regards to CVD and IJD can be found in chapter 2.
Traditional and novel cardiovascular risk factors 
Traditional risk factors for CVD, such as smoking, dyslipidemia and hypertension, 
are more often present in patients with IJD and contribute to the CVD risk, but 
cannot fully explain the excess morbidity and mortality found in IJD patients. (6)  In 
addition, for some risk factors the contribution to CVD incidence is different than in 
the general population, such as that of lipids (i.e. higher lipid levels are associated 
with lower risk). Also, anti-inflammatory therapy may influence the effects of these 
traditional risk factors on CVD risk. (7-9) Finally, some non-classical risk factors 
have been associated to CVD development in recent years (e.g. thyroid function, 
insulin resistance, body composition, single nucleotid polymorphisms (SNPs), 
lipidomics). (10-15) However, their exact degree of contribution to CVD risk in these 
patients is still under debate. 
Inflammation as a risk factor for accelerated atherosclerosis
In the last few decades, inflammation has been linked to atherogenesis and the 
development of atherosclerotic lesions. (16-18) Nowadays, atherosclerosis itself 
is regarded as an inflammatory process with inflammatory cells involved in all its 
stages. (16-18) The chronic inflammation inherent to IJD is presumed to play an 
important role in the development and progression of atherosclerosis, and might 
explain the excess CVD risk in these patients. Chronic inflammation enhances 
endothelial dysfunction, induces maladaptive remodeling of the vascular wall, 
and influences the composition of an atherosclerotic plaque, resulting in plaque 
instability. (19, 20) In line with this, in patients with RA coronary plaques are more 
frequent, more severe and more prone to rupture. (21, 22) Additionally, patients with 
RA have worse outcomes after an acute coronary syndrome, with increased and 
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earlier recurrence of myocardial infarction (MI) and an increased risk of death. (21, 
22) Also, higher inflammatory burden and disease flares have been associated with 
higher number of new CVD events in RA. (23) Other studies have demonstrated that 
the increased CVD risk in RA is  independent of traditional risk factors, suggesting 
a role of inflammation in the development of atherosclerosis. (24) 
CVD risk prediction and management
As IJD are prevalent conditions worldwide, appropriate risk assessment and 
management strategies are mandatory to improve survival, healthcare costs and, 
most importantly, quality of life for affected patients. (25) Apart from optimal anti-
inflammatory therapy and management of traditional CVD risk factors, novel RA-
specific biomarkers associated with CVD might improve risk prediction in these 
patients. Presently, there are no IJD-specific CVD risk algorithms with superior 
predictive value available, whereas we know that CVD risk algorithms designed 
for the general population do not accurately predict CVD risk for IJD patients. (26) 
In the era of personalized medicine, tapering or stopping treatment with anti-
inflammatory agents, mainly biologic agents, is becoming common practice. 
Imaging studies could help elucidate whether successfully tapering or stopping 
anti-inflammatory therapy has any adverse effects on vascular morphology or CVD 
risk, as tapering could have adverse CVD effects, e.g. when this is done in patients 
with ongoing vascular inflammation.
Aims of this thesis
1. To assess the magnitude of CVD risk in IJD, with a focus on RA and PsA
2. To investigate traditional and novel risk factors associated with CVD in IJD
3. To increase awareness of the excess morbidity and mortality due to CVD 
in IJD
4. To recommend strategies for CVD risk management in IJD
Outline of this thesis
In chapter 2, we give an overview of the increased CVD risk in the most prevalent 
IJD (i.e. RA, AS, PsA), associated traditional and novel risk factors, and the effects 
of optimal anti-inflammatory therapy on CVD risk and risk factors. In chapter 3, we 
investigated whether co-existent thyroid dysfunction in RA patients affects CVD 
risk. In chapter 4, we questioned whether polymorphisms of the IL-32 promoter 
SNP rs4786370 predisposes to modified lipoprotein profiles in patients with RA, 
as a possible explanation of an elevated CVD risk. In chapter 5, the effects of 
etanercept treatment on traditional CVD risk factors in PsA patients was explored. 
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In chapter 6, we studied the risk for new CVD events in RA over time compared 
with patients with type 2 diabetes and the general population. For chapter 7, we 
formed a EULAR taskforce to update the EULAR recommendations for CVD risk 
management in patients with IJD. In chapter 8, we investigated if non-canonical 
NF-kB signalling is upregulated in IJD as a marker of neovascularization and an 
unstable plaque profile. In chapter 9, we measured arterial wall inflammation with 
an 18F-FDG-PET/CT in patients with early RA, established RA, osteoarthritis and 
healthy persons. In chapter 10, we assessed changes in arterial wall inflammation 
with an 18F-FDG-PET/CT after six months of anti-inflammatory therapy in patients 
with early and established RA. In chapter 11, we investigated whether interferon 
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ABSTRACT
Inflammatory joint diseases (IJD), including rheumatoid arthritis (RA), ankylosing 
spondylitis (ASp) and psoriatic arthritis (PsA) are prevalent conditions worldwide 
with a considerable burden on health care systems. IJD are associated with 
increased cardiovascular (CV) disease-related morbidity and mortality. In this 
review, we present an overview of the literature. Standardised mortality ratios are 
increased in IJD compared to the general population, i.e. RA 1.3 – 2.3, ASp 1.6 – 1.9 
and PsA 0.8 – 1.6. This premature mortality is mainly caused by atherosclerotic 
events. In RA, this CV risk is comparable to that in type 2 diabetes. Traditional CV 
risk factors are more often present and partially a consequence of changes in 
physical function related to the underlying IJD. Also, chronic systemic inflammation 
itself is an independent CV risk factor. Optimal control of disease activity with 
conventional, targeted synthetic and biological disease-modifying antirheumatic 
drugs (csDMARDs, tsDMARDS and bDMARDs) decreases this excess risk. High 
grade inflammation as well as anti-inflammatory treatment alter traditional CV 
risk factors, such as lipids. In view of the above-mentioned CV burden in patients 
with IJD, CV risk management is necessary. Presently, this CV risk management is 
still lacking in usual care. Patients, general practitioners, cardiologists, internists 
and rheumatologists need to be aware of the substantially increased CV risk in 
IJD and should make a combined effort to timely initiate CV risk management in 
accordance with prevailing guidelines together with optimal control of rheumatic 




Inflammatory joint diseases (IJD) are characterized by chronic inflammation of the 
joints and related tissues. IJD comprise a broad range of related disorders of which 
rheumatoid arthritis (RA) and spondyloarthropathies are the most common. 
RA is the archetype of a systemic immune-mediated disease and it is defined as 
a chronic symmetric inflammation primarily involving the synovial joints (table 1) 
[1]. RA affects approximately 1% of the general population worldwide and the 
prevalence increases with age [2]. Alongside joint involvement, the systemic 
inflammation distinctive for RA can affect other organs including the bowels, 
skin, lungs, kidneys, nervous system and also the heart and blood vessels [2]. RA 
leads to severe pain, major disability and premature death [1 2]. The majority of 
these deaths are attributed to atherosclerotic cardiovascular disease in particular 
[3]. Spondyloarthropathies are a group of various rheumatic diseases of which 
ankylosing spondylitis (Asp) and psoriatic arthritis (PsA) are the most frequently 
occurring disorders (table 1). Shared clinical features of spondyloarthropathies 
are axial joint inflammation, enthesitis, dactylitis and oligoarthritis [4]. In addition, 
there is a genetic association with HLA-B27 [4]. Extra-articular organ systems 
such as the eyes (anterior uveitis), bowels (inflammatory bowel disease or Crohns 
disease), skin (psoriasis) and the cardiovascular (CV) system are often affected [5]. 
Like RA, mortality is increased in ASp and PsA [5] and it is linked to cardiovascular 
comorbidities. Approximately 0.4 – 1.9% of the general population suffers from 
spondyloarthropathies, of which 0.1 – 0.6 % accounts for ASp [4] and 0.04 – 1% for 
PsA [6]. 
As IJD are prevalent conditions worldwide with a considerable burden to health 
care systems, knowledge and awareness of the increased CV risk is required to 
timely initiate cardiovascular risk management in these patients. In this review we 
present an overview of the literature on this subject.
Cardiovascular Morbidity and Mortality in Inflammatory Joint Diseases
Mortality rates are significantly increased in patients with RA compared to the 
general population, with reported standardized mortality ratios between 1.3 and 
2.3 [3]. A large excess of these deaths is attributable to CV disease, predominantly 
ischemic heart disease and cerebrovascular disease. A recent meta-analysis of 14 
observational cohort studies comprising over 40.000 RA patients shows an overall 
increased relative risk of a first ever CV event in RA patients of 1.48 (95% CI 1.36-
Chapter 2. Atherosclerotic Cardiovascular Disease 
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Table 1. Characteristics of the major rheumatic diseases




Arthritis of three or 
more joints
Elevated CRP and ESR
Positive RF and anti-
CCP antibodies
Predominant in females 
in 2-3:1 ratio
Onset in 4th,5th or 6th 
decade
Arthritis of SI- and axial-
joints
Ankyloses of spinal column 
Associated with HLA-B27 
genotype
Elevated CRP and ESR in 
approximately 50%
Predominant in men 3:1
Onset generally before 
the age of 30, but often 
delayed diagnosis due to 
lack of disease knowledge 
and misdiagnosis, 
especially in women
Inflammation of distal 
joints (DIPs>PIPs) 
Psoriasis
Slight predominance in 
males






















CV disease main cause 
of death, mainly due to 
atherosclerotic disease
Increased mortality rate
CV main cause of death
Both atherosclerotic 





*Many rheumatic disease characteristics share symptoms; therefore this list includes the 
typical major characteristics, but is in no means an exclusive or complete list of symptoms. 
Anti-CCP: anti citrullinated protein antibody, CRP: C-reactive protein, CVD: cardiovascular, 
DIP: distal interphalangeal joint, DMARDs: disease modifying anti rheumatic drugs, DM2: 
diabetes mellitus type 2, ESR: Erythrocyte Sedimentation Rate, MI: myocardial infarction, 
NSAIDs: non-steroidal anti-inflammatory drugs, PIP: proximal interphalangeal joint, RF: 
Rheumatoid Factor, SI: sacro-iliac 
1.62), mainly caused by an increased risk of myocardial infarction, cerebrovascular 
accidents and congestive heart failure [7]. These CV events were predominantly 
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of atherosclerotic origin, but vasculitis, primary thrombogenesis and myocarditis 
may have played a pathogenetic role in their development. Although some studies 
suggest that the disease course of RA has become milder in recent years as a result 
of advances in medicinal treatment, CV disease related mortality has remained 
equally elevated over the past five decades. This might be due to underrecognition 
and undertreatment of CV risk factors, a lack of optimal disease control by 
medication or favorable effects of anti-inflammatory therapy on CV risk may only 
be noticeable on a population average after decades of treatment. Similar to RA, 
mortality is also increased in ASp, with standardized mortality ratios up to 1.9. An 
increased incidence of atherosclerotic events is responsible for the majority of 
deaths in this disease [8]. In PsA, standardized mortality ratios are reported up to 
1.6. These patients are at an increased risk of myocardial infarction, but data on 
cerebrovascular disease is conflicting. A recent study reports an increased risk of 
major atherosclerotic events (hazard ratio (HR) 1.24 95%CI 1.03-1.49) in untreated 
PsA patients, even after adjustment for traditional CV risk factors [9]. 
Conventional Cardiovascular Risk Factors in Inflammatory Joint Diseases 
Smoking
Smoking is an acknowledged cause of CV morbidity and mortality. The CV risk 
associated with smoking is dose and duration dependent, but there is no lower 
limit for detrimental effects. The exact mechanism by which smoking increases 
CV risk is unknown, but it is suggested that smoking has effects on endothelial 
function, platelet function, fibrinolysis, lipids and vasomotor function through 
reactive oxygen species triggering inflammatory processes in arterial tissues. Any 
type of smoking is an environmental risk factor for development of RA and it is also 
associated with increased disease severity [10]. A higher prevalence of smoking is 
reported in RA patients compared to controls [11]. Smoking does not appear to be 
associated with the development of Asp but it does influence clinical, functional 
and radiological disease outcomes. Data regarding the prevalence of smoking 
in both Asp and PsA is not univocal with several studies reporting increased 
prevalences whereas others do not. 
Physical activity
In the general population exercise reduces CV risk, possibly through dampening of 
inflammation measured by C-reactive protein levels. Therefore, exercise might also 
have beneficial effects on CV risk in IJD. On average, RA patients are less physically 
active, which has been associated with a higher risk of CV events. Recent studies 
show a beneficial effect of exercise therapy on vascular function, cardiorespiratory 
Chapter 2. Atherosclerotic Cardiovascular Disease 
24
fitness and CV risk in RA [12]. Active disease and disease-related deterioration of 
functional status renders patients with ASp and PsA less physically active than 
controls which has been associated with a worse prognosis and premature death 
[5]. For ASp, physical training is the cornerstone of treatment, positively affecting 
disease activity and probably simultaneously decreasing CV risk. 
Dyslipidaemia
While high serum total cholesterol (TC), low density lipoprotein cholesterol 
(LDLc) and triglycerides (TG) are associated with increased CV risk in the general 
population, RA patients with active disease have instead low serum levels of TC 
and LDLc, while the CV risk is elevated [13]. Possibly, the simultaneous decrease in 
high density lipoprotein cholesterol (HDLc) during disease flares and the negative 
effects of inflammation on the anti-atherogenic properties of HDLc and LDLc 
cause this increased CV risk. The lipid profile in ASp and PsA is similarly affected 
by disease activity [5]. In addition to inflammatory changes in lipids, certain lipid-
particles themselves are capable of influencing inflammatory pathways. HDLc is 
able to intervene in the interaction between T-cell lymphocytes and macrophages, 
making it an inflammation modifier. Decreasing inflammatory activity through 
medical treatment generally improves, i.e. normalizes, the lipid profile in IJD as 
HDLc levels also improve with treatment. Thus, the increase in TC and LDLc after 
anti-inflammatory treatment does not translate into an increased CV risk, but is 
a reflection of a good response to therapy. In addition, suppressing inflammation 
may enhance HDLc efflux function even in the absence of quantitative changes in 
lipids. However, the clinical relevance of short term changes in lipid particles on CV 
outcomes remains to be determined.
Dyslipidaemia in the general population can be effectively treated with statins 
reducing CV risk. Statins appear equally effective in patients with IJD [14]. 
Furthermore, statins have anti-inflammatory properties and may thus induce an 
additional CV risk reduction when combined with anti-inflammatory therapy. In 
addition, it should be noted that lipid levels during high disease activity are lower in 
IJD and this leads to a possible underestimation of CV risk. Therefore, lipid levels 
should be assessed during periods of low disease activity or disease remission. If 
this is not possible, the TC/HDLc-ratio should be used as this is the most stable 
lipid marker under inflammatory conditions [15]. This ratio correlates better with 
C-reactive protein levels and subsequent CV event risk in comparison to TC or 
HDLc alone and is therefore a more appropriate predictor of CV risk in IJD rather 
than the individual lipid levels [15].
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Blood pressure
A recent meta-analysis found no clear difference in blood pressure between RA 
patients and non-RA controls, whereas most other studies found an increased 
prevalence of hypertension [11 16]. This disparity might be explained by under-
recognition of hypertension in RA. The prevalence of hypertension and its 
contribution to CV risk in ASp is also unclear, as several studies report increased 
prevalences of hypertension in ASp whereas others do not [5]. In PsA, several 
studies report increased prevalences of hypertension. Overall, there seems to 
be a tendency towards an increased prevalence of hypertension in RA, ASp and 
PsA. Currently, there is no evidence for a preferred antihypertensive agent in IJD 
disregarding an older report that ACE-inhibitors and ATII antagonists should be 
preferred in view of their anti-inflammatory properties. A far more important issue 
to address is that adequate treatment of hypertension in IJD is often lacking.
Body weight and body composition
Whether the body mass index differs between RA patients and the general 
population is unclear, but a low body mass index is associated with increased CV 
risk [16]. Patients with RA do seem to have more body fat for a given body mass 
index than controls. Rheumatoid cachexia, a condition in which the lean body mass 
or muscle mass is lost while fat mass is preserved or increased, is not uncommon in 
RA [17]. Interestingly, several small-scale studies in RA patients with active disease 
or a disease flare reported lower body mass index and fat free mass as compared 
to healthy controls, disappearing after treatment. Moreover, in most patients the 
body mass index often remains stable over the course of RA while the fat free mass 
is lost and fat mass is increased. Therefore, assessing only body mass index may 
underestimate CV risk in RA patients. ASp is associated with an increased body 
mass index that correlates with disease activity. PsA patients are reported to 
be more often overweight which correlates with physical health. Reducing body 
weight to a normal range through exercise improves body composition in IJD and 
could therefore simultaneously improve both CV risk and disease outcomes in 
these patients.
Insulin resistance and diabetes
Studies report conflicting results regarding the prevalence of diabetes mellitus type 
2 in RA patients. Both insulin resistance and diabetes mellitus type 2 are associated 
with CV disease in RA similar to the general population. Insulin resistance seems 
increased in patients with RA compared to controls. Insulin resistance in RA is 
associated with increased levels of C-reactive protein, erythrocyte sedimentation 
Chapter 2. Atherosclerotic Cardiovascular Disease 
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rate, interleukin-6 and tumor necrosis factor-α. Whether RA and diabetes mellitus 
type 2 are associated in a pathophysiological way is less clear. Insulin resistance is 
not increased in ASp, but it is increased in PsA, which might be due to a relatively 
higher body mass index in these patients. Similarly, diabetes mellitus type 2 
prevalence is higher in PsA versus controls, but this was not observed in ASp.
Systemic Inflammation Inherent to Inflammatory Joint Diseases  
Although traditional risk factors for CV disease are generally more often present in 
IJD patients, the excess morbidity and mortality cannot be explained by these risk 
factors alone. A study from 2010 demonstrated that RA is independently associated 
with CV disease development after adjustment for known traditional CV risk factors 
[18]. The CV risk in RA appears equal to that of diabetes mellitus type 2 [18 19]. A plausible 
explanation is that the chronic inflammatory burden of RA enhances endothelial 
dysfunction and consequently induces or accelerates atherosclerosis, as a higher 
inflammatory burden and an increased number of disease flares was associated 
with CV events in RA patients [20]. Moreover, atherosclerosis itself is regarded as 
an inflammatory process with inflammatory cells involved in all its stages [21 22]. 
The carotid intima media thickness is generally seen as a reliable surrogate 
marker for (preclinical) CV disease and is increased in RA patients as compared to 
matched non-RA controls. Inflammation causes maladaptive outward remodelling 
of the carotid artery, which is associated with plaque instability and rupture [23]. 
This adverse remodelling might further increase CV risk in RA [23]. It is currently 
unknown to what extent inflammation affects CV risk in ASp or PsA, but it is 
conceivable that the CV effects of inflammation in these patients are similar to 
that in RA. This is also implicated by numerous reports that carotid intima media 
thickness is also increased in ASp and PsA and the lipid profile is affected similarly 
to RA.
Effects of Anti-inflammatory Therapy on CV Risk
The anti-rheumatic treatment of RA is initiated with disease-modifying 
antirheumatic drugs (DMARDs), agents capable of interfering with the systemic 
inflammatory disease process, reducing or reversing disease symptoms and 
simultaneously improving quality of life. There are several classes of DMARDs 
including conventional synthetic DMARDs (csDMARDs), targeted synthetic DMARDs 
(tsDMARDs) and biological DMARDs, such as tumor necrosis factor-α inhibitors 
(TNFi, table 2). RA therapy starts with csDMARDs, often with methotrexate 
alone or combined with sulfasalazine or hydroxychloroquine, or (bridging) 
glucocorticosteroids. When remission or low disease activity according to the 
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definition is not reached within 6 months, a different csDMARD combination can 
be tried or one of the TNFi is added. Both csDMARDs and TNFi significantly reduce 
CV risk in RA patients (table 3). Several studies have shown beneficial effects of 
csDMARDs and TNFi on carotid intima media thickness [24], lipid profile, IR and 
metabolic syndrome in RA. Generally, treatment with csDMARDs and TNFi increases 
all lipid components, but predominantly HDLc resulting in a beneficial TC/HDLc-
ratio [25].  However, tocilizumab and tofacitinib may increase lipids, presumably 
due to interleukine-6 inhibition. Sustained elevations of lipids after treatment with 
these agents can effectively be reduced with statin therapy. Glucocorticosteroids 
rapidly and effectively lower inflammation in RA, but they have been associated 
with a dose-dependent increased risk of CV disease. Although the cumulative 
corticosteroid dose is significantly associated with CV disease, reducing high grade 
inflammation in patients with active disease may counter this adverse effect. 
In ASp, treatment starts with non-steroidal anti-inflammatory drugs (NSAIDs) in 
combination with regular physical exercise [26]. NSAIDs effectively reduce disease 
activity in the majority of ASp patients, but they might have a twofold effect on CV 
risk in ASp. The lowering of inflammatory burden, subsequent increase in physical 
activity and deceleration of bone remodelling might lead to a decreased CV risk. In 
contrast, side effects of NSAIDs like hypertension and renal damage might increase 
CV risk, especially in young ASp patients [27]. The average CV effects of NSAIDs 
in ASp remains unclear, and it is therefore unknown whether NSAIDs should be 
used intermittently or continuously. csDMARDs are generally not effective in ASp, 
but may be used for ASp patients with concurrent peripheral arthritis. If NSAIDs 
treatment fails, TNFi are initiated [26]. TNFi treatment in ASp is highly effective 
and possibly improves overall CV risk as improvements in lipid profile, vascular 
function and carotid intima media thickness are described after treatment. PsA 
patients are treated similar to RA patients, initially with csDMARDs and with TNFi 
in patients with persistent active disease. The effects of these treatments on CV 
risk in PsA are currently unknown. However, similarly to RA, TNFi improve the lipid 
profile and carotid intima media thickness in PsA.
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Table 2. Treatment options for rheumatic diseases and their cardiovascular effects
Group Examples Disease Cardiovascular effects Interactions with com-













in after MI, CVA and 
peripheral arterial dis-
ease, has an antiplate-
let clotting effect like 
aspirin, ticagrelor and 
clopidogrel   
Renal dysfunction, 
increased risk of (GI) 
bleeding in combination 
with anticoagulants, 
possible decrease of 
cardioprotective effect 
of aspirin and increase 
in thrombo-embolic 
complications, due to 
competitive COX inhibi-
tion, may decrease ef-
fect of antihypertensive 








RA, PsA Improvement of lipid 
profile, insulin resist-
ance and physical 
activity
Renal dysfunction 
with MTX, leflunomide 
can increase serum 
levels of furosemide, 
hydroxycholoquine 
and sulfasalazine can 













Improvement of lipid 
profile, insulin resist-
ance and physical 
activity
Acute heart failure in pa-
tients with pre-existing 
CHF class 3 and 4
T cell costimula-
tion inhibitor*
Abatacept RA ? ?
Anti-B cell agent* Rituximab (i.v.) RA ?, caution warranted  
in patients with known 
CV disease 









RA Increases lipids  due to 
IL-6 inhibition
May influence metabo-




Anakinra RA ? ?
Targeted synthet-
ic DMARDs
Tofacitinib RA, PsA Increases lipid levels 












Increase of insulin 
resistance, increase in 
blood pressure, heart 
failure, weight gain
Risk of hypokalaemia 
with diuretics, change in 
response to anticoagu-
lants, faster elimination 
of salicylates
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ASp: Ankylosing Sponydlitis, CHF: congestive heart failure, CVA: cerebrovascular accident, 
CV: cardiovascular, DMARDs: disease modifying anti rheumatic drugs, IJD: inflammatory 
joint disease, i.v: intravenously, s.c.:subcutaneous, NSAIDs: non-steroidal anti-
inflammatory drugs, PsA: psoriatic arthritis, MI: myocardial infarction, MTX: methotrexate, 
GI: gastrointestinal, RA: rheumatoid arthritis, *bDMARDs
Table 3. Effect of anti-inflammatory therapy on CV events
Anti-inflammatory agent CV risk factors CV events
csDMARDs Decrease in CRP, improvement of insulin 
resistance, lipid profile and physical activity
Decrease
tsDMARDs Decreased CRP, increases lipids Decrease 
bDMARDs Decreased CRP, improvement of insulin resistance 
and lipid profile (except tocilizumab increases lipid 
levels)
Decrease 
NSAIDs Increased blood pressure, possible increase 
in thrombo-embolic complications due to 
competitive COX-1 inhibition?
Increase 
Glucocorticosteroids Decreased CRP, increased insulin resistance, 





csDMARDs: conventional synthetic disease-modifying antirheumatic drugs, tsDMARDs: 
targeted synthetic disease-modifying antirheumatic drugs, bDMARDs: biological disease-
modifying antirheumatic drugs, CRP: c-reactive protein, COX: cyclooxygenase.
CV risk estimation in IJD
Currently, there are no IJD-specific CV risk prediction models with a validated 
performance. Risk prediction models for the general population underestimate the 
CV risk in IJD [28 29]. The EULAR recommendations for CV risk management advise 
the use of the SCORE algorithm with a multiplication factor of 1.5 for RA patients 
[30]. In apparently healthy persons, a 10 year risk of a first ever atherosclerotic event 
can be estimated with this algorithm, which includes gender, age, smoking status, 
blood pressure and total cholesterol or TC/HDLc ratio. In patients with established 
CV disease cardiovascular risk management should be initiated on all risk factors 
as there is already an inherent high risk of future events. As mentioned earlier, the 
TC/HDLc-ratio is a more appropriate predictor in IJD than individual lipids. Whether 
novel and IJD-specific factors such as carotid intima media thickness or specific 
biomarkers will improve risk prediction in IJD remains to be elucidated.
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DISCUSSION
IJD patients have an increased CV risk. Contributing factors are the increased 
presence of traditional CV risk factors and the CV effects of chronic inflammation 
inherent to IJD (figure 1).  It is widely acknowledged that the process of inflammation 
accelerates atherosclerosis in patients with IJD. Furthermore, inflammation 
regardless of its aetiology weakens the plaques cap, making the plaque unstable 
and more prone to rupture. It is currently unknown whether anti-inflammatory 
treatment can halt or even reverse this accelerated atherosclerotic process, but 
small studies do point towards this direction. As all antirheumatic treatments aim 
for inflammation reduction, they favourably affect CV risk. However, their use might 
also cause CV complications by causing an increased blood pressure, increases in 
lipids, kidney failure and even congestive heart failure. Therefore, while effective 
anti-inflammatory treatment might be beneficial in the average IJD patient, CV 
and anti-rheumatic treatment should always be individually evaluated, especially 
in case of CV disease history. 
Figure 1. Interplay between CV risk, inflammation and traditional CV risk factors
As there is overwhelming evidence for an increased CV risk in RA, these patients 
are considered to be a high risk category (see supplementary file for the full 
literature list). Therefore, in 2009, a specific CV risk management guideline from 
EULAR taskforce recommended to use a 1.5 multiplication factor when estimating 
CV risk in RA patients. For ASp and PsA, the evidence was less pronounced and 
thus the multiplication factor was not recommended. 
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CONCLUSIONS
IJD patients are at increased risk of CV disease related morbidity and mortality, 
particularly an increased incidence of atherosclerotic CV disease. For RA, this 
risk equals that of diabetes mellitus type 2. CV risk factors in IJD are the systemic 
inflammatory burden, the higher prevalence of traditional risk factors such as 
hypertension and dyslipidaemia, limitations in physical activity and medication 
use (figure 2). Patients, general practitioners, cardiologists, internists and 
rheumatologists should therefore all be aware of this significantly increased 
CV disease risk and need to initiate effective CV risk management according to 
existing guidelines, such as the EULAR evidence-based recommendations for 
cardiovascular risk management in patients with rheumatoid arthritis and other 
forms of inflammatory arthritis and the European Society of Cardiology guideline 
for CV disease prevention in clinical practice. Specific CV disease screening 
and treatment strategies for IJD patients need to be implemented as part of 
usual care. The rheumatologist should be responsible for ensuring that CV risk 
management is done, while the involvement of other health care professionals and 
the implementation of CV disease prevention programs may be defined locally. At 
present, effective CV risk management is lacking in clinical practice.
Figure 2. IJD and CV disease
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HYPOTHYROIDISM IS ASSOCIATED 
WITH AN INCREASED RISK OF 
NEW CARDIOVASCULAR EVENTS 













Autoimmune thyroid disease often coexists with rheumatoid arthritis (RA) and is 
associated with an elevated cardiovascular(CV) risk. However, studies in RA are 
scarce. To investigate whether autoimmune thyroid disease increases the risk of 
new CV disease (CVD) in RA. 
Methods
Thyroid-stimulating hormone (TSH) and serum free thyroxine(FT4) were assessed 
in 323 RA patients participating in an ongoing prospective cohort study designed 
to assess CV risk factors, morbidity and mortality. Cox proportional hazard models 
were used to calculate hazard rates (HR) for new CVD and adjusted for age, sex, 
smoking, prevalent CVD, thyroxine replacement therapy and RA duration. 
Results
Of the 323 participants, 65.3% were females aged 63 ± 7 years. At baseline 8.1% 
was hypothyroid (n=26, 16 clinical, 10 subclinical), 6.8% was hyperthyroid (n = 22, 13 
clinical, 9 subclinical) and 85.1% (n=275) was euthyroid. 94 patients (29.1%) developed 
a new CV event during follow up. Compared to the euthyroid patients, age, sex 
and prevalent CVD adjusted HR was 2.83 (95% CI 1.13-7.09 P=0.026) for subclinical 
hypothyroidism. Further adjustment for smoking, thyroxine replacement therapy 
and RA duration resulted in a HR of 3.0 (95% CI 1.19–7.54; P=0.02) for CV events in 
patients with subclinical hypothyroidism.
Conclusion
There was no difference in CVD between RA patients with hypothyroidism and 
hyperthyroidism vs. euthyroid patients. Coexistence of subclinical hypothyroidism 
with RA was associated with a higher occurrence of new CV events. Treatment 
trials are needed to determine whether thyroxine supplementation can further 
improve cardiovascular outcome in these patients.
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INTRODUCTION
In patients with rheumatoid arthritis (RA) the cardiovascular (CV) disease (CVD) risk 
is doubled, leading to an excess mortality (1-3). Several factors contribute to this 
amplified risk, such as traditional CV risk factors, inflammatory burden and the 
use of certain anti-rheumatic medications (e.g. non-steroidal anti-inflammatory 
drugs (NSAIDs) and glucocorticoids) (4). It is unclear which (combination of) 
factors eventually lead to, and fully explain the increased CVD risk in RA. Hence, 
investigating novel pathogenic mechanisms and pathways is relevant. 
Coexistence of autoimmune thyroid disease with RA has been associated with an 
elevated CVD risk, especially in hypothyroid patients, with Raterman et al. reporting 
an odds ratio (OR) of 4.1 and McCoy et al. a hazard ratio (HR) of 2.0 for new CV events (5, 
6). For subclinical hypothyroidism (defined as normal free thyroxine concentrations 
with an elevated thyroid-stimulating hormone level), this association is much less 
consistent (7, 8). In the general population, the same is observed in hypothyroid 
patients, with relative risks (RR) of 1.15 for myocardial infarction (MI) and 1.96 for 
cardiac death when compared with euthyroid persons (7, 9-11). In addition, Ning et 
al. described an increased CV risk in subclinical hypothyroidism, especially in those 
with TSH levels of 10 mU/L or higher (9).  Several other studies report an increased 
CVD risk in persons with subclinical hypothyroidism in the general population (10-
12), but not all studies have found this association (13, 14).
Thyroid hormones exert a variety of positive effects on the cardiovascular system, 
such as a positive inotropic effect on the heart and a decrease in vascular resistance 
due to increased production of nitric oxide (15). In contrast, hypothyroidism 
is associated with lipid abnormalities that might contribute to accelerated 
atherosclerosis (8, 16). In line with this, we previously reported a fourfold higher risk 
of CVD in female RA patients with clinical hypothyroidism compared with euthyroid 
RA patients (17). Since the existing literature is mostly of cross-sectional origin 
(i.e. reporting prevalence of CVD in RA patients with thyroid dysfunction instead of 
incidence), we have assessed the relationship between thyroid abnormalities and 
new CV events in a previously described cohort of RA patients (5), now with long 
term follow up.




The CARRÉ (CARdiovascular research and RhEumatoid arthritis) observational 
cohort study (n=353) was initiated to investigate the incidence of CVD and its risk 
factors in patients with longstanding RA. Study enrollment was between June 
2000 and January 2002. As previously described (1), patients were eligible if they 
fulfilled the 1987 American College of Rheumatology classification criteria, were 
diagnosed with RA between 1989 and 2001, and were aged between 50 and 75 years. 
The participants were followed for 15 years, with study visits at baseline, 3 years, 
10 years and a CV disease questionnaire in 2015 at 15 years. Study participants who 
were lost to follow up before the first study visit at 3 years were excluded from the 
analyses.  All CV events were confirmed in medical records. 
RA-related and thyroid function data
Demographic data, medical history, medication use, family history, and Disease 
Activity Score of 28 joints (DAS28) were assessed. C-reactive protein, erythrocyte 
sedimentation rate and (radiographic) erosions in hands and feet were assessed at 
all visits. Rheumatoid factor (RF), anti–citrullinated protein antibody (ACPA), TSH, 
serum free thyroxine (FT4), and thyroid peroxidase antibodies (anti-TPO) were 
only assessed at baseline and thyroid function was only available for 323 patients. 
Patients were classified into groups by their thyroid function as euthyroid, 
hyperthyroid (known diagnosis of hyperthyroidism or TSH <0.3 mU/L and FT4 
>24 pmol/L), hypothyroid (known diagnosis of hypothyroidism or TSH >4.0 mU/L 
and FT4 <10 pmol/L), subclinical hypothyroid (TSH>4.0 mU/L and normal FT4) and 
subclinical hyperthyroid (TSH<0.3 mU/L and normal FT4). 
CV risk factor assessments
Smoking status, blood pressure, body mass index (weight/height2 in kg/m2), 
total cholesterol (TC), high density lipoprotein cholesterol (HDLc), low density 
lipoprotein cholesterol (LDLc), triglycerides, TC/HDLc ratio, glucose, and HbA1c 
were assessed. 
CV disease assessment 
Fatal and non-fatal CV events verified in medical records were registered 
according to the International Statistical Classification of Diseases and Related 
Health Problems 9th revision (ICD-9 codes, 410.0 – 410.9, 435.9, 436, 443.9 and 798) 
as described previously (1). Sudden deaths were registered as CV mortality if this 
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was confirmed by autopsy. CV events were classified into prevalent CV disease at 
baseline and new CV events during follow up.  Patients were censored after the 
first fatal or non-fatal CV event or death due to other reasons. The last (event-free) 
follow up visit was used as censor date for the participants who were lost to follow 
up. At 15 years, the remaining participants were censored at study cessation time: 
March 1, 2015. Medical records of the patients lost to follow up were searched in 
order to extract data on the occurrence of CV events.
Statistical analysis
All data has been analysed with IBM SPSS statistics version 23. Data are presented 
as mean ± standard deviation, median with an interquartile range or numbers 
and percentages. Cox proportional hazard models were used to calculate hazard 
rates (HR) for new CV events in patients with RA subdivided into patients who 
are euthyroid, hyperthyroid, hypothyroid, subclinical hyperthyroid or subclinical 
hypothyroid. These models were corrected for the following confounders based on 
literature: age, sex, prevalent CVD, smoking, thyroxine replacement therapy, and 
RA duration. A p-value of below 0.05 was considered statistically significant.
RESULTS
The baseline characteristics of all patients are shown in table 1. Patients with 
missing thyroid function data, patients who were lost to follow up before the first 
study visit and non-caucasians (n= 30) were excluded. At baseline 8.1% of the 
patients had hypothyroidism (n=26, 16 clinical and 10 subclinical hypothyroidism), 
6.8% had hyperthyroidism (n = 22, 13 clinical and 9 subclinical hyperthyroidism) 
and 85.1% (n=275) was euthyroid. 12 patients with clinical hypothyroidism, 1 patient 
with hyperthyroidism and 1 patient with subclinical hyperthyroidism were receiving 
thyroxine replacement therapy (RT) and they were all female. For 13 patients the 
duration of hypothyroidism was available, which was 23 (15 – 36) years. Systolic and 
diastolic blood pressure, sex, anti-TPO levels and thyroxine replacement therapy 
differed between the different thyroid function groups at baseline (supplementary 
table 1).
Development of new CV events
94 patients with RA (29%) developed a CV event during a median follow up of 11 
years and 2916 patient years, resulting in an incidence rate of 3.22 CV events per 
100 patient years. 36% (n=9) of the hypothyroid, 30.4% (n=7) of the hyperthyroid 
Chapter 3. An explorative study
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Table 1. Baseline characteristics of all participants
N= 323
Demographics
   Age, years 63 ± 7
   Females, no. (%) 211 (65.3)
Cardiovascular risk factors
   Previous CVD, no. (%) 47 (14.6)
   Hypertension, no. (%) 197 (61)
      Systolic BP, mmHg 142 ± 20
      Diastolic BP, mmHg 81 ± 8
   TC/HDLc ratio 4.4 ± 1.5
      TC, mmol/L 5.8 ± 1.1
      HDLc, mmol/L 1.5 ± 0.5
      LDLc, mmol/L 3.7 ± 1.0
      Triglycerides, mmol/L 1.32 (0.96 – 1.82)
   Currently smoking, no (%) 94 (29.1)
      Pack years 19 (2-38)
   Body mass index, kg/m2 26.7 ± 4.8
   Diabetes, no. (%) 14 (4.3)
Thyroid function absolute
   TSH, mU/l 1.30 (0.91 – 1.90)
   Anti-TPO positive, no. (%) 36 (11.1)
     Anti-TPO, U/mL 102 (65 – 295)
Thyroid function groups
   Euthyroid 275 (85.1)
   Hyperthyroid 22 (6.8)
   Hypothyroid 26 (8.1)
Medication
   Antihypertensive drugs 82 (25.4)
   Statins 37 (11.5)
   Aspirin 54 (16.7)
   Thyroxine replacement therapy, no. (%) 13 (4)
RA variables
   IgM-RF ≥30 U/mL 235 (72.8)
   ACPA ≥50 kU/L 167 (51.7)
   DAS28 3.9 ± 1.3
   Disease duration 7 (4 – 10)
   Erosion on radiographs 260 (80.5)
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Continuous variables are presented as mean ± SD or median (IQR). Categorical and dichotomous 
variables are presented as numbers and percentages (%). CVD = cardiovascular disease; BP = 
blood pressure; TC = total cholesterol; LDLc = low-density lipoprotein; HDLc = high-density 
lipoprotein; pack years = (packs smoked per day)*(years as a smoker); DM = type 2 diabetes 
mellitus; RA = rheumatoid arthritis; IgM-RF = immunoglobulin M rheumatoid factor; ACPA = 
Anti–citrullinated protein antibody; DAS28 = Disease Activity Score; TSH= thyroid-stimulating 
hormone; FT4= free thyroxine; anti-TPO= anti-thyroid peroxidase antibodies. 
and 28.2% (n=78) of the euthyroid RA patients developed a new CV event over time. 
Compared to the euthyroid persons, age and sex adjusted HR were 1.08 (95% CI 
0.50-2.36; P=0.84) for hyperthyroid patients and 1,48 (95% CI 0.72-3.04; P=0.28) for 
hypothyroid patients. A closer look at the subclinical hypothyroid patients revealed 
a significantly higher incidence of new CV events, with an age, sex and prevalent 
CVD adjusted HR of 2.83 (95% CI 1.13-7.09 P=0.03) (table 2, figure 1). Further 
adjustment for smoking, thyroxine replacement therapy and RA duration resulted 
in a HR of 3.0 (95% CI 1.19–7.54; P=0.02) for CV events in patients with subclinical 
hypothyroidism (figure 1).
Figure 1. Estimated survival probability stratified by thyroid function based on the 
multivariate Cox analysis
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Table 2. CV risk in thyroid dysfunction groups compared to euthyroid patients
HR* 95%CI P
Hyperthyroid 1.09 0.34-3.55 0.88
Hypothyroid 0.70 0.25-1.97 0.50
Subclinical hyperthyroidism 1.36 0.50-3.72 0.55
Subclinical hypothyroidism 2.83 1.13-7.09 0.03
*adjusted for age, sex and prevalent CVD
DISCUSSION
In this explorative study, the prevalence of thyroid disorders is twice as high in RA 
patients when compared with numbers reported for the general population (18, 19). 
More importantly, coexistence of subclinical hypothyroidism in RA is associated 
with an increased risk of new CV events when compared with euthyroid RA 
patients. This is an important finding, as coexistence of subclinical hypothyroidism 
amplifies the already high CVD risk in RA patients. Interestingly, none of the 
patients with subclinical hypothyroidism was receiving thyroxine replacement 
therapy, in contrast to the majority of the patients with hypothyroidism. All 
patients on thyroxine replacement therapy were female. As patients with clinically 
overt hypothyroidism are generally treated with thyroxine supplements, this may 
decrease CVD risk, although this warrants further confirmation in treatment 
trials. Regarding CVD risk factors, a significantly higher systolic blood pressure 
was present in RA patients with hypothyroidism, compared with the other groups. 
There were no significant differences in the other traditional CVD risk factors.
Several limitations need mentioning. First, although the prevalence of thyroid 
disorders was higher in our RA population, the total number of patients was still 
small. However, the findings of this explorative study are in line with existing 
literature and underscore the necessity of further research. Second, some 
patients with subclinical hypothyroidism spontaneously convert to euthyroidism. 
Unfortunately, there was insufficient data available to investigate this further. 
Lastly, we did not have any information about therapy in the hyperthyroidism group 
and the duration of the thyroid disorder in a large number of patients, which could 
have influenced the results.
Despite these limitations, our results show that subclinical hypothyroidism may 
further amplify CVD risk in RA patients. Whether there is a direct relationship 
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between subclinical hypothyroidism (and high anti-TPO levels) and the increased 
CVD risk we identified, needs to be elucidated in treatment trials. If external 
validation can confirm this amplified CVD risk, cardiovascular risk management is 
warranted in this subgroup of patients, and the next question is whether thyroxine 
supplementation can further improve cardiovascular outcome in subclinical 
hypothyroid RA patients.
Chapter 3. An explorative study
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   Age, years 63 ± 7 67 ± 7 61 ± 6 65 ± 8 64 ± 6
   Females, no. (%)* 171 16 6 13 5
Cardiovascular risk factors
   Previous CVD, no. (%) 42 3 0 0 2
   Hypertension, no. (%) 161 (58.5) 14 (87.5) 6 (60) 9 (69.2) 7 (71.8)
   Systolic BP, mmHg* 141 ± 16 157 ± 29 143 ± 18 145 ± 21 152 ± 20
   Diastolic BP, mmHg* 80 ± 8 86 ± 10 81 ± 15 83 ± 8 85 ± 7
   TC/HDLc ratio 4.38 ± 1.57 4.47 ± 1.71 4.44 ± 1.46 4.16 ± 1.13 4.23 ± 1.29
      TC, mmol/L 5.82 ± 1.13 5.56 ± 1.01 5.92 ± 1.67 5.99 ± 0.85 5.01 ± 0.63
      HDLc, mmol/L 1.46 ± 0.49 1.42 ± 0.55 1.45 ± 0.63 1.51 ± 0.30 1.27 ± 0.35
      LDLc, mmol/L 3.72 ± 1.05 3.49 ± 1.13 3.97 ± 1.18 3.95 ± 0.86 2.97 ± 0.53










   Currently smoking, no (%) 83 (30.2) 3 (18.8) 3 (30) 1 (7.7) 4 (44.4)
      Pack years 19 (2 – 40) 22 (0 – 40) 12 (0 – 18) 8 (0 – 26) 15 (2 – 24)
   Body mass index, kg/m2 27 ± 5 28 ± 4 27 ± 6.36 28 ± 6 29 ± 5
   Diabetes, no. (%) 13 (14.7) 1 (6.3) - - -
Thyroid function absolute










   Anti-TPO positive, no. (%)* 25 3 5 1 1
     Anti-TPO, U/mL* 10 (10 – 17) 10 (10 – 62) 82 (14 – 346) 10 (10 – 15) 10 (10 – 18)
Medication
   Antihypertensive drugs 68 (24.7) 6 (37.5) 1(10) 4 (30.8) 3(33.3)
   Statins 32 (11.6) 2 (12.5) 1(7.7) 2 (12.2)
   Aspirin 45 (16.4) 4 (25) 1(10) 1(7.7) 3 (3.33)
   Thyroxine replacement 
therapy, no. (%)*
- 12 (75) - 1(7.7) 1(11.1)
Continuous variables are presented as mean ± SD or median (IQR). Categorical and dichotomous 
variables are presented as numbers and percentages (%). *Statistically significant difference. 
CVD = cardiovascular disease; BP = blood pressure; TC = total cholesterol; LDLc = low-density 
lipoprotein; HDLc = high-density lipoprotein; pack years = (packs smoked per day)*(years as a 
smoker); DM = type 2 diabetes mellitus; RA = rheumatoid arthritis; IgM-RF = immunoglobulin M 
rheumatoid factor; ACPA = Anti–citrullinated protein antibody; DAS28 = Disease Activity Score; 
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Patients with rheumatoid arthritis (RA) are at higher risk of developing 
cardiovascular diseases (CVD). Interleukin (IL)-32 was previously shown to be 
involved in the pathogenesis of RA and might be linked to the development of 




To study the influence of a functional genetic variant IL-32 on lipid profiles and CVD 




Whole blood was obtained from individuals from the NBS cohort and RA patients 
from 2 independent cohorts. DNA was isolated and genotyped for the single 
nucleotide polymorphism (SNP) rs4786370 in IL-32. Lipid profiles were matched to 
the specific IL-32 genotypes.
Results
Genotype distribution of the IL-32 promoter SNP was similar in all three groups. 
Significantly higher levels of high-density lipoprotein cholesterol (HDLc) were 
observed in the NBS cohort and RA patients from the Nijmegen cohort homozygous 
for the C allele (p=0.0141 and p=0.0314 respectively). Moreover, the CC-genotype 
was associated with elevated low-density lipoprotein cholesterol (LDLc) and total 
cholesterol (TC) in individuals at risk for CVD (plaque positive) (p=0.0396; p=0.0363 
respectively).  
Conclusions
The rs4786370 promoter polymorphism in IL-32 is equally distributed in all cohorts. 
This genetic variant has a functional effect on the lipid profile, resulting in increased 
HDLc levels. Future studies should focus on the mechanism behind the increase in 




In patients with RA, CVD represents the leading cause of death. Various studies 
have demonstrated that besides behavioral risk factors and dyslipidemia, 
inflammation also plays a crucial role in the increased risk for CVD1. Additionally, 
inflammatory pathways in RA but also other chronic inflammatory diseases, 
including psoriasis and inflammatory arthritis, have been proposed to accelerate 
atherogenesis contributing to the increased CVD risk 2-4. These patients are 
continuously exposed to varying levels of inflammatory mediators (e.g. cytokines) 
that  may alter traditional CVD risk factors, including the lipid pattern, both at 
the concentration and composition level 5 6. Normally, a pro-atherogenic lipid 
profile consists of an increased total cholesterol (TC), low-density lipoprotein 
cholesterol (LDLc), triglycerides (TG), and a decreased high-density lipoprotein 
cholesterol (HDLc). However, in RA patients the lipid profile varies throughout 
different stages of the disease7 8. Particularly during active disease, these patients 
have low TC and LDLc levels, while their CVD risk is increased. Hence, due to the 
changeability of inflammatory  activity and anti-inflammatory medication, the 
individual lipid profiles may frequently fluctuate during the course of disease 
making it hard to draw conclusions about the impact of these changes on CVD risk 
9. Of all lipids, HDLc is the most susceptible to inflammatory changes in terms of 
both concentration as well as composition 10 11 12.  In line with this, it was previously 
shown that HDLc becomes less anti-atherogenic or even pro-atherogenic in 
RA patients with an increased inflammatory status9. Recently, IL-32 has been 
demonstrated to be an important key modulator of inflammation in RA13. In a 
previous study from our group, IL-32 was found to be highly expressed in synovial 
tissues from patients with moderate and severe rheumatoid arthritis and it was 
strongly correlated with the severity of joint inflammation. IL-32 can be induced by 
TNF and can on its own further potentiate TNF expression 14 15. Given this fact and 
the well-known roles of TNF in both RA and atherosclerosis, IL-32 was recently 
proposed to contribute to the development of atherosclerotic plaques. In 2009 
Dinarello et al described IL-32 as a critical regulator of endothelial cell function, 
possibly promoting atherosclerosis by potentiating IL-1β-induced ICAM-1 and by 
producing pro-inflammatory cytokines in these cells16. This pro-atherogenic role 
of IL-32 was further supported by a recent report, which showed enhanced IL-32 
expression in atherosclerotic arterial vessel walls17. Additionally, IL-32 was found to 
be expressed by macrophages, with highly increased expression after stimulation 
of these cells with pro-inflammatory components that were previously appointed 
to be involved in atherosclerosis (e.g. toll-like receptor (TLR) 3 agonist Poly I:C 
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and interferon-gamma (IFNγ)) 18-20.  Moreover, macrophages are known to play an 
important role in controlling cholesterol levels in  blood vessel walls as they engulf 
cholesterol, become foam cells, and take part in reverse-cholesterol transport 
(RCT) 21 22. Knowing that IL-32 expression can be highly induced in these cells upon 
inflammation, one can argue a role for IL-32 in cholesterol metabolism. Despite 
the suggested role of IL-32 in inflammation, CVD and disease progression in RA, 
studies investigating the IL-32 protein function and IL-32 gene polymorphisms 
with respect to these outcomes in RA are scarce 17. The present study aims to 
investigate the functional implications of a single nucleotide polymorphism (SNP) 
in the IL-32 gene on the lipid profile and CVD risk in RA patients.
METHODS
Patient cohorts
From the total number of participants from the NBS NIMA study, only a subgroup 
of 234 participants, from whom the IL32 promoter SNP was determined, were 
included in this study. The NBS is a population-based survey as described before23. 
Participants aged 50–70 yr were asked to visit the hospital to perform six non-
invasive measurements of atherosclerosis (NIMA) including pulse wave velocity 
(PWV), augmentation index (Aix), intima-media thickness (IMT), plaque thickness, 
ankle-brachial index (ABI) at rest and after exercise. Additionally, fasting venous 
blood samples were collected. All participants filled out a questionnaire about their 
previous history of vascular disease, medication use, smoking habits, and exercise 
habits. Prevalent CVD was defined as a reported myocardial infarction (MI), transient 
ischemic attack (TIA), stroke (CVA), peripheral arterial disease (PAD), coronary 
artery bypass or angioplasty, or treated angina. The Medical Ethics Committee of 
the Radboud university medical center, Nijmegen, The Netherlands approved the 
study protocol, and all participants provided written informed consent24.
Patients with RA who fulfilled the 1987 ACR criteria and/or the 2010 ACR/EULAR 
classification criteria for RA were recruited from the Radboudumc in Nijmegen, 
The Netherlands. These patients underwent a screening program of their CVD 
risk factors between July 2011 and August 2012. Disease-related parameters, lipid 
profile and history of cardiovascular events were registered (Table 1).  In addition, 
the Nijmegen inception cohort database was checked for patients who  had already 
been screened previously. The Nijmegen inception cohort is a prospective study 
that started in 1985 which includes regular visits for disease related parameters and 
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blood samples in patients with RA. Eventually, 297 patients have been identified as 
participants of both the inception cohort and the CVD screening program. These 
patients were included in this study. The stored blood samples of the inception 
cohort were used for the determination of the SNP in the IL-32 gene.
The CARdiovascular research and RhEumatoid arthritis (CARRÉ) study is an 
ongoing prospective cohort investigating cardiovascular (CV) disease and CV risk 
factors in 353 patients with RA. In 2000, a random sample was drawn of patients 
registered at the Jan van Breemen Institute (now Reade) in Amsterdam, The 
Netherlands. Patients were eligible if they fulfilled the 1987 American College of 
Rheumatology (ACR) classification criteria, were diagnosed with RA between 1989 
and 2001 and were aged 50 to 75 years. Patient enrollment was between 2001 and 
2002 with follow up visits in 2004-2005 and 2010-2011. CV endpoints were defined 
as a verified medical history of coronary, cerebral or peripheral arterial disease. 
(Table 1)
Table 1. Baseline characteristics of the cohorts
Cohort NBS NIMA (NN) Radboudumc (RA1) Reade (RA2)
N 234 297 353
Age, years 61 ± 6 60 ± 12 63 ± 8
Female, no (%) 120 (51.34) 155 (52.2) 232 (65.7)
Disease duration, years n.a. 9 (3-17) 7 (4 – 10)
Rheumatoid factor positive, no (%) n.a. 202 (68.2) 256 (72.5)
Anti-citrullinated protein antibodies 
positive, no. (%)
n.a. 160 (53.9) 187 (54.5)
History of CVD, no (%) 57 (24.4) 63 (22.6) 51 (14.4)
DAS28 n.a. 2.97 (1.18) 3.90 (1.35)
Diabetes, no (%) 14 (6.0) 18 (6.1) 17 (4.8)
Systolic blood pressure, mmHg 130 ± 17 132 ± 17 142 ± 20
Diastolic blood pressure, mmHg 78 ± 10 77 ± 10 81 ± 9
Total cholesterol, mmol/L 5.92 ± 1.11 5.2 ± 1.13 5.77 ± 1.12
HDL cholesterol, mmol/L 1.39 ± 0.40 1.3 ± 0.34 1.46 ± 0.48
LDL cholesterol, mmol/L 3.89 ± 0.98 3.1 ± 1.07 3.69 ± 1.03
Triglycerides, mmol/L 1.29 (0.91-1.81) 1.53 (1.09-2.14) 1.32 ( 3.04 – 4.42)
Values are presented as mean ± SD, median (IQR) or numbers (percentages). 
CVD: cardiovascular disease, DAS28: disease activity score 28, HDL: high density 
lipoprotein; LDL: low-density lipoprotein. 
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DNA isolation and Taqman genotyping  
Blood was obtained from 297 RA patients from the Radboudumc (RA1), 353 RA 
patients of the Jan van Breemen Institute (Reade)(RA2) and 234 individuals 
from the NBS NIMA study (NN). Genomic DNA was extracted from leukocytes 
in peripheral venous blood as previously described25. The genetic variant in the 
IL32 promoter (rs4786370) polymorphism was determined using the TaqMan SNP 
assay C_27972515_20, (Thermofisher, Foster City, CA, USA). The TaqMan qPCR 
assays were performed on the AB StepOnePlus polymerase chain reaction system 
(Applied Biosystems). Negative controls were included in the assay. No duplicates 
were used.
Statistical analysis  
Normality was tested using the D’Agostino and Pearson omnibus normality test. 
Continuous variables are presented as mean and standard deviation (SD) or as median 
followed by the interquartile range (IQR). Categorical variables are presented as 
number followed by percentage. The differences between allele frequency and lipid 
concentrations measured in RA patients and individuals from the NN cohort were 
analyzed using the Mann-Whitney test. Chi-square test was used to test for differences 
between categorical variables. A p-value less than 0.05 was considered statistically 
significant (*p<0.05 and **p<0.01). Data was analyzed using GraphPad Prism v5.0. 
RESULTS
Genotype distribution of an IL32 promoter SNP is comparable between 
individuals from the NN cohort and RA patients  
The genotype distribution of the IL32 promoter SNP (rs4786370) (Fig. 1A) was 
compared between three different cohorts.  One cohort consisted of individuals 
from the NBS NIMA cohort (NN). The other two cohorts consisted of RA patients, 
one group of patients treated at the Radboudumc Nijmegen (RA1) and the other 
at the Reade Clinic in Amsterdam (RA2). No significant differences in genotype 
frequencies were observed between the three cohorts (Figure 1B).  
The IL32 promoter SNP affects HDLc levels in both individuals from the NN 
cohort and RA patients
We studied the concentration of HDLc in each cohort because of its importance in 
development of cardiovascular disease. As shown in figure 2, in all three cohorts 
individuals having the CC genotype show higher levels of HDLc compared to either 
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individuals with the CT and TT genotype with a significant increase in HDLc within 
the NN and RA1 cohort. Moreover, individuals carrying one C-allele show a small 
increase in HDLc levels. Concluding, the C-allele for the IL-32 promoter SNP is 
linked to an increase in HDLc levels independent of having RA.
Fig. 1. A. Location of the IL32 promoter 
SNP within the IL32 region on chromosome 
16. B. Genotype  frequencies of the IL32 
rs4786370 promoter SNP in individuals 
from the NN cohort (NN; CC:19.2%, 
CT:45.7%, TT:35%), RA patients from the 
Radboudumc Nijmegen (RA1; CC:16.1%, 
CT:51%, TT:32.9%) and RA patients 
from the Reade clinic Amsterdam (RA2; 
CC:23%, CT:47.1%, TT:29.9%). Chi-square 
analysis (IBM SPSS Statistics v.22) showed 
no significant differences in genotype 
distribution between the cohorts. 
 
Fig. 2. A HDL cholesterol levels stratified 
for the IL-32 promoter SNP (rs4786370) 
genotype in individuals  from the NN cohort 
(TT#82, CT:#107, CC:#45, NN cohort) and 
RA patients from two different cohorts 
(RA1; TT:#96, CT:#149, CC:#47 and RA2; 
TT:#104, CT:#164, CC:#80). A significant 
induction in HDL cholesterol was observed 
in both individuals from the NN cohort and 
RA patients of the RA1 cohort carrying the
C allele (NN; p=0.0141,RA1; p=0.0314 and RA2; p=0.8450). Values are expressed as means ± 
SEM. p-values are calculated using Mann-Whitney U-test, *p < 0.05 Graphpad prism v5.03.
 
 
HDLc levels are affected by the IL32 promoter SNP independent of the 
presence of plaques 
Within the NN-cohort we were able to stratify the genotype frequency 
































Chapter 4. IL-32 promoter SNP rs4786370 predisposed to modified lipoprotein profiles 
58
ultrasound (Fig. 3A-D). The percentage of individuals with the CC genotype 
seemed to be higher in the plaque negative group compared to the plaque 
positive group; 20% vs. 18% respectively although this did not reach statistical 
significance. Additionally, individuals carrying the CC or CT genotype showed 
higher HDLc levels than individuals with the TT genotype independent of 
having plaques. Nevertheless, individuals with the CT genotype and having 
a plaque showed a decrease in HDLc (CT- versus CT +: p<0.0004) (Fig.3B). 
Both LDLc and TC were not affected by the SNP in IL32 itself. However, higher 
levels of both LDLc and TC were observed in individuals who were found positive 








































































Fig. 3. A-D. Lipoproteins stratified for IL-32 promoter SNP rs4786370 and the presence or 
absence of plaques in individuals from the NN cohort. Genotype frequency, HDL cholesterol, 
LDL cholesterol and total cholesterol concentrations were determined in these individuals. 
Number of individuals CC-:25, CC+:20, CT-:61, CT+:46, TT-:37, TT+:45. Chi-square analysis 
(IBM SPSS Statistics v.22) showed no significant differences in genotype distribution 
between the groups. Values are expressed as means ± SEM. p-values are calculated using 






































































Fig. 4. A-D. Lipoproteins stratified for IL-32 promoter SNP rs4786370 and the presence or 
absence of an previously described CVD. Allele frequency, HDL Cholesterol, LDL Cholesterol 
and Total Cholesterol concentrations were determined in patients with RA from the RA2 
cohort (Reade center Amsterdam). Number of individuals: CC-:63(37.5%), CC+: 17(21.1%), CT-
:145(30.2%), CT+:18(, TT-:90 , TT+: 14. Chi-square analysis (IBM SPSS Statistics v.22) showed 
no significant differences in allelic distribution between the cohorts. Values are expressed 
as means ± SEM. p-values are calculated using Mann-Whitney U-test, *p < 0.05 Graphpad 
prism v5.03.
HDLc is linked to the IL32 promoter SNP and the prevalence of CVD events 
in RA patients 
CVD  is a common problem in RA and the composition of cholesterol levels plays 
a crucial role herein. To determine if the IL-32 promoter SNP was involved in 
both these parameters, genotypes and cholesterol levels were determined in RA 
patients (RA1 cohort) with versus without a history in CVD  (Fig.4A-D). No differences 
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were observed in genotype distribution between the two groups (Fig.4A). Even 
so, HDLc levels were lower in individuals with a history of CVD, reaching lowest 
concentrations in individuals with the TT genotype (Fig.4B).  In contrast, patients 
carrying the CC genotype showed the highest levels of HDLc as was also observed 
within the individuals from the NN cohort(Fig 3B). Besides, lower levels of LDLc 
and TC were observed in individuals with a history of CVD (Fig. 4C,D). This was 
completely opposite from what was found in individuals from the NN cohort as 
shown in figure 3C,D. Overall, patients with a history of CVD and carrying the TT 
genotype had lowest HDLc, LDLc and TC (Fig.4B-D). 
DISCUSSION
The major novel findings of this study are that a promoter SNP in the IL32 gene is equally 
distributed in individuals from the NN cohort as in RA patients, but at the same time 
that this SNP causes an increase in HDLc in both groups. This effect doesn’t seem 
to be influenced by disease activity, the use of medication, the presence of plaques 
or a history of CVD. In contrast, other lipid concentrations like LDLc and TC are not 
affected by the SNP but are linked with plaques or a history of CVD. This might further 
expand the knowledge about the underlying mechanisms for CVD in RA patients26-28. 
Although chronic inflammation is known to affect cholesterol concentration in the 
body resulting in lower HDLc and LDLc levels, some studies have not been able 
to show the benefit of increasing HDLc 28-32. Nevertheless, HDLc does play a role 
in lowering the risk for CVD, especially in individuals with chronic inflammatory 
diseases like RA 33 34. In RA there seems to be a tight relationship between the 
levels of HDLc, LDLc and disease activity, with lower levels during periods of active 
disease. 35-37. Even though this might speak against an increased risk for CVD, it 
is more the ratio between the levels of these different lipids (and probably their 
composition/function) that matters when assessing CVD risk. The fact that HDLc 
is decreased to a greater extent than the TC in these patients, results in a higher 
atherogenic index (the ratio between TC and HDLc) and therefore an increased 
CVD risk31 38. In addition, HDLc is less capable of exercising its anti-atherogenic 
functions if inflammation levels are still uncontrolled6. Conversely, when RA 
patients receive standard treatment including DMARDs and biological agents like 
anti-TNF therapy, cholesterol levels might increase, which correlates with the 
level of suppression of their disease activity38 39. In our study, no differences were 
observed in disease activity between genotypes concluding that the variation 
in HDLc was not caused by difference in disease activity. Nevertheless, CVD is 
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still the number one cause of death in RA, showing the importance of exploring 
how cholesterol metabolism and regulation is affected in these patients. 
IL-32 has previously been described to play a role in the pathogenesis of RA 
and additionally it has been suggested that IL-32 plays a role in atherosclerosis, 
presumably contributing to the increased CVD risk in this population. We recently 
showed that a SNP in the promoter region of the IL-32 gene seemed to be 
associated with lower basal expression of IL-32β in peripheral blood mononuclear 
cells (PBMCs) of RA patients 40. The same data showed lower pro-inflammatory 
cytokine production in PBMCs after stimulation with various compounds in patients 
bearing the CC genotype 40. Therefore, we hypothesized that this promoter SNP 
in IL-32 lowers CVD risk. To our knowledge, this is the first study demonstrating 
that a functional SNP in IL-32 is linked to an increase in HDLc in RA patients and 
individuals from the NN cohort, suggesting IL-32 by itself can affect cholesterol 
metabolism. Individuals carrying the CT genotype already showed higher HDLc 
levels compared to individuals bearing the TT genotype, while having the CC 
genotype results in even higher HDLc. This  suggests that having one C-allele might 
already affect IL-32 expression in a way that results in higher HDL cholesterol. 
The increased HDLc concentrations in individuals bearing the C-allele might be 
due to lower levels of TNFα, which is known to suppress cholesterol synthesis 41. 
Another possible explanation could be that expression of a specific IL-32 isoform 
affects intracellular pathways resulting in for example higher cholesterol efflux 
or increased level of apoA-I (the main protein component of HDLc). The SNP 
however only seems to affect HDLc since no observation was made in individuals 
from the NN cohort or RA patients linking the SNP to lower or higher LDLc or TC. 
In our study, RA patients with a history of CVD had lower LDLc and TC compared 
to patients without a history of CVD and also lower levels than individuals from the 
NN cohort. This might be explained by the fact that these RA patients probably 
received statins after going through an event. 
Our study has several limitations. Most of them are related to the difficulties of 
comparing the three heterogeneous cohorts. Various measurements like blood 
pressure or underlying disease (like diabetes) were not notified for all patients or 
individuals within the cohorts making it impossible to correct for all these factors. 
When taken together, we suggest a novel role for IL-32 in which a promoter SNP 
causes an increase in HDLc levels in individuals from the NN cohort and RA patients. 
This might have functional effects leading to a lower prevalence of carotid artery 
plaques. This has not been investigated in the present study, but should be taken 
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into account in future investigations. Our results lead to the assumption that IL-
32 is a previously unrecognized cytokine involved in the process of inflammation 
and cholesterol metabolism. However, currently we are still investigating the exact 
mechanism behind the role of IL-32 in cholesterol metabolism regulation. 
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To investigate the effects of etanercept (ETN) on lipid metabolism and other known 
cardiovascular disease (CVD) risk factors in patients with psoriatic arthritis (PsA).
Methods
In an observational cohort of 118 consecutive patients with PsA, CVD risk factors 
were assessed over 5 years. Mixed-model analyses were performed to investigate 
the effects of ETN therapy on CVD risk factors over time.
Results
Disease Activity Score in 28 joints, C-reactive protein (CRP), and erythrocyte 
sedimentation rate decreased during therapy with ETN. There was an increase in 
total cholesterol (TC), high-density lipoprotein cholesterol (HDLc), and low-density 
lipoprotein cholesterol. The TC/HDLc ratio remained unaltered. The apolipoprotein 
B to apolipoprotein A-I (apoB/apoA-I) ratio decreased significantly. An increase in 
CRP was associated with an increase in the apoB/apoA1 ratio.
Conclusion
Serum lipid concentrations showed small changes over a 5-year period of ETN 
therapyand were inversely associated with inflammatory markers. Other CVD risk 
factors remained stable.The apoB/apoA1 ratio decreased over time and an increase 
in disease activity was associated with an increase in this ratio. However, this 
modest lipid modulation cannot explain the observed beneficial CV effects of ETN, 
and ETN likely exerts those effects through inflammation-related mechanisms.
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INTRODUCTION
Psoriatic arthritis (PsA) is an inflammatory joint disorder (IJD) that occurs in 
approximately 14 to 30 percent of patients who are affected by the skin condition 
psoriasis. (1;2) In the last decade, severe psoriasis, but also rheumatic diseases 
such as rheumatoid arthritis (RA), have been associated with an increased risk of 
developing cardiovascular disease (CVD).(3) There is accumulating evidence that 
PsA should also be considered a disease that is accompanied by a heightened CVD 
risk (4;5). However, literature about the underlying mechanisms that generate 
this increased risk is scarce. In all inflammatory arthropathies, including PsA, 
accelerated atherosclerosis is observed as a consequence of inflammatory 
mediators that also play an important role in the development and progression of 
these disorders, such as tumor necrosis factor alpha (TNF-α). TNF-α is a powerful 
pro-inflammatory cytokine that induces inflammation in skin and joints, but also 
in vascular endothelium, by which it directly influences vascular morphology.
(6) Additionally, TNF-α is known to modify traditional risk factors for CVD, such 
as the lipid metabolism, insulin resistance and body weight, presumably further 
increasing CVD risk.(7) Indeed, an increased prevalence of lipid disorders, 
hypertension and obesity have been reported in both psoriasis (8) and PsA. (3;9;10) 
Yet, hyperlipidemia, an important and modifiable CVD risk factor, is rarely observed 
in its ‘classic’ form in IJD (11). Generally, inflammation induces a decrease in all serum 
lipids and this is usually reversed by effective anti-inflammatory therapy, though 
conflicting literature exists. It is suggested that other lipid measurements, such as 
apolipoprotein B (apo B) and the ratio between apolipoprotein B and apolipoprotein 
A-I (apo B/apo A1 ratio) might be better predictors of CVD risk in these patients, 
as conventional lipid profiles are difficult to interpret in the context of high-grade 
inflammation. (12;13) Optimal anti-inflammatory therapy is thought to reduce CVD 
risk in all IJD and this might be mediated by favorable changes in cardiovascular 
risk factors (e.g. the lipid profile). (14) However, the long-term effects of anti-
inflammatory treatment, especially of biological agents, on CVD risk and CVD risk 
factors in patients with PsA have not yet been adequately investigated. Etanercept, 
a potent inhibitor of TNF-α, has beneficial effects on CVD risk in patients with RA, 
an effect thought to be partially mediated by favourable effects on the lipid profile.
(15) For PsA, literature on the association between disease activity and lipid levels 
is limited, although it is assumed that lipids are also modified by inflammation in 
PsA. (16) Thus far, long-term effects of etanercept on lipid levels and other CVD risk 
factors in PsA are unknown. Therefore, we investigated the effects of etanercept 
therapy on cardiovascular risk factors, with special focus on lipid profiles, in a 
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cohort of patients with PsA with extended follow up.
METHODS
Study population
118 consecutive patients who were diagnosed with PsA and scheduled to receive 
their first ever prescription of etanercept were recruited for an observational 
cohort at the department of Rheumatology in the Jan van Breemen Institute in 
Amsterdam between April 2004 and February 2014. The diagnosis of PsA was made 
by a rheumatologist. All patients started etanercept according to the consensus 
statement on initiation of treatment with biologicals . Treatment was with 
subcutaneous administration of etanercept alone, either 50 mg once a week or 25 
mg twice a week, or with concomitant methotrexate and/or prednisone. The study 
was conducted in compliance with the declaration of Helsinki and approved by the 
local Medical Ethics Committee of Slotervaart Hospital, approval number P0538 
was provided. Written informed consent was obtained from all patients.
Study design
Patients visited the Rheumatology outpatient clinic at the Jan van Breemen 
Institute for study assessments at baseline, 1, 3, 6 and 12 months and every 
following year up to 5 years of etanercept therapy. Disease activity was measured 
with the Disease Activity Score (DAS28), the Psoriasis Area and Severity Index 
(PASI), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Prior 
and current medication use, systolic and diastolic blood pressure and body mass 
index (BMI = weight / height2, in kg/m2) were recorded at each visit. Triglycerides 
(TG) and total cholesterol (TC) were assessed using an enzymatic colorimetric test. 
High density lipoprotein cholesterol (HDLc) was measured using polyethylene glycol 
(PEG) modified enzymes. Low density lipoprotein cholesterol (LDLc) was calculated 
using the Friedewald formula when triglycerides were lower than 4.5 mmol/l. TC/
HDLc ratios were calculated. Apolipoprotein A1 (apo A) and apolipoprotein B (apo 
B) were measured in a subpopulation of 81 patients with an immunoturbidimetric 
assay. All blood samples were determined batch wise. 
Statistical analysis
Data are presented as mean ± standard deviation (SD) in case of normal distribution 
and otherwise as median and interquartile range (IQR) or numbers and percentages. 
Log transformations were done if necessary. Mixed models analyses were 
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performed to assess the changes in CV risk factors over time and their relation to 
disease activity parameters such as DAS28, CRP and ESR, because this method is 
designed for analyzing cohort data with missing values. The unstructured random 
covariance type was used. Patients were only included in the analysis if study 
assessments were performed at baseline and at least at one other visit during follow 
up. The univariate models were adjusted for potential confounders age, gender, 
disease duration, concomitant MTX, prednisone, NSAIDs, antihypertensives and 
statin use. A P-value less than 0.05 was considered statistically significant. All data 
were analyzed with SPSS version 20.0. 
RESULTS
The study population consisted of 118 patients with a mean age of 47 ± 13 years 
and a nearly equal proportion of men (n=58) and women (n=60). The baseline 
characteristics are presented in table 1. Patients had a median psoriasis duration 
of 13 (5 – 22) years and a median arthritis duration of 6 (2 – 13) years. 12 patients had 
previously been treated with adalimumab and 1 with infliximab. 53 patients were 
using methotrexate (MTX) and 9 patients were using prednisone concomitantly 
with etanercept. The median duration of etanercept treatment was 4 (2 – 5) years.
Table 1. Baseline characteristics
n=118
Demographics
   Age, years 47 ± 13
   Female, no. (%) 60 (50.8)
PsA related factors
   Psoriasis duration, years 13 (5 – 22)
   Arthritis duration, years 6 (2 – 13)
   Psoriasis Area Severity Index 0 (0-2)
   Disease Assessment Score 28 4.36 ± 1.39
   Swollen joint count, no. 5 (2 – 10)
   Tender joint count, no. 7 (3 – 15)
   ESR, mm/h 16 (6 – 28)
   CRP, mg/L 6 (2 – 14)
   VAS disease activity 59 ± 24
   Health assessment questionnaire 1.0 (0.5 – 1.6) 
Antirheumatic agents 
table continues
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n=118
   Previous biologics, no (%)
   Concomitant methotrexate use, no (%)
   Methotrexate dose, mg/wk
   Concomitant Prednisone use, no. (%)
   Prednisone dose, mg/day
   Other DMARDs*, no (%)









   Current smoking, no. (%) 15 (12.7)
   Body mass index, kg/m2 27 ± 6
     Obesity, no. (%) 67 (56.8)
   Systolic blood pressure, mmHg 130 ± 22
   Diastolic blood pressure, mmHg 81 ± 10
     Hypertension, no. (%) 47 (39.8)
   Diabetes mellitus, no (%) 8 (6.8)
   Antihypertensive use, no (%) 28 (23.7)
   Statin use, no. (%) 11 (9.3)
   Creatinine, umol/L 75 ± 18
Lipid profile
   Total cholesterol, mmol/L 5.31 ± 1.24
   HDL cholesterol, mmol/L 1.43 ± 0.43
   LDL cholesterol, mmol/L 3.21 ± 1.05
     LDL ≥ 2.5, no. (%)* 88 (74.6)
   Triglycerides, mmol/L 1.29 (0.85 – 1.87)
   Total cholesterol/HDLc ratio 3.99 ± 1.37
   Apolipoprotein A1, g/L** 1.55 ± 0.42
   Apolipoprotein B, g/L** 0.89 ± 0.27
   ApoB/Apo A1 ratio** 0.6 ± 0.2
Values are presented as mean ± SD, median (IQR) or numbers (percentages). VAS= visual 
analogue scale, NSAIDs= nonsteroidal anti-inflammatory drugs, HDL= high density lipoprotein, 
LDL = low density lipoprotein.*sulfasalazine, hydroxychloroquine, leflunomide, *dyslipidemia, 
**Apolipoproteins were only available for a subgroup of 81 patients. 
Changes in inflammatory parameters
Study assessments were performed at baseline, 4, 16, 28, 52, 104, 156, 208 and 260 
weeks. ESR, CRP and DAS28 decreased significantly over time, with the greatest 
decrease in the first month after the start of etanercept treatment (figure 1). 
DAS28 remained high in patients who discontinued therapy after 28 (3.13±1.65 vs. 
1.98±1.08; p=0.003) and 52 weeks (2.86±1.45 vs. 1.62±0.94; p=0.001). CRP and ESR 
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were significantly elevated in the patients who discontinued therapy after 28 (ESR 
9 (3-30) vs. 4 (2-8);p=0.028 and CRP 2 (1-12) vs. 2 (1-3); p=0.049) and 52 weeks (ESR 
19 (5-39) vs. 4 (2-7); p=0.009 and CRP 5 (2-10) vs 1(1-2); p=0.003). In the mixed models 
analysis patients who discontinued therapy had higher DAS28 in comparison to 
patients who continued etanercept treatment over 5 years (RC 0.56 95%CI 0.12-
0.99; p=0.013). The PASI did not differ between these patients (data not shown). 
The reasons for discontinuing therapy were remission (n=8), failure (n=11), adverse 
events (n=10), migration or non-response (n=9), pregnancy wish (n=1), and other 
unknown reasons (n=3). 
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Figure 1. Etanercept therapy status of the PsA cohort patients.
Changes in CVD risk factors over time during etanercept therapy
At baseline 39.8% of the patients had hypertension, 74.6% had dyslipidemia and 
56.8% was overweight. TC/HDLc ratio was above 3.5 in 56.4% of the patients and 
6.8% had diabetes.
The mixed models analysis showed a significant increase in TC, HDLc and LDLc 
over 5 years after correction for age, gender, disease duration, concomitant MTX, 
prednisone and statin use. Apo A1 and Apo B measurements were available in a 
subpopulation of 81 patients. The ApoB/ApoA1 ratio decreased significantly over 
5 years, while the TC/HDLc-ratio remained stable (table 2). Blood pressure, BMI, 
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creatinine, and triglycerides remained stable over the years (table 2). The mean 
lipid levels per visit are shown in figure 2.
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Figure 2. Disease activity parameters. 
CRP= C-reactive protein, ESR= erythrocyte sedimentation rate, DAS28= disease assessment 
score 28. CRP and ESR are presented as median (IQR), DAS28 is presented as mean ± SD.
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Table 2. Mixed models analysis of changes in CVD related factors over 5 years
Mean RC 95% CI P-value
Systolic blood pressure 130 ± 20 -0.001 -0.02 – 0.02 0.92
Diastolic blood pressure 81 ± 11 0.002 -0.01 – 0.01 0.66
BMI 27 ± 5 0.002 -0.0001 – 0.004 0.07
Creatinine 75 ± 17 -0.003 -0.01 – 0.01 0.55
Total cholesterol 5.38 ± 1.12 0.0008 0.0001 – 0.001 0.03
    Adjusted* 0.0008 -0.0001– 0.002 0.02
HDLc 1.34 ± 0.45 0.0005 0.0001 – 0.001 <0.01
    Adjusted* 0.0005 0.0002 – 0.001 <0.01
LDLc 3.19 ± 0.98 0.0008 -0.0001 – 0.002 0.03
    Adjusted* 0.0009 -0.0001 – 0.002 0.02
Triglycerides 1.37 ( 0.96 – 2.00 -0.00003 -0.0005 – 0.0005 0.99
TC/HDLc-ratio 4.01 ± 1.30 0.0006 -0.0006 – 0.002 0.31
Apo A1^ 1.59 ± 0.34 0.00001 -0.0005 – 0.0005 0.98
Apo B^ 0.89 ± 0.24 -0.0001 -0.0004 – 0.0001 0.34
ApoB/apoA1 ratio^ 0.58 ± 0.20 -0.0002 -0.0005 – 0.00001 0.06
    Adjusted* -0.0003 -0.0005 - -0.00005 0.02
BMI=body mass index, HDLc= high density lipoprotein cholesterol, LDLc= low density lipoprotein 
cholesterol, TC/HDLc- ratio = total cholesterol to high density lipoprotein cholesterol ratio, 
Apo A1= apolipoprotein A1, Apo B = apolipoprotein B, ApoB/ApoA1 ratio = apolipoprotein B to 
apolipoprotein A1 ratio.
*adjusted for age, gender, disease duration, concomitant MTX, prednisone and statin use.
^subanalysis of 81 patients at baseline with apo a1 and apo b measurements available.
Relationship between CVD risk factors and disease activity
In the mixed models analyses changes in DAS28 were associated with changes in 
diastolic blood pressure, TC, HDLc and triglycerides (table 3). One point increase in 
DAS28 was associated with an increase in diastolic blood pressure, a decrease in 
TC and triglycerides. This association was still significant after adjustment for age, 
gender, disease duration and concomitant medication use (table 3).  There was a 
trend for an increased apo B/ apo A1 ratio with one point increase in DAS28 (p=0.057). 
A point increase in DAS28 was associated with an increase in HDLc. However, this 
was not significant after correction for above mentioned variables. The TC/HDLc 
ratio did not change significantly with changes in DAS28. When patients were split 
into responders vs. nonresponders, patients with a DAS28 above 2.6 as opposed to 
patients with a DAS28 under 2.6 had lower TC and triglycerides, while the HDLc was 
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increased (table 4). An increase in CRP was associated with a decrease in TC (RC 
-0.09, 95%CI -0.16 – -0.02, P= 0.02) and an increase in the apo B/Apo A1 ratio (RC 
0.03 95%CI 0.004 – 0.05, P=0.02). There was a trend for a decrease in triglycerides 
(RC-0.04, 95%CI -0.08 – 0.003, P=0.07) and in apo A1 (RC -0.05, 95%CI -0.09 – 0.01, 
P= 0.077) after adjustment for above mentioned confounders.
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Figure 3.  Changes in lipid profile over a 5-year period. Values are presented as means ± SD.
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Figure 4.  Changes in apolipoproteins over a 5-year period. Values are presented as means 
± SD.
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Table 3. Association between DAS28 and CVD related factors over 5 years
Mean RC 95% CI P-value
Systolic blood pressure 130 ± 20 0.43 -0.41 – 1.28 0.31
Diastolic blood pressure 81 ± 11 0.64 0.12 – 1.17 0.02
     Adjusted* 0.56 0.03 – 1.09 0.04
BMI 27 ± 5 -0.001 -0.099 – 0.097 0.98
Creatinine 75 ± 17 -0.18 -0.76 – 0.39 0.53
Total cholesterol 5.38 ± 1.12 -0.05 -0.09 – -0.007 0.02
    Adjusted* -0.05 -0.09– -0.01 0.02
HDLc 1.34 ± 0.45 0.04 0.01 – 0.06 0.007
    Adjusted* 0.03 0.000001 – 0.05 0.05
LDLc 3.19 ± 0.98 -0.02 -0.06 – 0.03 0.47
Triglycerides# 1.37 ( 0.96 – 2.00) -0.03 -0.05 – -0.01 0.006
   Adjusted* -0.03 -0.06 – -0.01 0.008
TC/HDLc-ratio 4.01 ± 1.30 -0.04 -0.11 – 0.02 0.21
Apo A1^ 1.59 ± 0.34 -0.0008 -0.03 – 0.03 0.96
Apo B^ 0.89 ± 0.24 0.009 -0.008 – 0.03 0.29
ApoB/apoA1 ratio^ 0.58 ± 0.20 0.01 -0.003 – 0.03 0.11
    Adjusted* 0.014 -0.0004 – 0.03 0.057
BMI=body mass index, HDLc= high density lipoprotein cholesterol, LDLc= low density lipoprotein 
cholesterol, TC/HDLc- ratio = total cholesterol to high density lipoprotein cholesterol ratio, 
Apo A1= apolipoprotein A1, Apo B = apolipoprotein B, ApoB/ApoA1 ratio = apolipoprotein B to 
apolipoprotein A1 ratio.
^subanalysis of 81 patients at baseline with apo a1 and apo b measurements available.
*adjusted for age, gender, disease duration, concomitant MTX, prednisone, nsaids, 
antihypertensives and statin use.
#log transformed
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Table 4. CV risk factors in DAS28>2.6 vs. DAS28<2.6 over 5 years
Responder Nonresponder RC 95% CI P-value
Systolic blood pressure 128 ± 19 133 ± 20 2.01 -0.65 – 4.67 0.14
Diastolic blood pressure 80 ± 10 82 ± 12 1.27 -0.37 – 2.92 0.13
BMI 25.9 ± 3.8 28.7 ± 5.8 -0.27 -0.55 – 0.004 0.05
Creatinine 76 ± 14 74 ± 21 -0.80 -2.26 – 0.66 0.28
Total cholesterol 5.45 ± 1.02 5.29 ± 1.25 -0.16 -0.29 – -0.02 0.03
    Adjusted* -0.017 -0.31– -0.03 0.02
HDLc 1.31 ± 0.45 1.38 ± 0.45 0.11 0.04 – 0.18 0.004
    Adjusted* 0.08 0.009 – 0.16 0.03
LDLc 3.23 ± 0.92 3.15 ± 1.07 -0.06 -0.20 – 0.07 0.35
Triglycerides# 1.37 (0.99 – 2.04) 1.38 (0.95 – 1.90) -0.09 -0.16 – -0.01 0.02
   Adjusted* -0.09 -0.16 – -0.01 0.02
TC/HDLc-ratio 4.01 ± 1.26 4.03 ± 1.34 -0.08 -0.27 – 0.11 0.41
Apo A1^ 1.57 ± 0.25 1.60 ± 0.41 -0.01 -0.12 – 0.09 0.81
Apo B^ 0.86 ± 0.21 0.90 ± 0.26 -0.0002 -0.05 – 0.05 0.99
ApoB/apoA1 ratio^ 0.57 ± 0.18 0.59 ± 0.21 0.03 -0.02– 0.07 0.21
BMI=body mass index, HDLc= high density lipoprotein cholesterol, LDLc= low density lipoprotein 
cholesterol, TC/HDLc- ratio = total cholesterol to high density lipoprotein cholesterol ratio, 
Apo A1= apolipoprotein A1, Apo B = apolipoprotein B, ApoB/ApoA1 ratio = apolipoprotein B to 
apolipoprotein A1 ratio.
*adjusted for age, gender, disease duration, concomitant MTX, prednisone, antihypertensives 
and statin use.
^subanalysis of 81 patients at baseline with apo a1 and apo b measurements available.
#log transformed
DISCUSSION
Etanercept therapy effectively reduced DAS28, CRP and ESR, as markers of disease 
activity, in patients with PsA, with the greatest reduction of disease activity at six 
months. This reduction persisted until five years of therapy in those who continued 
treatment. At baseline a substantial proportion of the patients had hypertension 
(39.8%), dyslipidemia (74.6%) and was overweight (56.8%). In addition, 56.4% of the 
patients had an elevated TC/HDLc ratio and 6.8% had diabetes. This is consistent 
with previous reports of an increased prevalence of traditional CVD risk factors 
in PsA patients.(3;9) Interestingly, the majority of patients showed nearly normal 
TC, HDLc and TG values at baseline. Over a five year period of etanercept therapy, 
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patients with PsA showed a significant increase in TC, HDLc and LDLc. Similarly 
as in RA, where it has been reported that during times of active inflammation, 
LDLc and HDLc decrease, while anti-inflammatory treatment, for example with 
TNF inhibitors, can reverse this. There is a non-linear relationship between lipid 
levels and CVD risk in inflammatory joint disorders (most data is available for RA). A 
decrease in lipid levels (i.e. total cholesterol, LDL cholesterol and triglycerides), is 
often seen in patients with active inflammation, while their CVD risk is increased. 
During treatment with anti-inflammatory agents lipid levels increase in these 
patients, which is considered to be a normalization of lipid levels. In this study, 
we demonstrated that this phenomenon also holds true for PsA, i.e. treatment 
with etanercept increases lipid levels. This increase in lipids should probably be 
considered as a normalization of serum lipid levels and a reflection of effective 
anti-inflammatory therapy, rather than an adverse effect of etanercept. To avoid 
misinterpretation of cardiovascular risk status in these patients, measurement 
of lipid levels for the purpose of cardiovascular risk estimation should preferably 
be performed when disease activity is stable or in remission. The other CVD risk 
factors, i.e. blood pressure, BMI, creatinine, and TG remained stable over the 
years, although there was a trend for an increase in BMI in these patients (p=0.07). 
Increases in BMI with TNFi treatment has been described previously in patients 
with psoriasis (16-18) and PsA.(18) Furthermore, the TC/HDLc-ratio remained stable 
over 5 years, which is to be expected as these lipid values generally change in the 
same direction during inflammation and suppression of inflammation with therapy.
(17) Normally, this would indicate that the CVD risk remains stable over 5 years. 
However, there was a significant decrease in the apoB/apoA1 ratio over time, which 
could reflect a decrease in CVD risk. A previous study showed that the ApoB/ApoA1 
ratio is associated with an increased risk of fatal myocardial infarction in men 
and in women (RR 1.23, 95%CI 1.18-1.27 and 1.38, 95%CI 1.25-1.52 respectively).(18) 
Intriguingly,  elevated disease activity markers, i.e. DAS28 and CRP, were associated 
with an unfavorable lipid profile, i.e. lower TC and triglycerides but an increase in the 
apo B/apo A1 ratio (RC 0.03 95%CI 0.004 – 0.05), a possible reflection of an increase 
in CVD risk. Also, there was a trend for a decrease in apo A1, the cardio protective 
component of HDLc, with one point increase in CRP. In line with this, over time an 
increase in DAS28 was associated with a small increase in diastolic blood pressure 
(0.56 mmHg  per point increase in DAS28)  and there was a trend for an increased 
HDLc and apoB/apoA1 ratio per point increase in DAS28 (p=0.057). This might 
seem surprising, as HDLc is known as cardio protective and most studies report 
a decrease in HDLc during inflammation, although these studies have focused on 
RA and not on PsA. These ‘conflicting’ results may indicate that a raise in HDLc 
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does not necessarily translate into a favorable lipid and CVD risk profile in patients 
with high disease activity, as HDL composition rather than its levels determine its 
function.(19) 
HDLc which is normally considered anti-atherogenic, could change into a pro-
atherogenic molecule due to modification of HDLc subcomponents under 
inflammatory conditions. In our study, the decrease in apo A-I (trend) and the 
increase in apoB/apoA1 ratio, with elevation of inflammatory markers, suggest a 
change in the HDLc molecule to a more pro-atherogenic HDLc under high-grade 
inflammation. Thus, we consider the higher TC and TG in patients with low DAS28 
scores in this study a normalization of serum lipid levels and a reflection of effective 
anti-inflammatory therapy. Conversely, the patients with high DAS28 who had lower 
total cholesterol and triglycerides, and higher HDL cholesterol are considered 
to have a worse CVD risk profile, also in accordance to existing literature on this 
subject. 
Several limitations should be considered. The changes in lipid levels were small 
in this study and the clinical relevance of such small changes is probably limited. 
Additionally, apolipoprotein values were only available in a subpopulation of 
patients. Therefore, mixed models was used as it is designed to analyse this type 
of data. However, we expect that these findings will be even more significant in 
a larger group of patients, as we have already found significant differences in 
apolipoproteins in this small group of patients with PsA. 
Nevertheless, our study demonstrates stable CVD risk factors, especially a stable 
lipid profile in a heterogeneous population of patients with PsA over a five year 
period of etanercept therapy. To our knowledge, no other study has described 
changes in CVD risk factors over an extended period of time in patients with PsA 
receiving TNFi therapy, although a beneficial effect of TNFi on surrogate markers 
of atherosclerosis (i.e. carotid intima media thickness) in PsA has been reported.
(20) Furthermore, significant changes in apoB/apoA1 ratio, BMI and diastolic blood 
pressure were found over time during etanercept therapy, reflecting a possible 
beneficial effect on lipid subcomponents, blood pressure, body composition, and 
consequently CVD risk in these patients. However, these changes were only small 
and require further study. Modulation of lipids and other known CVD risk factors 
probably only partially explains the favourable effects of anti-TNF therapy on CVD 
risk. Hence, the presumed beneficial effects of TNFi on CVD risk in PsA appears to 
be mediated by other mechanisms, likely related to inflammation. 
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Cardiovascular (CV) disease risk is increased in rheumatoid arthritis (RA). However, 
long- term follow-up studies investigating this risk are scarce.
Methods
CARRÉ is a prospective cohort study investigating CV disease and its risk factors 
in 353 patients with longstanding RA. CV endpoints were assessed at baseline, 
3, 10 and 15 years after the start of the study and are compared to a reference 
cohort(n=2540) including a large number of patients with type 2 diabetes(DM).
Results
95 RA patients developed a CV event during 2973 person-years, resulting in an 
incidence rate of 3.20 per 100 person-years. 257 CV events were reported in the 
reference cohort during 18874 person-years, resulting in an incidence rate of 1.36 
per 100 person-years. Age and sex adjusted hazard rates(HR) for CV events were 
increased for RA(HR 2.07, 95%CI 1.57–2.72, P<0.01) and DM (HR 1.51, 95%CI 1.02–
2.22, P=0.04) compared to the non-diabetic participants. HR was still increased 
in RA (HR 1.82, 95%CI 1.32–2.50, P<0.01) after additional adjustment for CV risk 
factors. Patients with both RA and DM or insulin resistance had the highest HR for 
developing CV disease (2.21, 95%CI 1.01–4.80, P=0.046 and 2.67, 95%CI 1.30–5.46, 
P<0.01, respectively).
Conclusion
The incidence rate of CV events in established RA was more than double that of 
the general population. RA patients have an even higher risk of CV disease than 
patients with DM. This risk remained after adjustment for traditional CV risk factors 
suggesting that systemic inflammation is an independent contributor to CV risk.
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INTRODUCTION
Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) morbidity 
and premature death of CV origin, when compared to the general population.(1) 
Several underlying mechanisms are suggested. Traditional CV risk factors, including 
hypertension, dyslipidaemia, smoking, type 2 diabetes, a sedentary lifestyle and 
obesity, are associated with the development of CV disease in RA, similar to the 
general population.(1) RA is characterized by chronic systemic inflammation (i.e., 
not limited to the joints), which is thought to be another major contributor to CV 
disease development in these patients.(2-4) Systemic inflammation appears to 
increase CV risk independently and beyond traditional CV risk factors, while it 
also potentially alters existing CV risk factors in these patients (3;5;6). A recent 
meta-analysis of 14 observational cohort studies showed an overall increased CV 
risk of about 50% in patients with RA, compared to non-RA participants.(7) Other 
studies report standardized mortality ratios (SMRs) as high as 2.7 compared with 
the general population, (8;9) SMRs that appear to be constant over 50 years,(10) 
although this has been challenged by a study reporting decreasing mortality in the 
last decade.(11) However, study results are heterogeneous, and most studies have 
a follow up shorter than 10 years. In 2009, our group also reported an increased CV 
risk in a cohort of RA patients compared with a population-based reference cohort 
over 3 years of follow up.(4) We now report on the incidence and risk of fatal and 
non-fatal CV events in this cohort over a maximum follow up period of 15 years, 
compared with a representative sample cohort of the general population focusing 
on prevalence and incidence of type 2 diabetes mellitus (DM) and its complications.
Patients and Methods
To investigate the risk of incident CV disease in participants with RA vs. DM and 
the general population, the CARRÉ study cohort and the Hoorn study cohort were 
compared. In both populations data regarding demographics, RA-related variables, 
risk factors for CV disease, and new or incident CV events after the start of the 
study, was collected. A brief description of both study cohorts is written below.
The CARRÉ study
The CARRÉ (CARdiovascular research and RhEumatoid arthritis) study was initiated 
in 2000 with the purpose of investigating CV disease and its risk factors in patients 
with longstanding RA. As previously described by van Halm et al.12, patients were 
eligible for participation if they were registered at the Jan van Breemen Institute 
(Reade since 2009) in Amsterdam, the Netherlands, fulfilled the 1987 American 
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College of Rheumatology classification criteria, were diagnosed with RA between 
1989 and 2001, and were aged between 50 and 75 years. Patient enrolment was 
done between January 2001 and January 2002. In total 353 patients with RA 
were followed prospectively for 15 years. Study assessments were performed at 
baseline, 3 years (2004 - 2005), and 10 years of follow up (2010 - 2011). Participants 
were called for a CV disease questionnaire in 2015 (15 years of follow up) to assess 
the occurrence of CV events during the study period. All reported events since the 
start of the study were confirmed with medical records.
The Hoorn study 
The Hoorn study is a Dutch cohort study of glucose metabolism and other 
cardiovascular risk factors that began in 1989 (13). The cohort and its baseline 
measurements have been described in detail previously (14). Briefly, a random 
selection of 3,553 men and women 50–75 years old was taken from the population 
register. A total of 2,540 (71.5%) agreed to participate, and after the exclusion of 
56 non-caucasian participants, the Hoorn Study population comprised 2,484 men 
and women. All Hoorn participants were subject to an extensive and repeated 
cardiovascular screening program similar to that used in our CARRÉ study. The 
local Medical Ethics Committee approved both studies (METc VUmc, Amsterdam, 
The Netherlands, 2001.198) and all participants gave their written informed consent 
at the baseline visit. An overview of the two cohorts is shown in figure 1.
Assessment of RA-related values 
At baseline, demographic data, medical history, family history, and medication 
use of all patients with RA were recorded. Additionally, the Health Assessment 
Questionnaire (HAQ) was performed and a Disease Activity Score of 28 joints 
(DAS28) was calculated. IgM-rheumatoid factor (IgM-RF), anti–citrullinated 
protein antibody (ACPA) were only assessed at baseline. C-reactive protein (CRP), 
erythrocyte sedimentation rate (ESR) and the presence of erosions in hands and 
feet with radiographs were assessed at all visits.
Assessment of traditional CV risk factors 
CV risk factors were assessed for all subjects according to identical protocols in both 
studies, as described previously (4). The assessments included smoking status, 
systolic and diastolic blood pressure (BP), body mass index (BMI, weight/height2 in 
kg/m2), waist to hip ratio and in fasting blood samples total cholesterol (TC), high 
density lipoprotein cholesterol (HDLc), low density lipoprotein cholesterol (LDLc), 
triglycerides (TG), TC/HDLc ratio, glucose, HbA1c, and creatinine. Hypertension was 
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defined as a systolic BP above 140 mmHg and/or a diastolic BP above 90 mmHg and/
or current use of antihypertensive agents. DM was assessed in both study cohorts 
according to the 1999 World Health Organization criteria.(15) Patients were grouped 
according to fasting glucose levels into normal fasting glucose <6.1 mmol/L (<110 
mg/dL), impaired fasting glucose (IFG) or insulin resistance ≥6.1 – <7.0 mmol/L (110 
– 125 mg/dL) and DM if glucose ≥ 7.0 mmol/L (≥126 mg/dL) or treated with glucose 
lowering agents.
Figure 1. Study design of the CARRÉ and Hoorn study cohorts 
CARRÉ= Cardiovascular Research and Rheumatoid Arthritis, IFG= impaired fasting glucose, 
DM= type 2 diabetes mellitus, RA= rheumatoid arthritis. 
Assessment of CV disease
Prevalent CV disease at baseline and incident fatal and non-fatal CV events at 
follow up were registered separately according to the International Statistical 
Classification of Diseases and Related Health Problems 9th revision (ICD-9 codes, 
Chapter 6. A 15 year longitudinal study
94
410.0 – 410.9, 435.9, 436, 443.9 and 798). CV disease was defined as a verified 
medical history of coronary heart disease (i.e. myocardial infarction, percutaneous 
coronary intervention, coronary angiography with significant stenosis, stent 
placement or coronary artery bypass graft), cerebral arterial disease (e.g. 
cerebrovascular accident, transient ischemic attack or carotid endarterectomy) 
or peripheral arterial disease (e.g. ankle brachial pressure index <0.50, peripheral 
arterial reconstructive surgery or limb amputation). Sudden deaths were only 
considered to be CV mortality when this was confirmed by autopsy. After study 
entry, participants were censored after the first new fatal or non-fatal CV event 
or death due to other reasons. CV events before baseline (prevalent CV disease) 
in medical records of study participants were registered separately for additional 
correction in statistical analyses, but were not used as new incident CV event cases 
for the primary outcome. The remaining patients were censored at study cessation 
time: March 1, 2015. Only the first CV event during follow up was recorded. Patients 
that were lost to follow up were censored at date of their last (event-free) follow up 
visit. In order to extract data on the occurrence of CV events of the patients lost 
to follow up, medical records were searched for the most recent medical status.
Statistical analysis
The baseline characteristics of both study cohorts were compared with parametric 
and nonparametric tests as appropriate. Incidence rates for fatal and non-fatal CV 
events were calculated per 100 person years. The risk of developing CV events 
was compared between patients with RA without DM, the non-diabetic general 
population and patients with DM but without RA by calculating hazard ratios (HR) 
with Cox proportional hazards models. These hazard models were adjusted for 
potential confounders identified at baseline and in earlier studies (4). Prevalent 
CV disease was not excluded from the analyses, except where stated otherwise. 
Figure 2 was created using the corrected group prognosis method as described by 
Ghali et al. (31) Several hazard models were made (table 3): the first model corrected 
adjusted for age and gender; the second model additionally adjusted corrected for 
systolic blood pressure, use of antihypertensive agents, total cholesterol, high-
density lipoprotein cholesterol, statin use, smoking in pack years, body mass index 
and aspirin use. The HR were first calculated for all patients. In the secondary 
analysis, patients with prevalent CV disease were excluded. Additionally, the risk of 
developing CV events in patients with both RA and type 2 DM was compared to the 
other groups of patients (table 4). All analyses were performed with the software 
package IBM SPSS statistics (version 19, Armonk, New York). A p-value of less than 
0.05 was considered as statistically significant.
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RESULTS
Baseline characteristics of both study populations
Of the 353 patients with RA at baseline, 326 patients were included in the primary 
analyses (figure 1). Their baseline characteristics as well as those from the Hoorn 
study reference cohort are shown in table 1. Of these, 27 were lost to follow up later 
on in the study due to migration, not wishing to participate due to a high burden 
or death. The median follow up duration was 11 years, with a minimum of 2 months 
and a maximum of 15 years. The majority of the RA patients was female (65%) with 
a mean age of 63 ± 7 years. The median disease duration was 7 (4 – 10) years with a 
mean DAS28 score of 3.9 ± 1.3. 236 (72%) patients were IgM-RF positive, 168 (52%) 
were ACPA positive and 263 (81%) had erosions in the hands or feet. Patients with 
RA were slightly older than the reference cohort and had more often prevalent CV 
disease (15% vs. 11%), hypertension (61% vs. 32%), a longer cumulative exposure to 
smoking, and more often used antihypertensive drugs, statins or aspirin.
Table 1. Patient characteristics of the RA population and the reference cohort at baseline
RA population (n=326) Reference cohort (n=1869)
Demographics
  Age, years 63 ± 7* 62 ± 7
  Women, no. (%) 212 (65)* 976 (52)
Cardiovascular risk factors
   Previous CVD, no. (%) 48 (15)* 198 (11)
   Hypertension, no. (%) 200 (61)* 601 (32)
   Smoking, no. (%)
        Never 71 (22)* 630 (34)
        Former smoker 159 (49)* 666 (36)
        Current smoker 96 (29)* 562 (30)
        Pack years 18 (2-38)* 12 (0-28)
Glucose status, no. (%)
        Normal fasting glucose levels 283 (87) 1501 (80)
        IFG levels 26 (8) 206 (11)
        DM 16 (5) 162 (9)
        Known/newly diagnosed DM 14/8 73/89
   Systolic BP, mmHg 142 ± 20* 135 ± 20
   Diastolic BP, mmHg 81 ± 8* 82 ± 10
   TC, mmol/L 5.79 ± 1.13* 6.63 ± 1.16
   HDLc, mmol/L 1.45 ± 0.49* 1.32 ± 0.37
   LDLc, mmol/L 3.71 ± 1.04* 4.59 ± 1.06
table continues
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RA population (n=326) Reference cohort (n=1869)
   Triglycerides, mmol/L 1.32 (0.96 – 1.84) 1.40 (1.00–1.90)
   TC/HDLc ratio 4.38 ± 1.55* 5.36 ± 1.72
   Waist/hip ratio 0.9 ± 0.1 0.9 ± 0.1
   Body mass index, kg/m2 26.7 ± 4.8 26.5 ± 3.4
Medication, no. (%)
   Antihypertensive drugs 84 (26)* 373 (20)
   Statins 37 (11)* 29 (2)
   Aspirin 54 (17)* 62 (3)
RA-related factors
   Age at RA diagnosis, years 55 ± 8 -
   Disease duration, years 7 (4 – 10) -
   IgM-RF ≥30 U/ml, no. (%) 181 (56) -
   ACPA ≥50 kU/l, no (%) 168 (52) -
   Erosion on radiographs, no. (%) 263 (81) -
   DAS28, range 0-10 3.9 ± 1.3 -
   NSAIDs, no (%) 218 (67)
   Biologic agents, no. (%) 33 (10) -
   Methotrexate, no. (%) 195 (60) -
   Prednisone, no. (%) 54 (17) -
   Sulfasalazine, no. (%) 53 (16) -
   Hydroxychloroquine, no. (%) 24 (7) -
   Leflunomide, no. (%) 27 (8) -
   Other DMARD, no. (%) 20 (6) -
Continuous variables are presented as mean ± SD or as median (IQR). Categorical and 
dichotomous variables are 
presented as numbers and/or percentages. *Significantly different from the general 
population. CVD= cardiovascular disease, BP= blood pressure, TC= total cholesterol, LDLc= 
low-density lipoprotein cholesterol, HDLc= high-density lipoprotein cholesterol, pack years= 
(packs smoked per day)*(years as a smoker), IFG= impaired fasting glucose, DM= type 2 
diabetes mellitus, RA= rheumatoid arthritis, IgM-RF= immunoglobulin M rheumatoid factor, 
ACPA= anti– citrullinated protein antibody, DAS28= Disease Activity Score, DMARD= disease-
modifying antirheumatic drug 
New CV events in RA vs. the general population
In the CARRÉ study, 95 patients developed a CV event during a median follow up 
period of 11 years (range: 2 months to 15 years) and a total follow up time of 2973 
patient years, resulting in a CV disease incidence rate of 3.20 per 100 person 
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years (table 2). In the Hoorn study, 257 participants developed a CV event during 12 
years of median follow up (range: 1 month to 12 years) and a total follow up time of 
18874 patient years, resulting in a CV disease incidence rate of 1.36 per 100 person 
years (table 2). The occurring CV event subtypes are described in supplementary 
table 1. Age and sex adjusted Cox regression analyses showed a HR of 1.93 (95%CI 
1.51 – 2.45, P<0.01) for CV events in RA (table 2). Additional adjustment for CV risk 
factors resulted in a HR of 1.89 (95%CI 1.40 – 2.46, P<0.01) (table 2). Adjustment for 
prednisone use did not affect the HR significantly (data not shown). Exclusion of 
patients with prevalent CV disease at baseline resulted in comparable HRs (table 2). 
Table 2.  Hazard ratios for new CV events in patients with RA vs. the reference population.
RA population Reference population P-value
All patients, no. 326 1869
   Total follow up, years 2973 18874
   Fatal and nonfatal CV events, no. 95 257
   Incidence per 100 person-years 3.20 1.36
 Hazard Ratio RA vs. reference cohort
  Model 1* 1.93 (1.51 – 2.45) 1.00 <0.01
  Model 2# 1.89 (1.40 – 2.46) 1.00 <0.01
Patients with prevalent CVDΔ excluded, no. 278 1746
   Total follow up, years 2627 18008
   Fatal and nonfatal CV event, no. 69 225
   Incidence per 100 person-years 2.63 1.25
 Hazard Ratio RA vs. reference cohort
   Model 1* 1.75 (1.31 – 2.32) 1.00 <0.01
   Model 2# 1.96 (1.45 – 2.66) 1.00 <0.01
*Adjusted for age and sex. #Adjusted for age, sex, systolic blood pressure, antihypertensive 
agents, total cholesterol, high-density lipoprotein cholesterol, statins, smoking in pack 
years, body mass index, diabetes mellitus, and aspirin
ΔCVD according to the International Classification of Diseases criteria. CV= cardiovascular, 
RA= rheumatoid arthritis, CVD= cardiovascular disease.
New CV event in RA and DM vs. the reference population and in RA vs. DM 
Before conducting these analyses, RA patients with an impaired fasting glucose 
(n=26) or already diagnosed with DM (n=22) were excluded from the CARRÉ study 
and patients with an impaired fasting glucose (n=206) were excluded from the Hoorn 
study. Cox regression analyses comparing incident CV events were performed with 
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the remaining participants grouped into nondiabetic RA (n=278), DM (n=162) and the 
nondiabetic reference population (n=1501, table 3). The HR was increased for RA 
(HR 2.07, 95%CI 1.57 – 2.72, P<0.01) and DM (HR 1.51, 95%CI 1.02 – 2.22, P=0.04) in the 
age and sex adjusted model (table 3, figure 2). After adjustment for CV risk factors, 
the HR (1.82, 95%CI 1.32 – 2.50,P<0.01) remained significantly increased in RA while 
it was not significant in DM (HR 1.28, 95%CI 0.85 – 1.92, P=0.25) (table 3, figure 2), 
with similar results after exclusion of patients with prevalent CV disease (table 3). 
The adjusted survival curves of the non-diabetic reference population, participants 
with DM, and nondiabetic participants with RA are shown in figure 2. In addition, a 
direct comparison between participants with RA (n=278) and participants with DM 
(n=162) showed a higher HR for CV disease in RA when compared to DM (age and 
gender adjusted HR 1.64, 95%CI 1.07 – 2.53, P=0.02). 
Table 3. New CV events in RA and DM vs. the general population
HR 95% CI P-value
All patients
  Model 1
    Nondiabetic population 1.00 Reference -
    DM 1.51 1.02 – 2.22 0.04
    Nondiabetic patients with RA 2.07 1.57 – 2.72 <0.01
  Model 2
    Nondiabetic population 1.00 Reference -
    DM 1.28 0.85 – 1.92 0.24
    Nondiabetic patients with RA 1.82 1.32 – 2.50 <0.01
Patients with prevalent CVD excluded
  Model 1
    Nondiabetic population 1.00 Reference -
    DM 1.42 0.92 – 2.21 0.12
    Nondiabetic patients with RA 1.82 1.32 – 2.50 <0.01
  Model 2
    Nondiabetic population 1.00 Reference -
    DM 1.15 0.72 – 1.84 0.56
    Nondiabetic patients with RA 1.96 1.39 – 2.78 <0.01
Model 1: Adjusted for age and sex. Model 2: Adjusted for age, sex, systolic blood pressure, 
antihypertensive agents, total cholesterol, high-density lipoprotein cholesterol, statins, 
pack years, body mass index and aspirin. RA= rheumatoid arthritis, DM= type 2 diabetes 
mellitus, HR= hazard ratio, 95% CI= 95% confidence interval, CVD= cardiovascular disease
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Figure 2. Survival curves of participants with type 2 diabetes mellitus (black) vs. the 
non-diabetic reference population (green), adjusted for age, sex (A), and traditional 
cardiovascular risk factors (B); non-diabetic participants with rheumatoid arthritis (black) 
vs. the non-diabetic reference population (green), adjusted for age, sex (C) and traditional 
cardiovascular risk factors (D). 
New CV events in subgroups of RA, insulin resistance and DM vs. the 
general population
1501), individuals with insulin resistance (IR, n= 206), individuals with DM (n= 162), 
participants with RA but without IR or DM (n=278), study participants with RA and 
IR (n=26), and participants with RA and DM (n=22 ). Compared to the non-diabetic 
general population, patients with RA and IR resp. DM had the highest risk of 
developing a CV event when the hazard model was corrected for age and gender 
followed by the other RA patients. Results were similar after additional correction 
for systolic blood pressure, antihypertensive agents, total cholesterol, HDLc, statin 
use, smoking, body mass index, aspirin use and prevalent CV disease (table 4). The 
risk of developing CV events was compared between the non-diabetic general 
population (n= 
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Table 4. New CV events in RA with IR and DM vs. the general population.
HR 95% CI P-value
All patients
Model 1
  Reference population, normal glucose tolerance









1.51 1.03 – 2.23 0.04
    + Normal glucose tolerance
    + Insulin resistance










  Model 2 
   General population, normal glucose tolerance







   DM
   RA
1.30 0.87 – 1.95 0.20
    + Normal glucose tolerance
    + Insulin resistance










Model 1: Adjusted for age and sex. Model 2: Adjusted for age, sex, systolic blood pressure, 
antihypertensive agents, total cholesterol, high-density lipoprotein cholesterol, statins, 
smoking in pack years, body mass index and aspirin. RA= rheumatoid arthritis, DM = type 2 
diabetes mellitus, HR = hazard ratio;,95% CI = 95% confidence interval, CV= cardiovascular.
DISCUSSION
In our second report on this cohort, now with a median follow up of 11 years, the 
increased risk of CV disease in RA already seen after 3 years of follow up (4) was 
confirmed, now at a level more than double that of the non-diabetic general 
population. Traditional CV risk factors, such as hypertension, smoking, older age 
and previous CV disease partially explained this increased risk. However, the Cox 
proportional hazard models adjusted for these risk factors still showed an almost 
twofold increased CV risk in participants with RA. In participants with DM, the 
increased CV risk was almost fully explained by traditional CV risk factors. In RA, 
high-grade systemic inflammation most likely amplifies CV risk, as suggested 
previously.(3-5) Recently, Curtis et al. reported the highest incidence rate of acute 
myocardial infarction in patients with RA and DM, followed by patients with DM 
only, RA only and neither RA or DM. (29) We found similar results (highest HR) for 
participants with RA and IR or DM, but in our study, participants with RA only had a 
higher CV disease risk than participants with DM only. This might be explained by 
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differences in study design and population and definitions of CV disease outcome. 
More importantly, both studies underline and establish that RA is a risk factor for 
the development of CV disease. 
I
nterestingly, although we had a low number of observations, the risk of IR or DM 
appeared additive to that of RA, suggesting that in such patients risk factors should 
be approached aggressively. In participants with RA, TC, LDLc and triglycerides 
were lower than in the non-diabetic general population, while HDLc was higher. 
In the past, several publications have described this phenomenon as the ‘lipid 
paradox’, in which above mentioned observation is not translated into a lower, but 
paradoxically into a higher CV risk in RA patients.(17-19) However, we identified an 
increased CV disease risk in RA, regardless of the effect of these lipid changes on 
this CV risk, as we adjusted for TC, HDLc and statin use in our analyses. Optimal 
treatment of RA results in a normalization of lipid levels in these patients.(20-23) 
Unfortunately, this study also demonstrates that, although patients with RA have 
an increased presence of certain known risk factors for CV disease, only a small 
proportion of RA patients is receiving appropriate treatment with antihypertensive 
agents and statins. This finding is also in line with other studies,(24-27) suggesting 
that appropriate management of lifestyle factors and CV risk factors is lacking 
in these patients. Possible explanations could be that local CV risk management 
programs are ineffective or that patients and physicians are unaware of the 
magnitude of this risk. In addition, current CV risk assessment tools are inaccurate 
and risk assessment is performed using general population algorithms (e.g. SCORE 
and Framingham Risk Score). Some risk factors, such as lipids, are influenced by 
inflammation and are not an appropriate indicator for CV risk during periods of 
active disease.(19) Therefore, CV risk algorithms that accurately predict CV risk in 
RA as well as multidisciplinary CV risk assessment and management are certainly 
of additional value. Above all, creating awareness of this increased CV risk among 
patients and clinicians is of great importance.
The major strength of our study is its long follow up duration in which the 
occurrence of both fatal and non-fatal CV events were recorded in patients with 
RA and in the general population. Our previous study had a follow up duration of 
only 3 years, with few events, resulting in limited power, but in the current study 
the long term observation and the number of events was sufficient to overcome 
this. However, the present study also has some limitations. The Hoorn study was 
conducted approximately 10 years before the CARRÉ study. The definition of 
certain diseases, their assessment, and management may have changed during 
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this period. This may have influenced our results. Additionally, CV disease incidence 
has declined over the last decades in the Netherlands which could translate into 
less incident CV disease in the patient with RA (28). However, comparing both 
groups would in this case only lead to an underestimation of the CV risk in patients 
with RA. Additionally, the Hoorn study may have included some patients with RA 
which we could not identify due to insufficient data, but this would also only result 
in an underestimation of the CV risk in RA. Another important matter is that the 
prevalence of MTX and biologic treatment at baseline is not representative of the 
current clinical practice. Treatment guidelines have changed over the last decade 
and this could have influenced the CV disease incidence in the RA population. 
However, the effect of antirheumatic treatment on CV disease risk in patients with 
RA was not the research question of this study. 
In conclusion, our study demonstrates a more than twofold higher CV risk in 
participants with RA when compared with the non-diabetic general population. 
In this study, this risk is even higher than the CV risk of patients with DM. In 
accordance with our previous study from 2009 (4), adjustment for CV risk factors 
still results in a significant residual CV disease risk for patients with RA, indicating 
that systemic inflammation is likely an independent contributor to CV risk in RA. 
This underscores that both optimal anti-inflammatory treatment of RA as well as 
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Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders 
(IJD) have increased cardiovascular disease (CVD) risk compared to the general 
population. In 2009 a EULAR taskforce recommended screening, identification 
of CVD risk factors and CVD risk management largely based on expert opinion. 
In view of substantial new evidence, an update was conducted with the aim of 
producing CVD risk management recommendations for patients with IJD that now 
incorporates an increasing evidence base. 
Objectives
To update the 2009 EULAR recommendations concerning the assessment and 
management of CVD risk in persons with IJD.
Methods
A multidisciplinary steering committee (representing 13 European countries) 
comprised 26 members including patient representatives, rheumatologists, 
cardiologists, internists, epidemiologists, a health professional and fellows. 
Systematic literature searches were performed and evidence was categorized 
according to standard guidelines. The evidence was discussed and summarised by 
the experts in the course of a consensus finding and voting process. 
Results
Three overarching principles were defined. First, there is a higher risk for CVD in RA, 
and this may also apply to AS and PsA. Second, the rheumatologist is responsible 
for CVD risk management in patients with IJD. Third, the use of NSAIDs and 
corticosteroids should be in accordance with treatment specific recommendations 
from EULAR and ASAS. Ten recommendations were defined, of which one is new, 
and six were changed compared to the 2009 recommendations. Each designated 
an appropriate evidence support level.
Conclusion
The present update extends on the evidence that CVD risk in the whole spectrum 
of IJD is increased. This underscores the need for CVD risk management in these 
patients. These recommendations are defined to provide assistance in CVD risk 
management in IJD, based on expert opinion and scientific evidence.  
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INTRODUCTION
Cardiovascular disease (CVD) risk in patients with rheumatoid arthritis (RA) and 
other inflammatory joint disorders (IJD), in particular ankylosing spondylitis (AS) 
and psoriatic arthritis (PsA), is substantially elevated compared to the general 
population. For RA, the magnitude of this excess risk appears comparable to 
that reported for patients with diabetes mellitus 1-3, necessitating aggressive and 
targeted CVD risk management. In 2009, a European League Against Rheumatism 
(EULAR) task force was convened to critically appraise existing evidence on CVD 
risk in patients with IJD. This EULAR task force formulated ten recommendations 
for the screening and identification of CVD risk factors and the implementation 
of CVD risk management in IJD (see Supplementary file 1).4 In view of substantial 
new evidence, an update of the CVD risk management recommendations was 
performed.
In general, CVD risk management involves the determination of a cardiovascular 
risk profile of an individual patient by using values including gender, age, smoking 
status, blood pressure, lipid values and diabetes mellitus status. These variables 
are used in risk prediction algorithms such as Framingham5 and the Systematic 
Coronary Risk Evaluation (SCORE)6 to calculate a 10-year risk of CVD events. When 
this CVD risk exceeds a certain value, i.e. a 10-year risk of 10% for a fatal or non-
fatal CVD event (Framingham) or a 10-year risk of 5% for fatal CVD events (SCORE), 
lifestyle changes and treatment with lipid lowering agents is recommended. In 
accordance with current CVD prevention guidelines, a healthy lifestyle should of 
course be recommended to all persons, including patients at low- and intermediate 
cardiovascular risk. Additionally, the ESC guideline on cardiovascular disease 
prevention in clinical practice also recommends CVD risk stratification for patients 
with hypertension.61 The initiation of antihypertensives depends on the grade of 
hypertension and total cardiovascular risk. Drug treatment is recommended for 
patients with grade 3 hypertension, but also grade 2 and grade 1 hypertension with 
a high CVD risk.61 Validated RA-specific CVD risk prediction models with a proven 
superiority over general population CVD risk prediction algorithms are currently 
lacking.7 Furthermore, the existing general population risk prediction models that 
aid the identification of patients who would benefit from primary prevention of CVD 
have been shown to inaccurately estimate the CVD risk in RA.7;8 Therefore, in 2009 
the EULAR task force advocated the use of a 1.5 multiplication factor for these 
risk prediction models when certain RA disease characteristics were present.4 
In addition, certain commonly used variables in existing CVD risk prediction 
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algorithms are influenced by inflammation and anti-inflammatory therapy. These 
risk factors behave differently in patients with IJD than in the general population, 
necessitating clarification and practical guidelines for rheumatologists in daily 
clinical practice. 
For this update a new EULAR task force reviewed all the previous recommendations 
from 2009 on CVD risk management in IJD. New areas were addressed, including 
the value of imaging in the routine assessment of CVD risk. 
METHODS 
Task force
With the approval of the EULAR Executive Committee, the convenor (MN) and 
methodologist (DS) who guided the task force in 2009 formed a new task force with 
the aim of reviewing and updating the 2009 EULAR recommendations for CVD risk 
management in RA and other IJD (supplementary file 1). The task force comprised 
26 members from 13 European countries, including two patient representatives, 14 
rheumatologists, two cardiologists, three internists, one health care professional 
and four fellows. The entire process was conducted in accordance with the 2014 
EULAR standardised operating procedures.9 
Literature search
The convenor (MN) started by formulating a list of potential research questions. 
These were discussed and refined during a teleconference with other members 
of the task force. Thereafter, the fellows (RA, SH, SR, MH) under guidance of 
the convenor (MN) and the methodologist (DS), compiled the search terms for a 
comprehensive systematic literature review to cover all the research questions. 
The protocol for the literature search was based on the Preferred Reporting Items 
for Systematic Reviews and Meta-Analysis (PRISMA)-statement (www.prisma-
statement.org). The Wiley/Cochrane Library, PubMed and Embase.com were 
searched from inception (by RA, SH, MH and librarians LJS and JCFK). Wiley/
Cochrane Library was searched up to 9 February 2015, PubMed up to 10 February 
2015 and Embase.com up to 13 February 2015. A single search was conducted 
embracing all aspects of the different research questions. The following search 
terms were used (including synonyms and closely related words) as index terms 
or free-text words: ‘rheumatoid arthritis’ or ‘spondyloarthritis’ and ‘cardiovascular 
disease’ and ‘cholesterol’ or ‘blood pressure’ or ‘smoking’ or ‘diabetes’ or ‘chronic 
kidney insufficiency’ or ‘sex factors’ or ‘vitamin D’ or ‘adrenal cortex hormones’ or 
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‘tumor necrosis factor’ or ‘anti-inflammatory agents’ or ‘inflammation’ or ‘carotid 
intima media’. The full search strategies for Wiley/Cochrane Library, PubMed and 
Embase.com are shown in Supplementary file 2. 
All duplicates were removed from the results of the first search (Figure 1). The 
remaining studies were screened by title and abstract by six investigators (RA, SH, 
SR, MH, DS and MN) for suitability. Titles and abstracts were eligible if the abstract 
contained clear information about the aims and objectives of the study. From this 
selection of abstracts, full text articles were assessed for eligibility by the fellows 
(RA, SH, SR, MH). References of included articles were manually scanned for other 
relevant studies. The included articles were evenly divided among the four fellows, 
based on their area of expertise. Each fellow read the full texts and distilled and 
summarized the most important results. From these results, also taking into 
account the ten 2009 recommendations, ten concept recommendations were 
derived.  
Consensus finding
The EULAR task force held a one-day meeting with all members on March 31st, 2015. 
During this meeting the ten concept recommendations were presented by the 
four fellows. All ten concept recommendations were discussed and subsequently 
adapted or dropped, and new recommendations were formulated. The principles 
guiding the consensus meeting were: 1) all of the 2009 recommendations were 
reconsidered on the basis of new evidence 2) any of the 2009 recommendations could 
be kept unchanged, be modified or be totally abandoned 3) new recommendations 
could be added. After the meeting, the updated and new recommendations were 
graded based on the methodological strength of the underlying literature and 
were categorised according to the GRADE system.21 Thereafter, the ten concept 
recommendations were sent out by e-mail for anonymous voting. All members 
of the task force were asked to indicate their level of agreement for each 
recommendation on a 0–10 scale (0, no agreement at all; 10, full agreement). The 




In total, 9,328 articles were identified. After removal of duplicates, 6,783 articles 
were screened by title and abstract. In total, 961 full text articles were assessed 
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for eligibility by the fellows (RA, SH, SR, MH). Ultimately, 264 articles were included 
(Figure 1). 
Figure 1. Flow chart of the search and selection process
 RA= rheumatoid arthritis, AS = ankylosing spondylitis, PsA = psoriatic arthritis
Overarching principles
The task force defined three overarching principles of CVD risk management in RA 
and other IJD (Table 1).
A.  Clinicians should be aware of the higher risk for CVD in RA compared to the 
general population. This may also apply to AS and PsA. 
Acknowledging the increased CVD risk in IJD was included as a recommendation 
in our previous guideline of 2009. However, in view of its generic nature, 
this ‘recommendation’ was moved to the overarching principles section of 
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this paper. Since the publication of the 2009 EULAR recommendations, the 
evidence for an enhanced CVD risk in IJD has increased. For example, it was 
shown in a large Danish cohort study that the risk of myocardial infarction (MI) in 
RA patients is comparable to that in diabetes mellitus patients.2 Furthermore, 
in the same study the risk of MI in RA was found to be approximately 70% higher 
than in the general population, which corresponds with the risk in 10-year 
older non-RA subjects.3 Regarding mortality in RA, a meta-analysis including 
8 studies with follow-up ranging from the year 1955 to 1995 concluded that 
the standardized mortality rates (SMRs) in RA were elevated compared with 
the general population (i.e. pooled SMR 1.47, 95% CI 1.19 – 1.83) and that these 
SMRs did not change over time.10 Data from the Norfolk Arthritis Register with 
follow-up until 2012 revealed comparable results with increased all-cause 
mortality in patients with RA compared to the general population along with 
stable SMRs over the past 20 years.2322 New evidence strengthens the notion 
that the excess risk of CVD morbidity and mortality in patients with RA is 
related to both traditional and novel CVD risk factors.11;12
Recent studies reveal increased SMRs in AS, ranging from 1.6-1.9.13-15 These 
studies report either death of circulatory origin or infection as the main 
cause of death in these patients.26;29 Compared to controls, AS patients have 
an increased risk of vascular death and CVD events. 16,30-35 Dyslipidaemia, 
17 increased prevalence of hypertension, 18-20 diabetes mellitus, 18;19 and 
increased carotid intima media thickness (cIMT) or atherosclerotic plaques 
21-23 have all been reported in AS. Furthermore, an increased prevalence of 
(non-) atherosclerotic cardiac disease is reported in AS, such as aortic valve 
dysfunction and conduction disorders, but it is currently unknown whether 
and to what extent this affects CVD risk.48;49 In PsA, reported SMRs range from 
0.8 to 1.6.14;24 Overall, patients with PsA are at an increased risk of CVD events, 
however data on stroke are more conflicting.25-28 Likewise, in PsA CVD risk 
seems to be influenced by an increased prevalence of CVD risk factors such as 
hypertension,27;29;30 and increased arterial stiffness.31 
B. The rheumatologist is responsible for CVD risk management in patients with 
RA and other IJD.
CVD risk management should be defined locally due to different health 
care systems and economic priorities in each country. Therefore, CVD risk 
management may include other healthcare professionals than rheumatologists. 
In clinical practice it is not always clear who bears responsibility for CVD risk 
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management in patients with IJD and the task force therefore recommends 
that the responsibility to ensure that a CVD risk assessment is performed 
should be with the treating rheumatologist. 
 
C. The use of NSAIDs and corticosteroids should be in accordance with 
treatment specific recommendations from EULAR and the Assessment of 
Spondyloarthritis international society (ASAS).32;33
Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are 
commonly used for the treatment of IJD and these agents effectively lower 
disease activity and inflammation. However, both treatment options have 
been associated with an increased CVD risk.34-36 As these medications are 
often indispensable in tackling disease activity in patients with IJD, the task 
force feels that their use should be evaluated on an individual patient level. 
Furthermore, lowering disease activity may have beneficial effects on the CVD 
risk. Therefore, the task force recommends to use NSAIDs and corticosteroids 
according to treatment specific guidelines. 
Recommendations 
In line with the 2009 guideline we opted to give again ten recommendations for 
CVD risk management. In total, 3 recommendations remained unchanged, 6 
recommendations were altered and there is 1 new recommendation. One of the 
2009 recommendation (#1) was moved to the overarching principles as described 
previously. A list of the updated recommendations, including the levels of evidence 
with the strength of recommendation and the level of agreement based on voting 
by the task force, is shown in Table 1. The recommendations follow a logical 
sequence, and they are not listed in sequence of importance. All recommendations 
are discussed in detail below.
1. Disease activity should be controlled optimally in order to lower CVD risk in all 
patients with RA, AS or PsA (Unchanged, LOA 9.1 (1.3))
In the previous recommendations from 2009 the importance of control of disease 
activity to lower CVD risk was emphasized. New evidence still portrays an association 
between higher cumulative inflammatory burden and increased CVD risk in RA.37-
42 Disease duration does not seem to affect CVD risk independently.38 However, 
disease activity as well as the number and duration of flares over time do contribute 
to the risk of CVD.37-40 There is now additional evidence showing a reduction of CVD 
risk in patients treated with disease modifying antirheumatic drugs (DMARDs). 
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Table 1. Overarching principles and recommendations
Levels of evidence  






A. Clinicians should be aware of the higher risk for CVD in RA 
compared to the general population. This may also apply to AS 
and PsA.
B. The rheumatologist is responsible for CVD risk management in 
patients with RA and other IJD.
C. The use of NSAIDs and corticosteroids should be in 
accordance with treatment specific recommendations from 
EULAR and ASAS.
Recommendations
1. Disease activity should be controlled optimally in order to lower 
CVD risk in all patients with RA, AS or Ps.
2. CVD risk assessment is recommended for all patients with 
RA, AS or PsA at least once every five years and should be 
reconsidered following major changes in anti-rheumatic therapy.
3. CVD risk estimation for patients with RA, AS or PsA should be 
performed according to national guidelines and the SCORE CVD 
risk prediction model should be used if no national guideline is 
available.
4. TC and HDLc should be used in CVD risk assessment in RA, 
AS and PsA and lipids should ideally be measured when disease 
activity is stable or in remission.
5. CVD risk prediction models should be adapted for patients with 
RA by a 1.5 multiplication factor, if this is not already included in 
the model.
6. Screening for asymptomatic atherosclerotic plaques by use 
of carotid ultrasound may be considered as part of the CVD risk 
evaluation in patients with RA.
7. Lifestyle recommendations should emphasise the benefits of a 
healthy diet, regular exercise and smoking cessation.
8. CVD risk management should be carried out according to 
national guidelines in RA, AS or PsA, antihypertensives and 
statins may be used as in the general population.
9. Prescription of NSAIDs in RA and PsA should be with caution, 
especially for patients with documented CVD disease or in the 
presence of CVD risk factors. 
10. Corticosteroids: for prolonged treatment, the glucocorticoid 
dosage should be kept to a minimum, and a glucocorticoid taper 
should be attempted in case of remission or low disease activity; 






















AS: ankylosing spondylitis, ASAS: Assessment of spondyloarthritis international society, 
CVD: cardiovascular disease, EULAR: European League against Rheumatism, HDLc: high 
density lipoprotein cholesterol, IJD: inflammatory joint disorder NSAID: non-steroidal anti-
inflammatory drug, PsA: psoriatic arthritis, RA: rheumatoid arthritis, SCORE: systematic 
coronary risk evaluation, TC: total cholesterol 
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Reducing inflammation is important in RA for CVD risk management, but the type 
of treatment may be less important. Conventional synthetic DMARDs (csDMARDs), 
in particular methotrexate (MTX), as well as biological DMARDs (bDMARDs), such 
as the TNF-inhibitors (TNFi), are often associated with a significant reduction 
in CVD risk in RA patients.34;37;39;41;43-50 The CVD risk appears to decrease even 
further after long term use.41;44 Reduction of disease activity after treatment 
with tocilizumab or rituximab shows a beneficial effect on carotid intima media 
thickness (cIMT), a surrogate marker for CVD, and CVD risk in a limited number of 
studies.42;51-53 Beneficial effects of TNFi and MTX on arterial stiffness have also 
been described.31;35;54-59 One study described a reduction in aortic inflammation and 
stiffness measured by 18 F FDG PET-CT after TNFi treatment in patients with RA.60 
For both AS and PsA, evidence for the association between inflammation and an 
enhanced CVD risk is less abundant compared to RA. In view of shared pathogenic 
mechanisms, it is plausible that decreasing the inflammatory burden in AS and 
PsA will also have favourable effects on the CVD risk in these patients. Therefore, 
control of disease activity, as is routinely recommended, is expected to lower CVD 
risk for both AS and PsA.
2. CVD risk assessment is recommended for all patients with RA, AS or PsA at 
least once every five years and should be reconsidered following major changes 
in anti-rheumatic therapy (Changed, LOA 8.8 (1.1))
CVD risk assessment is recommended for all patients with RA, AS or PsA at least 
once every five years, so that lifestyle advice and CVD preventive treatment can 
be initiated when indicated. The advice to screen IJD patients for CVD risk on a 
yearly basis has been changed to screening every five years, which is in line with 
the latest European Society of Cardiology (ESC) guidelines.61 Currently, there is no 
evidence that annual CVD risk assessment compared to five year risk assessment 
leads to a more significant reduction in CVD mortality or morbidity in IJD patients. 
Depending on the CVD risk algorithm that is used for screening, patients can be 
categorised as having low- to moderate risk (e.g. SCORE < 5%), high risk (e.g. 
SCORE ≥ 5% and < 10%) and very high risk (SCORE ≥10%). Once screened, patients 
with a low risk can be routinely screened again after five years. However, if the risk 
is intermediate rescreening may be done sooner, especially if disease progression 
is more rapid. Patients with a high risk or established CVD should be treated for 
all present CVD risk factors according to existing guidelines. A healthy lifestyle 
should of course be recommended to all persons, including patients with low- and 
intermediate cardiovascular risk. CVD risk evaluation should be reconsidered after 
117
major changes in anti-rheumatic therapy, i.e. the initiation of bDMARDs or other 
drugs that may cause pronounced increases in low density lipoprotein cholesterol 
(LDLc) or alter other CVD risk factors, so that doctors can act accordingly.62;63 
3. CVD risk assessment for patients with RA, AS or PsA should be performed 
according to national guidelines and the SCORE CVD risk prediction model 
should be used if no national guideline is available (Unchanged, LOA 8.7 (2.1))
Evidence is scarce with regards to the validity of disease-specific CVD risk 
prediction models to accurately predict risk in individual patients with RA, and it is 
therefore currently recommended to perform risk evaluation according to general 
population guidelines. Several novel and RA disease specific factors have been 
associated with an increased risk of CVD, but at present it is uncertain if these 
factors will meaningfully and cost-effectively improve CVD risk prediction in RA 
patients.
4. Total cholesterol (TC) and high density lipoprotein cholesterol (HDLc) should 
be used in CVD risk assessment in RA, AS and PsA and lipids should ideally be 
measured when disease activity is stable or in remission (Changed, LOA 8.8 (1.2))
The relationship between serum lipid levels and CVD risk is non-linear and 
potentially paradoxical in RA. Patients with RA with highly active disease generally 
have lower serum TC and LDLc levels compared to the general population, while 
their CVD risk is elevated.62;64-67 As described in the 2009 recommendations, these 
patients also have reduced serum levels of HDLc and higher levels of triglycerides 
(TG) as compared to healthy controls.67-70 In general, controlling disease activity 
has widespread effects on the lipid profile. Treatment with TNFi and/or csDMARDs 
(mainly MTX) results in an overall increase of lipid components, but mostly HDLc, 
which improves the TC/HDLc-ratio.38;68-82 A limited number of studies have 
reported beneficial effects of rituximab (RTX) and tocilizumab on individual lipid 
components.52;83;84 However, the net effect of treatment with these agents is an 
overall increase of individual lipid components without changes in TC/HDLc-
ratio.42;85-90 The same appears to be true for tofacitinib.89 Still, statins are effective 
at reducing lipid levels in tocilizumab or tofacitinib treated patients with sustained 
elevations of TC and LDLc.88;89 As described in the 2009 recommendations, the TC/
HDLc-ratio is a better CVD risk predictor in RA than individual lipid components.67;91 
From a practical point of view both TC and HDLc can be used when using online 
calculators. As lipid components appear to be modifiable by disease activity and 
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anti-inflammatory therapy, assessment of the lipid profile should preferably be 
done when a patient has stable disease or is in remission.  
5. CVD risk prediction models should be adapted for patients with RA by a 1.5 
multiplication factor, if this is not already included in the risk algorithm (Changed, 
LOA 7.5 (2.2))
The SCORE risk calculator is recommended for CVD risk prediction in the general 
population by the ESC guidelines.61 However, CVD risk prediction models developed 
for the general population do not include non-traditional CVD risk factors and 
hence there is a possibility of underestimation of future CVD if these models 
are applied in patients with RA. It is indeed reported that several CVD prediction 
models inaccurately predict the risk of CVD in RA patients.7;92;93 The 2009 EULAR 
recommendations for CVD risk management suggested a multiplication factor of 
1.5 to the calculated total CVD risk if the patient fulfilled certain disease-specific 
criteria (i.e. disease duration of more than 10 years, rheumatoid factor (RF) or 
anti-citrullinated protein antibody (ACPA) positivity and the presence of certain 
extra-articular manifestations).120 It has been argued that the application of this 
multiplication factor does not reclassify as many patients as was expected into 
a more appropriate risk category.8;94 In addition, QRISK 2, a CVD risk prediction 
model that includes RA as a risk factor with a multiplication factor of 1.4 for all 
RA patients,95 tended to overestimate the CVD risk in patients with RA. QRISK 2 
estimates the risk of fatal and non-fatal CVD combined.7 Currently, there are no 
alternative CVD risk prediction models with a proven accuracy and superiority for 
IJD patients. Based on all recent epidemiology, this multiplication factor is still the 
most evidence-based way of estimating CVD risk in patients with RA. Therefore, 
the use of an RA adapted risk prediction model is recommended over the use of 
an unadapted general population model, since there is a higher level of evidence 
on their predictive value. Based on this, the EULAR task force still recommends 
to adapt general population CVD risk algorithms (except for QRISK 2 in which the 
multiplication factor is intrinsic to the algorithm) with a 1.5 multiplication factor 
for all patients with RA. In contrast to the 2009 recommendations, the presence 
of certain RA-specific criteria is not mandatory anymore for the application of this 
multiplication factor, as evidence on the increased CVD risk in early RA and RA 
patients without extra-articular manifestations has emerged.96;97
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6. Screening for asymptomatic atherosclerotic plaques by use of carotid 
ultrasound may be considered as part of the CVD risk evaluation in patients with 
RA. (New, LOA 5.7 (3.9))
The presence of carotid plaques is associated with poor CVD-free survival and is 
strongly linked to future acute coronary syndrome (ACS) in patients with RA, with 
a rate of ACS of 1.1 (95% CI 0.6, 1.7) per 100 person years (pyrs) for RA patients 
with no carotid plaques and 4.3 (95% CI 2.9, 6.3) per 100 pyrs for those with 
bilateral plaques.54;98 RA specific factors contribute to the presence of carotid 
atherosclerosis in addition to traditional CVD risk factors.99 Disease duration and 
disease activity have been shown to be associated with plaque size and vulnerability 
in patients with RA.100;101 The most recent ESC Guidelines on CVD prevention in clinical 
practice recommend considering screening for carotid artery atherosclerosis in 
patients with moderate CVD risk (Class: IIa, Level of evidence: B, GRADE: strong).61 
Autoimmune diseases like RA, systemic lupus erythematosus and psoriasis were 
acknowledged as diseases with increased CVD risk. Occlusive arterial disease of 
the lower limbs and carotid artery disease are considered to be coronary heart 
disease equivalent conditions in the European Atherosclerosis Society (EAS)/ESC 
guidelines, and lipid lowering therapy is recommended (Class: I, Level of evidence: 
A, GRADE: strong).61 Due to the high pre-test probability for detection of carotid 
artery plaques by use of ultrasound in RA patients, and the clinical consequence of 
indication for statin treatment if a carotid plaque is present, this procedure could 
be of additional value for CVD risk evaluation. Ultrasound of the carotid arteries to 
identify atherosclerosis has been shown to reclassify a considerable proportion 
of RA patients into a more appropriate CVD risk group in accordance with current 
guidelines.61;102
7. Life style recommendations should emphasise the benefits of a healthy diet, 
regular exercise and smoking cessation. (Changed, LOA 9.8 (0.3))
Since the 2009 recommendations no new strong evidence has emerged on the role 
of smoking on CVD risk in IJD and hence this recommendation remains unchanged. 
Thus, patients should be advised to stop smoking and directed towards the 
locally defined evidence-based smoking cessation programs, even if they failed 
previously. The 2009 recommendations did not discuss diet or exercise, but it 
was mentioned in the research agenda.4 Research on the role of exercise in RA 
management has advanced considerably since 2009. Physical inactivity is common 
in RA patients, and has been associated with an adverse CVD risk profile.124-126 There 
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is accumulating data that structured exercise therapy has beneficial CVD effects in 
RA patients, at least in the short and medium term.159;160 Exercise has been shown 
to reduce long-term inflammation in epidemiological studies conducted in the 
general population and increased physical activity was associated with lower levels 
of CRP.127 This has also been demonstrated in a study with RA patients in which 
a 6-month exercise program lowered CRP levels, probably related to a reduction 
in body fat.128 Moreover, improvements in both micro- and macrovascular function 
were found after 3 months of exercise in RA.129 To date, no studies have shown any 
adverse effects as a result of exercise.130  Hence, in RA, high-intensity exercise is 
not contraindicated and should be encouraged in those already accustomed to 
activity. Physical activity that is enjoyable is more likely to be sustained. 
A Mediterranean diet is characterized by a high consumption of fruit, vegetables, 
legumes and cereals, and contains less red meat and more fish compared to 
common Western diets. Olive oil or vegetable oil is used as the primary source of 
fat intake. This diet has been shown to reduce the incidence of major CVD events 
in the general population.131 In RA, the positive effect of a Mediterranean diet 
may be mediated by the effect of this diet on disease activity.132 However, there 
is no specific evidence available on the effect of dietary modifications on CVD 
risk in patients with IJD. Therefore, we recommend following national guidelines 
regarding a healthy diet as part of a healthy lifestyle. 
An important issue remaining is how lifestyle interventions should be advocated 
to IJD patients. Studies in this field demonstrate that if information is provided, 
this should be linked to behavioural education.133 A randomized controlled trial in 
RA patients evaluated the effect of cognitive behavioral patient education with 
regard to modifiable CVD risk factors in people with RA: patients receiving this 
intervention had more knowledge, and improved behavioral intentions, however, 
actual behavior did not differ between groups.134 Obviously, this area is in need of 
more research.
8. CVD risk management should be carried out according to national guidelines 
in RA, AS or PsA, antihypertensives and statins may be used as in the general 
population (Changed, LOA 9.2 (1.3))
Hypertension is a major modifiable risk factor contributing to increased CVD risk in 
IJD.125 Several mechanisms may lead to the development of hypertension, including 
the use of certain anti-rheumatic drugs such as glucocorticosteroids, NSAIDs, 
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ciclosporin and leflunomide.126;127 It is important to realize that hypertension 
seems to be both underdiagnosed and undertreated in patients with RA.103 For 
the management of hypertension and hyperlipidaemia, there is no evidence that 
treatment thresholds should differ in patients with IJD compared to the general 
population. In the last years no new evidence has emerged that angiotensin 
converting enzyme (ACE) inhibitors and angiotensin II (ATII) receptor blockers should 
be the preferred treatment choice for hypertension in RA patients. Therefore, the 
previous treatment preferences for ACE-inhibitors and AT-II receptor blockers 
have been omitted. 
Since the 2009 recommendations several studies have assessed the efficacy of 
statins in patients with RA. Statins appeared to be at least equally effective in 
reducing cholesterol levels, atherosclerotic burden and CVD morbidity and mortality, 
and they do not have more adverse reactions in RA patients when compared to 
non-RA controls.66;104-110 In addition, statins have anti-inflammatory properties 
that may result in an even greater CVD risk reduction when combined with anti-
inflammatory therapy in RA, but studies on this effect are scarce.111-113 A few pre-
clinical studies found unfavourable effects of statins on RTX efficacy in patients 
with haematological malignancies.114;115 However, several clinical studies showed no 
significant differences in outcome between statin users and non-users receiving 
RTX treatment for a haematological malignancy.116-119 Clinical trials investigating 
this issue in RA are scarce. Three clinical studies in RA found no adverse effect of 
statins on RTX efficacy.120-122 Only one observational study reported a significant 
difference in disease activity six months after first RTX treatment in statin users 
as compared to non-users, but this finding was borderline significant (p=0.049) 
in a small sample size of statin-exposed patients (n=23 exposed vs n=164 non-
exposed).123 Obviously, further research is necessary to address this issue properly. 
9. Prescription of NSAIDs in RA and PsA should be with caution, especially for 
patients with documented CVD disease or in the presence of CVD risk factors. 
(Changed, LOA 8.9 (2.1))
The 2009 recommendations advocate that NSAIDs should be used with caution 
in this population or may even be contraindicated.135;136 Since the publication of 
the former recommendations, new evidence has emerged on the role of cyclo-
oxygenase-2 inhibitors (COXIBs) and non-selective NSAIDs in CVD risk. A recent 
meta-analysis concluded that, overall, both non-selective NSAIDs and COXIBs have 
an adverse effects on CVD outcomes in patients with RA and PsA.145 However, the 
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increased CVD risk was mainly observed for rofecoxib, which was withdrawn from 
the market in 2004. There is evidence that NSAIDs might increase CVD risk in RA 
to a lesser extent in comparison to the general population than was previously 
thought.36 Hence, there is no evidence to be stricter with NSAID treatment in 
patients with RA than what is recommended in the national guidelines for non-
RA patients. Safety data regarding the use of NSAIDs in patients with IJD and 
prevalent CVD comorbidities is lacking. Naproxen seems to have the safest CVD risk 
profile.34;36 In general, diclofenac is contra-indicated in patients with established 
congestive heart failure (NYHA class II-IV), ischaemic heart disease, peripheral 
arterial disease or cerebrovascular disease, and new evidence supports similar 
restrictions for ibuprofen use.20 
For patients with AS, NSAIDs are recommended as first-line drug treatment by 
the ASAS/EULAR group in the recommendations for the management of pain and 
stiffness in AS patients, and an individual clinical evaluation regarding NSAIDs use 
in AS patients with established CVD is therefore needed.148 
10. Corticosteroids: for prolonged treatment, the glucocorticoid dosage should 
be kept to a minimum, and a glucocorticoid taper should be attempted in case 
of remission or low disease activity; the reasons to continue glucocorticoid 
therapy should be regularly checked. (Unchanged, LOA 9.5 (0.7)
Corticosteroids rapidly and effectively reduce inflammation in RA, but they have 
also been associated with an increased CVD risk, although the literature shows 
conflicting results. Since the 2009 recommendations, new studies have found a 
dose and duration dependent increase in CVD risk associated with corticosteroid 
use in RA.35;137;138 A relatively high daily dose (i.e. already starting from 8-15 milligrams 
per day), a high cumulative dose and a longer exposure to corticosteroids (in years) 
appear to be associated with a higher CVD risk.35;138-140 Some authors argued that 
this increased CVD risk was confounded by indication, as it was no longer significant 
after correction for disease activity.41;141-143 On the contrary, other studies that had 
corrected for disease activity still found a (cumulative) dose and duration dependent 
increase in CVD related morbidity and mortality in RA patients.35;144However, this 
does not mean that confounding by indication has been addressed and this is a 
major limitation of all safety studies on corticosteroids. There is no conclusive 
evidence about the long-term effects of corticosteroids, particularly in low daily 
dosage, on safety outcomes including CVD events in RA. In patients with active 
disease, the benefit of reducing high grade inflammation may counteract the 
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adverse CVD effects of corticosteroid use, not only by reduction of inflammation, 
but also by improving mobility. In other words steroids may help to abrogate the 
harmful effect of inflammation on the CVD system, but they will still carry their 
own adverse effects on CVD risk. Altogether, from a CVD prevention point of view, 
the lowest effective dose of corticosteroids should be prescribed for the shortest 
possible duration in the treatment of active IJD. This recommendation is in line 
with the EULAR recommendations on management of glucocorticoid therapy.33
DISCUSSION
The 2015 update of the 2009 EULAR recommendations for CVD risk management 
in IJD comprises three overarching principles and ten recommendations. The first 
overarching principle reinforces and extends the evidence of an increased CVD 
risk in IJD. The second principle indicates the responsibility of the rheumatologist 
for coordinating CVD risk management in patients with IJD, whereas the last 
principle aims to put this recommendation update more in line with other (EULAR) 
recommendations. 
CVD risk assessment in IJD
Presently, the enhanced CVD risk in RA, but also in AS and PsA, is widely 
acknowledged. Thus far,  fully validated RA-specific CVD risk prediction models 
that both improve on general population models and are cost-effective are lacking, 
although multiple attempts have been made.7,147,148 Some even question the need 
for a disease specific CVD risk prediction model for RA, although existing models 
inaccurately estimate the CVD risk in these patients.7;8 In 2009, this led to the 
addition of a 1.5 multiplication factor for the calculated CVD risk in RA patients if 
certain disease characteristics were present.4 Meanwhile, alternative approaches 
have also been advocated, e.g. to increase the age of an RA patient by 15 years145 
or adding a multiplication factor of 1.4.3 Currently, it is unknown what approach 
would be most appropriate. In the light of this, the task force opted to retain the 
1.5 multiplication factor to correct for the increased CVD risk in RA compared 
to the general population. However, considering that the CVD risk is already 
increased in early disease or at disease onset and in patients without extra-
articular manifestations, the three disease-specific criteria for the application 
of this multiplication factor were removed. This makes the estimation of CVD risk 
in RA patients easier and therefore more feasible for daily clinical practice. As no 
conclusive evidence has emerged regarding the precise CVD risk in AS and PsA, 
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the task force opted not to include a multiplication factor for these diseases. In 
line with the ESC Guidelines, the recommendation to perform CVD risk assessment 
was extended to once every five years for patients found to be at low cardiovascular 
risk as there is no evidence that CVD risk assessment every year for IJD reduces 
CVD risk more than screening every five years.146 In patients with an intermediate 
risk for CVD, screening should be performed more often. Patient at high- to very 
high cardiovascular risk should promptly be treated for existing CVD risk factors. 
The new recommendation (#6) includes the option of screening for carotid plaques 
in RA patients as a tool for CVD risk assessment, because carotid plaques are 
associated with future ACS in patients with RA. Whether routine screening of the 
carotid arteries is possible in daily clinical practice will depend on local availability. 
The LOA of 5.7 (3.9) for recommendation #6 possibly indicates the absence of 
evidence for routine screening of the carotid arteries in general. 
CVD risk reduction in IJD
Just as in the 2009 recommendations, the importance of optimal anti-
inflammatory therapy for CVD risk reduction in RA is emphasised in this update. 
There is accumulating evidence that decreasing the inflammatory burden in RA 
translates into a lower CVD risk. As inflammation is related to CVD risk in all IJD, 
we extrapolated this recommendation to AS and PsA, although further evidence 
for these types of IJD would be valuable. Equally important is the treatment of 
traditional CVD risk factors that are present in these patients according to national 
guidelines. However, awareness of some issues when performing risk estimation 
and management in patients with IJD is important. Active arthritis is associated with 
reduced lipid levels that increase (i.e. normalize) during effective anti-inflammatory 
treatment. Biologics have the most pronounced lipid increasing effect, which 
has led to mandatory lipid assessment during treatment with tocilizumab.89 
However, it is also important to realize that the anti-atherogenic properties of 
HDLc cholesterol improve during biologic treatment. 83;84 Therefore, it is important 
to assess the net effect of lipid modulation by biologics. Currently, the effect of 
these changes on CVD outcomes is not known. In addition, awareness of possible 
adverse effects of certain medications such as NSAIDs and corticosteroids has 
been emphasized. Except for smoking cessation, lifestyle recommendations were 
not given in our previous guideline. Since then accumulating data demonstrate that 
regular physical activity has beneficial CVD effects in RA patients and hence, this 
has been incorporated in the updated recommendations. In addition, favourable 
CVD effects have also been observed for a Mediterranean diet, albeit that a formal 
study in patient with IJD has not yet been conducted. As it is not likely that the 
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effect of diet would be different in patients with IJD than in the general population, 
we also added this in our lifestyle recommendation. 
Conclusion
In general, the level of agreement (LOA) for the recommendations was (very) 
high, except for recommendations #5 (LOA 7.5) and #6 (5.7). As in 2009, the level 
of evidence was moderate for most of the recommendations. Therefore, several 
important questions that arose during the development of these recommendations 
remain unanswered. These questions have been put on the research agenda (Box 
1). The 2015 update of the EULAR recommendations for CVD risk management 
in patients with RA and other forms of IJD confirms and further extends the 
evidence of an increased CVD risk in the whole spectrum of IJD and reinforces 
the need for proper CVD risk management in these patients. As these updated 
recommendations are based on a pan-European consensus, it is hoped that they 
will facilitate CVD risk management in daily clinical practice, ultimately leading to a 
decreased CVD burden in our patients.
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Box 1. Research agenda
Research agenda 
1. Can we make adjustments to the current CVD risk models to improve estimation of CVD risk in 
patients with IJD?
2. How high is the CVD risk in patients with spondyloarthropathies or non-radiographic axial SpA 
compared to the general population?
3. What is the benefit/risk ratio of intensive anti-inflammatory therapy on CVD risk in patients 
with IJD?
4. Is the increased CVD risk in patients with spondyloarthropathies independent of 
traditional risk factors and what is the association between CVD risk and inflammation in 
spondyloarthropathies?  
5. Is there an increased prevalence of cardiac abnormalities, including aortic valve dysfunction 
and conduction disorders in patients with spondyloarthropathies and how does this affect 
overall CVD risk?
6. How does treatment with NSAIDs affect the CVD risk in IJD patients, in particular patients 
with AS?
7. Should we treat patients with AS continuously or intermittently with NSAIDs from a CVD point 
of view?
8. Should treatment targets for blood pressure and lipids be different in patients with IJD from 
the general population?
9. What is the effect of different modes of action of antirheumatic drugs on CVD risk?
10. What is the relationship between residual disease activity and CVD risk in RA patients on 
stable DMARD therapy?
11. Is there additional value in measuring lipid sub-particles in patients with IJD for estimation of 
CVD risk?
12. What is the added value of ultrasound of the carotid arteries to measure c-IMT and reveal 
presence of atherosclerotic plaques in IJD patients regarding CVD risk estimation and in 
which (sub) population should we conduct this?
13. What is the additional value of novel biomarkers for CVD risk prediction?
14. What is the best technique for implementing lifestyle changes and education in IJD patients?
15. Health economics. Are interventions cost-effective in terms of reducing the number of fatal 
and non-fatal CVD events? 
16. Is the prevalence of venous thrombotic events in IJD patients increased? If so, what are the 
underlying mechanisms?
AS: ankylosing spondylitis, CVD: cardiovascular disease, DMARD: disease modifying anti 
rheumatoid drug IJD: inflammatory joint disorder, IMT: intima media thickness, NSAID: non-
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Neovascularization is associated with atherosclerotic plaque instability and 
increased chance of myocardial infarction (MI). Patients with chronic inflammatory 
diseases (CID) have increased risk of developing atherosclerosis and recent 
evidence demonstrates that NF-κB inducing kinase (NIK)-mediated noncanonical 
NF- κB signaling in endothelial cells (EC) is linked to inflammation and angiogenesis. 
Here we hypothesized that NIk may also be activated in EC of atherosclerotic lesion 
microvessels.
Methods
Using cohorts of atherosclerotic lesions from coronary and carotid arteries, we 
quantified NIK expression in microvessels in plaque microvessels and compared in 
to pathological markers including inflammatory cell content, plaque characteristics 
and MI. Differences in gene transcripts were evaluated between stable and ruptured 
lesions.
Results
NIK+EC were present in both coronary and carotid lesions. In CID patients, plaques 
with stenosis >40% had increased numbers of NIK+ EC and higher content of 
immune cells (p<0.05) as compared to controls. Immune cells per NIK+EC was also 
greater in CID patients (p<0.05) with pronounced differences as stenosis increased. 
In unstable lesions, NIK+EC were elevated as were EC expressing CXCL12 (p<0.05). 
NIK+EC were increased in lesions containing lipid content >40% (p<0.05) and more 
abundant in coronary artery lesions implicated in MI (p<0.05). These vessels also 
associated with atheromatous rather than fibrous plaque morphology (p<0.05). 
Transcriptomic profiling demonstrated that components of noncanonical NF-κB 
pathway were also upregulated in ruptured plaques (p<0.05).
Conclusions
NIK+EC are associated with chronic inflammation in advanced lesions and are 
linked with markers of local inflammation, lipid content as well as an unstable 
plaque phenotype and development of MI. Therefore, targeting noncanonical NF-




Cardiovascular disease (CVD) is a leading cause of death worldwide, often caused 
by atherosclerosis, which serves as a basis for cardiac events such as myocardial 
infarction (MI) and stroke (1, 2). Over the last decades, it has become increasingly 
clear that atherosclerosis is a chronic inflammatory process. Recent studies have 
demonstrated that most lesions contributing to acute coronary syndrome have a 
grade of stenosis less than 50%, but are classified as unstable lesions characterized 
by massive inflammatory cell infiltration, necrotic lipid core formation and a thin 
fibrous cap (3, 4). Unstable plaques are more prone to rupture, which is the main 
underlying cause of luminal thrombosis in acute coronary syndrome and occurs in 
75% of patients dying of an acute MI (5).
A major factor contributing to plaque instability is neovascularization, which 
occurs when lesions begin to grow in size due to both immune cell infiltration and 
medial smooth muscle cell proliferation (6). The increase in cell numbers creates 
a demand for oxygen and nutrients, which in combination with growth away from 
the supplying vasa vasorum in the adventitial layer, causes the plaque to become 
hypoxic (7). Hypoxic signals not only stimulate microvessel outgrowth from the 
adventitia into the medial and intimal lining containing the atheroma, but also 
attract immune cells that further fuel inflammation and disease progression 
(8). The newly formed vessels are generally immature and leaky in nature, which 
makes them susceptible to hemorrhage, resulting in increased interstitial pressure 
within the lesion as well as an accumulation of free cholesterol that is taken up 
by macrophages. These processes add to instability of the plaque and enhanced 
chance of rupture (9).
Chronic inflammatory diseases (CID) have long been associated with an increased 
risk of CVD (10). In rheumatoid arthritis (RA), atherosclerosis occurs in higher 
frequencies as compared to the general population and is considered to be of 
a more progressive phenotype as lesions develop at a faster rate with plaque 
morphology that may be more vulnerable and prone to rupture(11, 12). Interestingly, 
several mechanisms implicated in RA pathogenesis, such as cytokines, immune 
cells, genetic and environmental risk factors, also contribute to atherosclerosis 
(13). Patients with psoriatic arthritis (PsA) also have an increased risk of CVD that 
may be attributed to metabolic abnormalities, such as impaired glucose tolerance 
and pro-atherogenic lipid profiles, as PsA patients tend to have higher instances of 
obesity and diabetes (14). The link between inflammatory bowel disease (IBD) and 
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CVD is not as robust as in arthritis, although endothelial cell (EC) dysfunction has 
been associated with IBD (15). Nevertheless, several studies established a modestly 
increased relative risk of CVD in patients with ulcerative colitis and Crohn’s disease 
(16, 17). Although there are many differences between these CID, they all have 
chronic inflammation in common, which creates a systemic inflammatory burden 
that is likely to contribute to atherosclerosis.
Recent work by our group has demonstrated a role for the noncanonical NF-κB 
pathway in EC activation and pathological angiogenesis in the context of chronic 
inflammation and cancer, whereas this was not observed in healthy tissues (18). 
The noncanonical NF-κB pathway can be activated through ligation of TNF receptor 
superfamily (TNFRSF) members such as LTβR, CD40, BAFF and Fn14, all of which 
have been implicated in atherosclerotic plaque development (19-22). Under 
homeostatic conditions NF-κB inducing kinase (NIK) is continuously degraded, 
however, upon activation of these receptors, stabilization of NIK occurs, which 
subsequently phosphorylates IKKα and further leads to partial degradation of 
p100 protein to p52. The p52 subunit can then form heterodimers, preferably with 
RelB, and translocate to the nucleus to activate gene transcription (23). CXCL12 
expression has been demonstrated to be strictly dependent upon noncanonical NF-
κB signaling in EC upon LTβR ligation (24). NIK+EC expressing CXCL12 are abundantly 
present in the inflamed synovial tissue of patients with inflammatory arthritis, 
including RA and PsA, and may contribute to perpetuation of inflammation through 
enhanced neovascularization and attraction of immune cells, as it is a potent 
mobilizer of several immune cell subsets such as T cells, B cells and macrofages 
(25, 26). CXCL12 is highly expressed at the protein level in atherosclerotic plaques, 
including in EC (27). Therefore, we hypothesized that active noncanonical NF-κB 
signaling may also occur in microvessels of atherosclerotic lesions, and be linked to 
neovascularization, the attraction of immune cells and possibly a more vulnerable 
plaque phenotype and adverse cardiovascular events such as MI. 
Here, we employ independent cohorts of atherosclerotic lesions (coronary arteries 
and carotid endarterectomy specimens), to investigate the activation status of the 
noncanonical NF-κB pathway in plaque microvessels and to determine if this is 





Post mortem epicardial coronary artery tissue was isolated from 11 patients with 
CID (i.e. rheumatoid arthritis, psoriatic arthritis or inflammatory bowel disease) 
and 11 matched controls without CID, all with fatal myocardial infraction (MI). The 
present study was conducted in accordance with the Declaration of Helsinki and 
according to the guidelines of the ethics committee of the VU Medical Center. The 
use of autopsy material after completion of the diagnostic process is part of the 
patient informed consent in the VU Medical Center. The patient characteristics 
are presented in Supplemental Table 1. Tissue was formalin fixed, embedded in 
paraffin and subsequently sectioned into multiple 5μm slices per region of the 
artery, including right coronary artery (RCA), left anterior descending artery (LAD) 
and circumflex coronary artery (Cx). To establish activation of the noncanonical 
NF-κB pathway in microvessels of the lesions, primary antibodies against CD31 (sc-
1506 Santa Cruz Biotechnology, Santa Cruz, CA, USA), CD34 (sc-7045 Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), NIK (ab19144 Abcam, Cambridge, UK), phospho 
IKKα Ser176/180 and CXCL12 (MAB350 R&D Systems, Abingdon, UK) were used in 
combination with secondary antibodies conjugated with alexa 488 (Invitrogen, 
Carlsbad, California, USA) or alexa 594 (Invitrogen, Carlsbad, California, USA) on 
adjacent tissue sections. Subsequent imaging was done at 20x magnification by 
confocal microscopy (Leica, Wetzlar, Germany). For quantification of the total 
number of immune cell infiltration into the plaque, primary antibodies against 
leukocytes (CD45) (M070129 DAKO, Glostrup, Denmark), macrophages (CD68) 
(M081401 DAKO, Glostrup, Denmark), neutrophils (myeloperoxidase) (A039829 
DAKO, Glostrup, Denmark) and mast cells (tryptase) (M705229 DAKO, Glostrup, 
Denmark) were used in combination with an HRP conjugated secondary antibody 
(Dako, Glostrup, Denmark) and visualized by bright field microscopy (Leica, Wetzlar, 
Germany) (Supplemental S1). The grade of stenosis of each coronary artery was 
previously calculated (lumen surface/lumen + intima surface, in percentage) as 
described (12).
Carotid artery specimens
A second cohort contained 36 patients undergoing carotid endarterectomy 
(CEA). Specimens were derived from the Athero-Express biobank, a longitudinal 
vascular biobank study that was approved by the Medical Ethics Committee of 
the University Medical Center Utrecht and in which participants provided written 
informed consent (28). The study adheres to the ethical guidelines set forth by the 
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Declaration of Helsinki. Patient characteristics are summarized in Supplemental 
Table 2. After endarterectomy, the atherosclerotic plaque was immediately 
processed in the laboratory. After dividing into 5-mm segments, the segment with 
the largest plaque burden was subjected to standardized histological examination. 
Plaques were classified as atheromatous, fibroatheromatous or fibrous based on 
semi-quantitative analysis of fat, macrophage (CD68), smooth muscle cell (α-actin) 
and collagen (Picro-sirius Red) content as described before(29). Size of lipid cores 
were derived from combining the hematoxylin and eosin and Picro-sirius Red 
staining. Plaque stability was determined previously as described (28) and recently 
reviewed in (30).
Plaque transcriptomics
Gene expression data were taken from an existing database (31). Microarray 
analysis was performed on RNA from ruptured and paired stable control segments 
from 22 human endarterectomy specimens that were obtained from the 
Maastricht Pathology Tissue Collection (MPTC). All use of tissue and patient data 
was in agreement with the “Code for Proper Secondary Use of Human Tissue in 
the Netherlands” (http://www.fmwv.nl). Illumina Human Sentrix-8 V2.0 BeadChip 
technology was used to detect differential mRNA expression.
RESULTS
Active noncanonical NF-κB signaling in microvessels of atherosclerotic 
lesions
We have previously demonstrated that noncanonical NF-κB signaling is active in 
EC in synovial tissue of patients with inflammatory joint diseases, as well as in solid 
tumor tissues (18). To evaluate whether microvessels in atherosclerotic lesions also 
exhibited active noncanonical NF-κB signaling, we performed immunohistochemical 
and immunofluorescence stainings on atherosclerotic plaques isolated from 
coronary arteries for NIK, the main regulating kinase of the noncanonical pathway, 
in combination with the EC markers CD31/34. Confocal analysis revealed that there 
was stable expression of NIK in the atherosclerotic lesions, mainly in CD31/34 
positive EC (Figure 1A). To ensure that downstream noncanonical NF-κB signaling 
was also occurring, we determined the phosphorylation status of IKKα in the 
same microvessels. Serine 176 and 180 were phosphorylated in these vessels 
indicating that NIK was functionally active in these cells (Figure 1B). Furthermore, 
we examined the expression of the noncanonical NF-κB-dependent chemokine 
CXCL12 in NIK+ vessels and observed strong co-localization of the two markers, 
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further substantiating that the noncanonical NF-κB pathway is active in these 
microvessels (Figure 1C). 
Figure 1. The noncanonical NF-κB pathway is activated in the microvessels of atherosclerotic 
lesions. Confocal microscopic images demonstrating active noncanonical NF-κB signaling in 
micro-vessels of atherosclerotic lesions from coronary arteries. A) NF-κB inducing kinase 
(NIK) and endothelial cell markers (CD31/34) B) activated inhibitor of nuclear factor kappa-B 
kinase alpha (IKKα Ser176/180) and CD31 C) CXCL12, a noncanonical NF-κB dependent 
chemokine, and NIK. (Representative of independent tissue staining from 3 patients; n=3)
Systemic inflammation is linked to NIK vessel density in atherosclerotic 
lesions with advanced stenosis greater than 40% 
Patients with CID have an increased systemic burden of inflammation, which may 
result in enhanced activation of signaling pathways related to inflammation in 
atherosclerotic lesions, including the noncanonical NF-κB pathway. To investigate 
this, we compared NIK+ microvessel density in atherosclerotic lesions of coronary 
arteries from patients with CID to those without. We observed that although 
NIK+ microvessels were present in lesions from both patient groups, the NIK+ 
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microvessel density was higher in CID patients when stenosis increased past 
40% (Figure 2A). Upon further investigation of these advanced lesions (>40%), we 
determined that the activation of the noncanonical NF-kB pathway within plaque 
microvessels was associated with significantly higher levels of CD68+ macrophages 
and tryptase (TRYP)+ mast cells (p<0.01; p<0.05) in CID patients as compared to 
control. Interestingly, in advanced plaques without NIK+ microvessels, there was no 
difference in the levels of these immune cells between patient and control groups, 
except for a small decrease in CD45+ leukocytes in CID patients (Figure 2B). Of note, 
the numbers of macrophages, leukocytes and mast cells per NIK+ microvessel were 
also higher in CID patients as compared to control, however this difference was 
remarkably enhanced in plaques with stenosis greater than 40%. No difference 
in myeloperoxidase (MPO)+ neutrophil content between patient groups was found 
(Figure 2C). These data suggest that activation of the noncanonical NF-kB pathway 
is heightened in advanced lesions of patients with CID and is linked to a more 
inflammatory plaque phenotype. 
NIK+endothelial cells correlate with the content of lymphocytes, 
macrophages and mast cells, but not neutrophils
Several activators of the noncanonical NF-κB pathway, including lymphotoxin β 
(LTβ) and CD40L, are expressed or produced by immune cells, and have been well 
established to play an essential role in immune cell extravasation. Consequently, 
constitutive activation of noncanonical NF-κB signaling in EC would lead to 
enhance immune cell infiltration (24). To determine if this hypothesis also holds 
true for the inflammatory plaque microenvironment, we examined the relationship 
between NIK+ microvessel density and composition of CD45+ leukocytes, CD68+ 
macrophages, myeloperoxidase (MPO)+ neutrophils and tryptase+ mast cells in the 
lesions. We observed significant correlations between NIK+ microvessels and CD45+ 
leukocytes (Ctrl: p<0.0001; CID: p<0.0001), CD68+ macrophages (Ctrl: p=0.0002; CID: 
p<0.0001) and tryptase+ mast cells (Ctrl: p<0.0001; CID: p<0.0001) in both control 
and CID patients, however the associations were stronger in CID patients (Figure 
3A-C; Supplemental Table 3). Furthermore, the link between NIK and the immune 
cells was further strengthened in lesions with stenosis greater than 40%. We did 
not find any link between NIK and MPO+ neutrophils (Figure 3D; Supplemental Table 
3). Importantly, a similar trend was recorded for macrophages in an independent 
cohort of atherosclerotic lesions obtained from carotid endarterectomy, as 
macrophage content increased with NIK+ microvessels (Supplemental S2). These 
findings additionally support the assertion that noncanonical NF-κB signaling in 
blood vessels is related to plaque inflammation and chronic inflammatory disease 
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enhances this. 
Figure 2. Systemic inflammation is linked to NIK vessel density in advanced atherosclerotic 
lesions of coronary arteries with stenosis greater than 40%. A) NIK vessel density in control 
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patients and those with chronic inflammatory disease (CID) classified by grade of stenosis. 
B) Immune cell density in control patients and CID in plaques with stenosis greater than 
40%; leukocytes (CD45), macrophages (CD68), mast cells (TRYP) and neutrophils (MPO). C) 
Quantification of total number of immune cells per NIK+ micro-vessel (* signifies p<0.05; ** 
signifies p<0.01). (Representative of staining from 249 lesions; n=249)
Figure 3. NIK expression in endothelial cells is associated with leukocytes, macrophages 
and mast cells in coronary atherosclerotic lesions. Correlation between NIK positive vessels 
and number of (A) lymphocytes (CD45), (B), macrophages (CD68) (C) mast cells (tryptase), and 
(D) neutrophils (myeloperoxidase; MPO) in atherosclerotic lesions of the coronary arteries. 
(Representative of staining from 249 lesions; n=249)
NIK+ microvessels are associated with plaque morphology and plaque 
instability
Plaque morphology plays an important role in the development of clinically manifest 
outcomes such as MI or stroke, with increasing plaque vulnerability leading to a 
greater chance of rupture and subsequent cardiovascular events (32). Lesion 
neovascularization advances plaque instability and based on our previous results, 
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we proposed that NIK activity in atherosclerotic microvessels may be associated 
with plaque instability. Using a second cohort of advanced atherosclerotic lesions 
isolated from carotid endarterectomy specimens, we were able to investigate the 
relationship between NIK+ microvessels and lesion vulnerability. Initial observations 
determined that NIK+ microvessels were on average higher in unstable lesions 
versus stable ones (Figure 4A), suggesting that there may be increased activation 
of noncanonical NF-κB pathway in unstable plaques. Additional analysis revealed a 
significant correlation between NIK+ and CD34+ vessels in both plaque phenotypes 
(p<0.0001), further implying that activation of the noncanonical pathway is linked to 
neovascularization in atherosclerotic lesions (Figure 4B). However, the increased 
level of NIK+ microvessels in unstable lesions was not just a reflection of a general 
increase in microvessels, as CD34+ vessels were not necessarily elevated within 
unstable plaques (Supplemental S3). Furthermore, we observed that CXCL12+ 
vessels were significantly increased in unstable plaques (p<0.05) (Figure 4C) and 
that NIK expression in microvessels strongly correlated with CXCL12 expression 
(p=0.0045), which is in line with previous findings demonstrating that activation of 
noncanonical NF-κB signalling in EC drives CXCL12 expression (24).
Next, we approached the question whether NIK expression was associated with 
plaque instability by examining the relationship between NIK+ microvessels and 
the lipid content of the carotid lesions. As lipid content increases and collagen 
deposition of the fibrous cap decreases, plaques are characterized as being more 
atheromatous and unstable, whereas fibrous plaques are regarded to be relatively 
stable (33). We found that the number of NIK+ microvessels was higher in lesions 
more atheromatous in nature as compared to fibrous ones (p<0.05) (Figure 4D). 
Furthermore, we observed that microvessels with active noncanonical NF-κB 
signaling were more prominently present in lesions with an evident lipid core 
greater than 40% as compared to those with less than 40% (Figure 4E). 
These data are the first to demonstrate that active noncanonical NF-κB signaling 
in atherosclerotic lesion microvessels is linked to plaque instability, which 
would imply that NIK expression in these vessels is also associated with adverse 
cardiovascular events. Indeed, this is also what we observed in the cohort of 
atherosclerotic plaques isolated from coronary arteries of patients suffering from 
a fatal MI, as NIK+ microvessel density was found to be significantly higher in lesions 
of the left anterior descending artery implicated in the MI as compared to lesions 
isolated from the same region that were not involved in the MI (p<0.05) (Figure 4F). 
This finding has striking implications, as active noncanonical NF-κB signaling in 
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EC has not been previously linked to unfavorable clinical outcome in patients with 
atherosclerosis and suggests that targeting this pathway may be beneficial in the 
treatment of the disease.
Figure 4. NIK
+
 microvessels are associated with plaque morphology and plaque instability. 
(A) NIK+ vessels in carotid endarterectomy plaque specimens characterized as either 
stable or unstable (n=40). (B) Correlation between NIK+ and CD34+ microvessels in carotid 
artery lesions (n=21). (C) CXCL12+ vessels in carotid endarterectomy plaque specimens 
characterized as either stable or unstable (n=40). Association of NIK positive vessels with 
(D) atherosclerotic plaque phenotype and (E) lipid content in lesions isolated from carotid 
endarterectomy (n=36). (F) Comparison of NIK positive vessel density in regions of the 
coronary artery either implicated in myocardial infarction (MI) or not: left anterior descending 
artery not implicated in MI (LAD-; n=100); left anterior descending artery implicated in MI 
(LAD+; n=82)(* signifies p<0.05) 
Ruptured plaques overexpress noncanonical NF-κB pathway related genes
To further validate that active noncanonical NF-κB signaling may be contributing 
to plaque instability, we examined the expression of noncanonical NF-κB related 
genes between ruptured and paired stable control segments of endarterectomy 
plaque specimens. Similar to the observation that NIK expression was increased 
in plaques with a more atheromatous phenotype, ruptured plaques contained 
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significantly higher gene expression levels of major signaling components of the 
noncanonical pathway, i.e. NIK, TRAF2, IKKα, p100/p52 and RelB (Supplemental 
table 3). As the noncanonical pathway acts downstream of several receptors, 
we also sought to identify which signaling axes in particular were upregulated 
in ruptured lesions. Expression of multiple members of the TNFRS family along 
with many of the corresponding ligands were established to be at higher levels in 
ruptured plaques, including LTβR, LIGHT, BAFF and RANK (Supplemental table 4). 
This is in line with previous reports implicating these factors in plaque vulnerability 
(34-39) and further illustrates the link between noncanonical NF- κB signaling and 
plaque instability.
DISCUSSION
Mounting evidence indicates that the noncanonical NF-κB pathway promotes 
disease progression in atherosclerosis, especially in the context of the CD40 
signaling axis (19, 34, 40). Several other members of the TNFRSF have also been 
implicated in this process, including the LTβR (20), BAFFR (21, 39) and RANK (36) 
as either a deletion of these noncanonical NF-κB pathway activating components 
in ApoE-/- mice on a high fat diet or neutralizing antibodies disrupting signaling 
through these axes, significantly ameliorate atherosclerotic plaque formation. 
The underlying mechanisms behind such observations are thought to be linked 
to adaptive immune responses, including T and B cell activation, or alternatively, 
to platelet function (41) Here, we describe the novel observation that active 
noncanonical NF-κB signaling occurs in EC of microvessels in atherosclerotic 
lesions and is associated with systemic and local inflammation, which may in turn 
be contributing to plaque instability and subsequently disease progression of 
atherosclerosis.
Previous studies characterizing noncanonical NF-κB signaling in blood vessels from 
patient samples found that NIK expression was exclusively present in pathological 
conditions such as arthritis and cancer, with no detectable levels found in matched 
non-pathological tissues (18). Based on these data, we investigated whether NIK 
was also increased in EC of atherosclerotic lesions and indeed, in plaques isolated 
both from coronary and carotid arteries we observed clear NIK expression in the 
microvessels. Furthermore, we observed increased expression of NIK in lesions 
of patients with a predisposing CID indicating that systemic inflammation can 
augment noncanoncial NF-κB signaling in atherosclerotic plaque microvessels. 
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Furthermore, we observed increased NIK+ microvessels in coronary lesions of 
patients with a predisposing CID indicating that systemic inflammation can augment 
noncanonical NF-κB signaling in atherosclerotic plaque microvessels. This may 
also explain the elevated levels of immune cells found in CID patients, especially in 
coronary plaques with stenosis greater than 40%. This enhanced activation may 
be a result of higher loads of inflammatory cytokines either circulating or in the 
adventitia of patients with CID, as has been previously described in the context of 
RA (42). Additionally, as noncanonical NF-kB signaling has been described to play a 
role in immune cell extravasation across the EC barrier, more constitutive signaling 
would lead to increased immune cell infiltration (24). Alternatively, this finding 
may also be due to a leakier microvessel phenotype, a hallmark of atherosclerotic 
plaque neovascularization. 
Local inflammation also appears to be a key factor associated with activated 
noncanonical NF-κB signaling in these microvessels in both CID patients and 
controls, as inflammatory immune cell content significantly correlated with 
NIK expression in microvessels. This seems logical given that immune cells 
express several activators of the noncanonical pathway such as LTβ, LIGHT, 
BAFF and CD40L. However, it remains to be elucidated whether the infiltration of 
immune cells is driving noncanonical NF-κB signaling in these microvessels, as 
inflammation has been demonstrated to drive angiogenesis and vice versa. It is 
likely that these processes support each other in a forward feeding loop, creating a 
chronic inflammatory state, which would further fuel atherogenesis.
Importantly, active noncanonical NF-κB signaling in microvessels of atherosclerotic 
lesions is linked to neovascularization, CXCL12 expression and plaque instability, 
which have not been previously described. Here, we establish increased expression 
of components of the noncanonical NF-κB pathway in ruptured versus paired stable 
control segments of carotid endarterectomy plaque specimens. Activation of the 
noncanonical pathway has been demonstrated to induce angiogenesis in EC, thus 
it is likely that a similar process also occurs in the atheroma microenvironment (18, 
43). This is also in line with our data which reveals significantly increased levels of 
NIK+ microvessels in more vulnerable atheromatous plaques of the carotid artery. 
Likewise, the activation of the noncanonical pathway in these microvessels might 
also be a marker of more immature and leaky vessels that is characteristic of lesion 
neovascularization, which would allow an increase in immune cell and erythrocyte 
infiltration, but also of small molecules such as lipids.  
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Finally, our finding that NIK+ microvessels in atherosclerotic lesions express 
CXCL12 is of particular interest as growing data indicates an important role for this 
chemokine in atherosclerosis. As CXCL12 is a powerful chemoattractant for immune 
cells, it may be contributing to the localized homing of inflammatory cells to the 
site of atherosclerotic lesions (26). Similarly, CXCL12 can also attract endothelial 
progenitor cells to sites of neovascularization. Furthermore, CXCL12 has the ability 
to activate platelets, increasing aggregation and setting the stage for thrombosis 
(27), which may explain why increased NIK expression in atherosclerotic lesions is 
associated with MI. CXCL12 has also been shown to stimulate the uptake of lipid 
rich platelets by macorphages, which (45) may link the noncanonical pathway to 
the fatty, atheromatous plaque phenotype, which we also observed in this study. 
Together these data further highlight the importance of NIK and the noncanonical 
NF-κB pathway in the CXCL12 signaling axis and its potential contribution to 
atherosclerosis. We have previously demonstrated that targeting of this pathway 
in EC using a small molecule NIK inhibitor prevents angiogenesis in a 3D model of 
synovial inflammation (47), and blocks adhesion and migration of immune cells in 
vitro (Kucharzewska et al, manuscript in preparation). Future studies are warranted 
to recapitulate this in the context of atherosclerosis. 
Together, our novel finding of active noncanonical NF-κB signaling in microvessels 
of atherosclerotic lesions and its association with inflammatory cell content as 
well as plaque instability and (fatal) cardiovascular events, further implicate the 
importance of this pathway in atherosclerosis. In conjunction with other reports 
relating this pathway to atherosclerotic plaque formation, this suggests that 
targeting the noncanonical NF-κB pathway may be an attractive therapeutic target 
in the treatment of atherosclerosis.
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Supplemental Figure S1 Representative staining of atherosclerotic lesions used 
for quantification: (A) Rabbit IgG isotype control (B) NF-κB inducing kinase (NIK) 
(C) CD45+ lymphocytes (D) CD68 + macrophages (E) Tryptase + mast cells (F) MPO + 
neutrophils (G) C-X-C chemokine motif ligand 12, CXCL12 
Supplemental Figure S2 NIK+ microvessels are linked to macrophage density in 
atherosclerotic lesions: Specimens of plaques isolated from endoarterectomy stained for 
the macrophage marker CD68 and NIK (n=36) 
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Rheumatoid arthritis (RA) is associated with higher risk of cardiovascular (CV) 
disease. Ongoing systemic inflammation is presumed to accelerate atherosclerosis 
by increasing inflammation in the arterial wall. However, evidence supporting this 
hypothesis is limited. We aimed to investigate arterial wall inflammation in RA vs 
osteoarthritis (OA), and its association with markers of inflammation and CV risk 
factors.
Methods
18-fluorodeoxyglucose PET combined with CT (18F-FDG-PET/CT) was performed 
in RA (n=61), and OA (n=28) to investigate inflammatory activity in the wall of large 
arteries. Secondary analyses were performed in patients with early untreated RA 
(n=30), and established RA, active under DMARD treatment (n=31) vs OA.
Results
Patients with RA had significantly higher 18F-FDG uptake in the wall of the carotid 
arteries (beta 0.27, 95%CI 0.11 – 0.44, P<0.01) and the aorta (beta 0.47, 95%CI 0.17 – 
0.76, P<0.01) when compared to OA, which persisted after adjustment for traditional 
CV risk factors. Patients with early RA had the highest 18F-FDG uptake, followed by 
patients with established RA, and osteoarthritis respectively. Higher erythrocyte 
sedimentation rate (ESR) and disease activity score of 28 joints (DAS28) values 
were associated with higher 18F-FDG uptake in all arterial segments. 
Conclusion
Patients with RA have increased 18F-FDG uptake in the arterial wall compared to 
patients with OA, as a possible marker of early atherosclerosis. Furthermore, a 
higher level of clinical disease activity and circulating inflammatory markers was 
associated with higher arterial 18F-FDG uptake, which may support a role of arterial 
wall inflammation in the pathogenesis of vascular complications in patients with 
RA.
Key points
Patients with RA have higher 18F-FDG uptake in the arterial wall.
Arterial wall uptake is associated with markers of inflammation, suggesting that it 
is a direct method for non-invasive visualisation of arterial inflammation. 
The highest arterial uptake was found in RA patients with high blood pressure 
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and TC/HDLc-ratio, suggesting that arterial inflammation is influenced by CV risk 
factors during active disease.
INTRODUCTION
Rheumatoid arthritis (RA) is associated with higher cardiovascular (CV) mortality 
when compared with the general population. (1, 2) This is only partially explained 
by the increased prevalence of traditional CV risk factors. (1) Chronic systemic 
inflammation, a characteristic feature of RA, is assumed to further increase CV 
risk in these patients. (1) Notably, inflammation is also considered fundamental in 
the development of atherosclerosis and acute atherothrombotic occlusions. (3) 
In fact, inflammatory activity of an atherosclerotic plaque (i.e. vulnerable plaque), 
rather than the degree of stenosis, is the major determinant of acute CV events. (4) 
If and how systemic inflammation interacts with local inflammation in the arterial wall 
is largely unknown. It has been suggested that systemic inflammation, for example 
by circulating pro-inflammatory cytokines, increases arterial wall inflammation, 
thereby accelerating plaque development and instability. (4) If this hypothesis is 
correct, systemic inflammation, for example induced by autoimmune disease, 
would be expected to be associated with increased arterial wall inflammation. In 
line with this, histologic evidence supports that patients with RA indeed have more 
vulnerable and inflamed atherosclerotic lesions than controls. (5) However, as most 
of these studies are of retrospective design (i.e. post-mortem) and performed in a 
single centre, the evidence they provide is useful for generating new hypotheses, 
but limited. Prospective studies exploring the effects of inflammation and anti-
inflammatory medication on vascular tissue are necessary.
Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography 
(PET/CT) has been proposed as an imaging modality for plaque inflammation. (6) 
In previous studies, increased FDG uptake has been reported in the arterial wall 
of RA patients when compared to healthy controls. (7-10) In the current study, 
we compared vascular wall FDG uptake as measured with 18F-FDG-PET/CT in RA 
patients to osteoarthritis (OA), and investigated its relationship with CV risk factors 
and inflammatory markers. New compared to earlier reports is that we included 
OA patients, which is of additional value, as their physical activity and use of 
medications such as non-steroidal anti-inflammatory drugs (NSAIDs) is similar 
to RA. (10-14) Furthermore, we performed whole body 18F-FDG-PET/CT scans in 
patients with early untreated RA, as well as established RA, with data on all large 
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arteries, as opposed to the majority of the other studies that only included the 
aorta and/or carotids.
PATIENTS AND METHODS
Study design and participants
Consecutive participants with active RA (i.e. disease activity score of 28 joints 
(DAS28) ≥ 4) of ≥50 years, and age-and sex-matched OA controls, were recruited 
from outpatient clinics of the departments of Rheumatology of Reade (n=86) and 
Amsterdam UMC, location VUmc (n=3), Amsterdam, the Netherlands. Exclusion 
criteria were hypersensitivity to any substance used for the 18F-FDG-PET-CT scan, 
active tuberculosis or other severe infections, pregnancy, moderate to severe 
heart failure (NYHA class III/IV), cancer, and limited life expectancy <12 months. 
Participants were categorized into three groups: newly diagnosed RA (n=30) 
scheduled to receive methotrexate (MTX) treatment, established RA (n=31) already 
on conventional DMARDs and scheduled to start a tumor necrosis factor alpha 
inhibitor (TNFi, adalimumab), and knee and/or hip OA confirmed on radiographs as 
controls (n=28). Patients with RA had to fulfil the 1987 or 2010 American College of 
Rheumatology (ACR) classification criteria. This study was approved by the medical 
ethics committee of the VU University in Amsterdam, The Netherlands. Informed 
consent was obtained from all patients participating in this study.
Study assessments
Demographic data, medical history, medication use, family history, disease duration, 
DAS28, IgM-rheumatoid factor (IgM-RF), anti-citrullinated protein antibody (ACPA), 
C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), plain-radiographic 
erosions in hands and/or feet, smoking status, blood pressure, body mass index 
(BMI, weight/height2 in kg/m2), waist to hip ratio (WHR), total cholesterol (TC), high 
density lipoprotein cholesterol (HDLc), low density lipoprotein cholesterol (LDLc) 
and triglycerides (TG) were assessed in all participants. Data and blood samples 
were collected on the same day that patients were scheduled to undergo the 
18F-FDG-PET/CT.
18F-FDG-PET/CT image acquisition
18F-FDG-PET/CT was performed according to established protocols using Gemini 
TF or Ingenuity TF (Philips Healthcare) PET/CT scanners at the Amsterdam UMC, 
location VUmc. Participants fasted for >6 hours before tracer injection. Just prior 
to injection venous plasma glucose was determined and in case of glucose > 11 
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mmol the scan was rescheduled. 18F-FDG (7 MBq/kg per scan time per bed position 
in accordance with international guidelines (16)) was injected intravenously. 
Afterwards the injection device was flushed with 20 mL of 0.9% NaCl and residual 
activity in the administration system was measured to determine the net injected 
dose. After a 90 minute rest period, of which 30 minutes full bed rest and no 
conversation allowed, a low-dose CT scan (120 kV, 35 mAs) was performed for 
localization and attenuation correction, followed by the total body PET scan 
(acquisition time: 2 minutes per bed position from head to groin and 1 minute 
per bed position from groin to toes). PET data were normalized and corrected 
for attenuation, decay and scatter according to a reconstruction method based 
on international guidelines. (16) 18F-FDG-PET/CT scans of healthy controls were 
performed on a Gemini TF scanner at the Amsterdam UMC, location AMC. These 
images only contained carotid arteries and the aorta. Participants were injected 
with comparable 18F-FDG doses (4.6-7.2 MBq/kg per scan time per bed position), 
also 90 min before image acquisition, and a comparable reconstruction method 
was used to the RA and OA participants from our study. 
18F-FDG-PET/CT image analysis
After visual inspection of the PET/CT images, the axial slice with the most intense 
18F-FDG uptake was determined for every arterial segment (hotspot method 
(17), figures 1 and 2). Regional arterial 18F-FDG uptake in this slice was quantified 
by drawing a region of interest (ROI) in this artery on the CT image, which was 
transferred to the PET image to determine the FDG uptake. The arterial maximal 
standardized uptake value (SUVmax) was calculated for each separate ROI using 
the maximal regional 18F-FDG uptake divided by the net injected 18F-FDG dose 
corrected for lean body mass and serum glucose level. SUVmax of the most-
diseased segment (MDS) was calculated by also including the two slices adjacent 
(one proximal and one distal) to the visually determined hotspot. (17) Additionally, 
SUVmax values were corrected for background activity by subtracting the mean 
blood SUV measured within the inferior or superior vena cava (VCI, VCS) from the 
arterial SUV value (cSUVmax). This method has been proposed as a new method for 
correcting for background FDG activity for atherosclerotic plaques compared to the 
maximal tissue-to-background ratio (TBRmax). (15, 18-21) As there is no consensus 
about the best way to calculate arterial FDG uptake, we have chosen to report all 
three values, i.e. SUVmax, cSUVmax and TBRmax. All images were analysed using 
an image analysis research tool for PET/CT developed in our hospital. The PET/CT 
images were judged by three independent observers (RA, AB, AvS). For 10 patients 
image analysis was performed by two observers, who were unaware of each 
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other’s findings. Intraclass correlation coefficients (ICCs) for all arterial segments 
were between 0.81 and 0.96, which represents excellent interobserver reliability 
according to Landis and Koch (see Supplementary Data S1, Supplementary Table 
S1 and Supplementary Figure S1, available at Rheumatology online, for ICCs, scatter 
and Bland-Altman plots). (22) The ascending aorta, aortic arch, descending aorta, 
abdominal aorta and left and right carotid, iliac and femoral arteries were quantified 
separately (figure 1), according to the predefined definitions that were previously 
published. (17) For statistical analyses, segments were combined (aorta: ascending, 
arch, descending and abdominal segments; carotid, femoral and iliac arteries: left 
and right segment) by using the segment with the highest uptake. The focal pattern 
and the intensity of the FDG uptake was suggestive of atherosclerosis, rather than 

















Figure 2. Example of a hotspot in the descending aorta on 18F-FDG-PET/CTi mages 
Arrows indicate hotspot in descending aorta on (A) sagittal (B) coronal and (C) trans axial fused 
PET/CT images. An example of a region of interest (ROI) is depicted in green on (D) trans axial 
CT image.
Statistical analyses
Data is presented in mean ± standard deviation (SD), median with interquartile 
range (IQR) and/or numbers (percentages). Baseline characteristics and SUVmax, 
cSUVmax, SUVmax MDS and TBRmax measurements between RA and OA or early RA 
and established RA were compared using t-test, chi square test and nonparametric 
tests. Multivariate linear regression analyses were used to assess whether group 
differences remained after adjusting for CV risk factors (age, sex, BMI, pack years, 
hypertension, TC/HDLc-ratio) and to evaluate the influence of CV risk factors and 
RA-related factors (e.g. markers of inflammation) on SUVmax and cSUVmax levels 
in the arterial wall. Post-hoc ANOVA for trend analysis was performed to investigate 
whether there was a trend for increase in SUVmax, cSUVmax, SUVmax MDS and 
TBRmax for subsequently osteoarthritis, established RA and early RA participants. 
We did not include healthy controls in any of the statistical analyses because of the 
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small number of participants (n=5).  Analyses were performed with SPSS, version 22 




The baseline characteristics of RA and OA patients are shown in table 1. 
Compared with OA, RA patients were more often current smokers, had more 
pack years, higher ESR and CRP and used more NSAIDs. In the subgroup analyses 
(Supplementary Table S2, available at Rheumatology online), patients with early RA 
had higher DAS28, ESR and CRP, and fewer erosions compared with established 
RA. Furthermore, they had a higher blood pressure, higher TC/HDLc ratio and lower 
HDL.
Table 1. Baseline characteristics of RA and OA patients
Rheumatoid arthritis (n=61) Osteoarthritis (n=28)
Demographics 
Age, years 63 ± 8 63 ± 6
Women, no. (%) 34 (55.7) 16 (57.1)
Median inclusion year, no. 2014 2016 
Cardiovascular risk factors
Previous CVD, no. (%) 13 (21.3) 9 (32.1)
Hypertension, no. (%) 34 (55.7) 19 (67.9)
Systolic BP, mmHg 135 ± 20* 132 ± 19
Diastolic BP, mmHg 82 ± 10 82 ± 8
Current smoking, no. (%) 15 (24.6)* 2 (7.1)*
Pack years 8 (0 – 30)* 2 (0 – 12)*
DM, no. (%) 10 (16.4) 3 (10.7)
Fasting glucose, mmol/L 5.7 ± 1.2 5.3 ± 0.6
TC/HDLc ratio 3.5 ± 1.3 3.4 ± 1.1
TC, mmol/L 4.9 ± 1.1 4.8 ± 1.0
HDLc, mmol/L 1.5 ± 0.7 1.5 ± 0.4
LDLc, mmol/L 2.8 ± 0.9 2.7 ± 0.9
Triglycerides, mmol/L 1 (0.8 – 1.5) 1.2 (0.9 – 1.6)
   Waist/hip ratio, cm a 0.92 ± 0.08 0.98 ± 0.18
   Body mass index, kg/m2 28 ± 6 29 ± 6*
table continues
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Rheumatoid arthritis (n=61) Osteoarthritis (n=28)
Medication, no. (%)
   Antihypertensive drug 29 (47.5) 16 (57.1)*
   Statin 16 (26.2) 12 (42.9)
   Aspirin 12 (19.7)* 11 (39.3)*
Disease-related factors
   Disease duration, years 1 (0.4 – 9)* 5 (3 – 11)*
   RF and/or ACPA positive, no. (%) 43 (70.5) -
   Erosions, no. (%) 21 (34.4) -
   Nodules, no. (%) b 6 (9.8) -
   DAS28, range 0-10 4.7 ± 1.1 -
   ESR, mm/h 22 (12 – 37)* 7 (4 – 13)*
   CRP, mg/L 8 (1 – 25)* 1 (1 – 3)*
RA medications, no. (%)
   NSAID 37 (60.7)* 6 (21.4)*
   COXIB 6 (9.8) 0 (0)
   Methotrexate 27 (44.3) -
   Prednisone 14 (22.9) -
   Other DMARD 17 (27.9) -
Continuous variables are presented as mean ± SD or as median (IQR). Categorical and 
dichotomous variables are presented as numbers and/or percentages. *statistically 
significant. IQR = interquartile range, CVD= cardiovascular disease, BP= blood pressure, TC= 
total cholesterol, LDLc= low-density lipoprotein cholesterol, HDLc= high-density lipoprotein 
cholesterol, pack years= (packs smoked per day)*(years as a smoker), DM= type 2 diabetes 
mellitus, RA= rheumatoid arthritis, RF= rheumatoid factor, ACPA= anti–citrullinated 
protein antibody, DAS28= Disease Activity Score of 28 joints, DMARD= disease-modifying 
antirheumatic drug, OA= osteoarthritis, ESR=erythrocyte sedimentation rate, CRP=C-
reactive protein, NSAID= nonsteroidal anti-inflammatory drug, COXIB= COX-2-selective 
NSAID. Missings: (a) 16%; (b) 23%, all other variables < 3%.
Arterial 18F-FDG uptake in RA, OA and healthy controls
Patients with RA had significantly higher SUVmax, cSUVmax and TBRmax in the 
aorta, femoral and carotid arteries when compared with OA patients (SUVmax 
figure 3.1A, Supplementary Table S3, available at Rheumatology online). This was 
still significant after correction for age, sex and other traditional CV risk factors 
(BMI, pack years, hypertension and TC/HDLc-ratio) for the aorta (SUVmax beta 0.47, 
95%CI 0.17 – 0.76, P<0.01; cSUVmax beta 0.35, 95%CI 0.08 – 0.62, P=0.01; TBRmax 
beta 0.60, 95%CI 0.06 – 1.13, P=0.03), carotid arteries (SUVmax beta 0.27, 95%CI 0.11 
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– 0.44, P<0.01; cSUVmax beta 0.13, 95%CI -0.01 – 0.28, P=0.06; TBRmax beta 0.32, 
95%CI -.002 – 0.64, P=0.05), femoral arteries (SUVmax beta 0.28, 95%CI 0.04 – 0.52, 
P=0.03; cSUVmax beta 0.20, 95%CI -0.02 – 0.42, P=0.07, TBRmax beta 0.29, 95%CI 
-0.06 – 0.64, P=0.10). In the sub analyses within the RA group (early vs. established), 
we found that the early RA group had the highest FDG uptake measured in SUVmax 
and cSUVmax, followed by established RA and OA (SUVmax figure 3.1B, all SUVmax 
figure 3.1A, Supplementary Table S4, available at Rheumatology online). SUVmax 
MDS gave comparable results to the SUVmax hotspot method, while TBRmax did 
not differ significantly between the three groups (Table 2 and Supplementary file 3, 
available at Rheumatology online). After adjustment for ESR or CRP the differences 
in SUVmax between the RA and OA patients were reduced or not significant 
anymore, suggesting that the SUVmax differences were at least partly explained 
by differences in systemic inflammation.
Figure 3. Arterial wall FDG uptake in RA vs OA
Crude and adjusted means with confidence intervals of arterial wall 18F-FDG uptake in RA (n=61) 
vs. OA (n=28) and early RA vs. established RA vs. OA analyzed with a linear regression analysis 
adjusted for age, sex, hypertension, TC/HDLc ratio, pack years and BMI. 
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Table 2. Arterial wall 18F-FDG uptake in early RA and established RA vs. OA
Beta 95%CI P-value
SUVmax
Carotid Early RA 0.242 -0.01 – 0.50 0.06
Established RA 0.328 0.74 – 0.58 0.01
Aorta Early RA 0.368 -0.07 – 0.81 0.10
Established RA 0.473 0.04 – 0.91 0.03
Iliac Early RA 0.095 -0.29 – 0.48 0.63
Established RA 0.082 -0.30 – 0.46 0.67
Femoral Early RA 0.323 0.05 – 0.59 0.02
Established RA 0.223 -0.06 – 0.50 0.12
SUVmaxMDS
Carotid Early RA 0.199 -0.01 – 0.41 0.06
Established RA 0.196 -0.01 – 0.40 0.06
Aorta Early RA 0.199 -0.10 – 0.50 0.18
Established RA 0.130 -0.17 – 0.43 0.38
Iliac Early RA 0.030 -0.23 – 0.29 0.81
Established RA 0.043 -0.21 – 0.30 0.73
Femoral Early RA 0.243 -0.003 – 0.49 0.05
Established RA 0.223 -0.03 – 0.48 0.08
cSUVmax
Carotid Early RA 0.220 -0.02 – 0.46 0.07
Established RA 0.218 -0.02 – 0.45 0.07
Aorta Early RA 0.375 -0.05 – 0.80 0.08
Established RA 0.390 -0.03 – 0.80 0.07
Iliac Early RA 0.042 -0.36 – 0.44 0.84
Established RA -0.040 -0.43 – 0.35 0.84
Femoral Early RA 0.299 0.06 – 0.54 0.02
Established RA 0.097 -0.15 – 0.34 0.43
TBRmax
Carotid Early RA 0.397 -0.02 – 0.82 0.06
Established RA 0.286 -0.13 – 0.70 0.17
Aorta Early RA 0.560 -0.16 – 1.28 0.12
Established RA 0.374 -0.33 – 1.08 0.29
Iliac Early RA -0.013 -0.68 – 0.66 0.97
Established RA -0.119 -0.77 – 0.53 0.72
Femoral Early RA 0.516 0.06 – 0.97 0.03*
Established RA 0.102 -0.37 – 0.57 0.66
RA= rheumatoid arthritis, OA=osteoarthritis, SUVmax=maximum standardized uptake value, 
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cSUVmax= corrected SUVmax, TBRmax=maximum tissue to background ratio. Reference= 
OA. Linear regression analyses adjusted for age, sex, hypertension, TC/HDLc ratio, pack 
years and BMI
Table 3. Association between arterial wall 18F-FDG uptake in SUVmax, inflammatory markers 
and medication
RA OA
Beta 95% CI P-value Beta 95%CI P-value
Carotid arteries
CRP 0.003 -0.020 – 0.008 0.29 0.004 -0.043 – 0.051 0.86
ESR 0.006 0.002 – 0.010 <0.01 0.001 -0.010 – 0.012 0.82
DAS28 0.060 -0.020 – 0.150 0.12 n.a. n.a. n.a
Diabetes 0.350 0.110 – 0.60 <0.01 -0.029 -0.550 – 0.490 0.91
Statin 0.050 -0.180 – 0.280 0.66 -0.183 -0.520 – 0.150 0.26
Antihypertensives 0.101 -0.103 – 0.304 0.33 -0.075 -0.377 – 0.226 0.61
Aspirin -0.019 -0.283 – 0.245 0.88 0.091 -0.214 – 0.396 0.55
Pack years 0.002 -0.001 – 0.006 0.20 -0.003 -0.015 – 0.009 0.62
Aorta
CRP 0.007 -0.003 – 0.017 0.16 0.009 -0.056 – 0.075 0.77
ESR 0.015 0.008 – 0.020 <0.01 0.008 -0.007 – 0.022 0.28
DAS28 0.190 0.040 – 0.340 <0.01 n.a. n.a. n.a.
Diabetes 0.470 -0.010 – 0.950 0.055 -0.024 -0.760 – 0.710 0.95
Statin 0.095 -0.340 – 0.530 0.66 -0.281 -0.750 – 0.190 0.22
Anithypertensives 0.138 -0.194 – 0.470 0.41 -0.140 -0.523 – 0.243 0.46
Aspirin -0.221 -0.637 – 0.194 0.29 0.279 -0.096 – 0.655 0.14
Pack years 0.001 -0.004 – 0.007 0.65 0.005 -0.011 – 0.021 0.54
Iliac arteries
CRP 0.018 0.010 – 0.025 <0.01 0.022 -0.022 – 0.066 0.30
ESR 0.010 0.004 – 0.020 <0.01 0.004 -0.006 – 0.015 0.37
DAS28 0.110 -0.020 – 0.240 0.097 n.a. n.a. n.a.
Diabetes 0.280 -0.130 – 0.70 0.18 -0.20 -0.698 – 0.292 0.40
Statin 0.150 -0.220 – 0.510  0.41 -0.20 -0.520 - 0.120 0.20
Antihypertensives -0.072 -0.347 – 0.202 0.60 0.039 -0.280 – 0.358 0.81
Aspirin -0.091 -0.434 – 0.252 0.60 0.176 -0.139 – 0.492 0.26
Pack years 0.003 -0.002 – 0.008 0.22 0.001 -0.011 – 0.014 0.82
Femoral arteries




Beta 95% CI P-value Beta 95%CI P-value
ESR 0.006 0.002 – 0.011 <0.01 -0.004 -0.015 – 0.007 0.48
DAS28 0.10 0.022 – 0.187 <0.01 n.a. n.a. n.a.
Diabetes 0.48 0.250 – 0.720 <0.01 -0.21 -0.770 – 0.340 0.44
Statin 0.21 -0.022 – 0.45 0.075 -0.20 -0.560 - 0.160 0.26
Antihypertensives 0.175 -0.053 – 0.403 0.13 -0.032 -0.370 – 0.305 0.85
Aspirin 0.072 -0.236 – 0.380 0.64 0.244 -0.083 – 0.572 0.14
Pack years 0.002 -0.002 – 0.006 0.35 -0.001 -0.013 – 0.011 0.87
Linear regression analyses were performed adjusted for age, sex, BMI, hypertension, 
packyears and TC/HDLc ratio as appropriate. RA= rheumatoid arthritis, OA=osteoarthritis, 
SUVmax=maximum standardized uptake value, CRP=C-reactive protein ESR=Erythrocyte 
sedimentation rate, DAS28=disease activity score 28, PWV=pulse wave velocity. 
Arterial 18F-FDG uptake association with markers of inflammation and CV risk factors
In RA, higher ESR was associated with a higher 18F-FDG uptake in the arterial wall of 
all arterial segments (i.e. carotid, aorta, iliac, and femoral arteries) after correction 
for age, sex, hypertension, TC/HDLc ratio, packyears and BMI (table 3). Pack 
years, NSAID use, hypertension, TC/HDLc-ratio, BMI, and WHR were not statically 
significantly associated with increased arterial 18F-FDG uptake for both RA and 
OA participants (data not shown). For RA participants, in some arterial segments 
higher CRP and DAS28 were significantly associated with a higher 18F-FDG uptake. 
In nearly all arterial segments, diabetes was associated with a significant increase 
in SUVmax in the arterial wall. Furthermore, in RA patients cSUVmax and TBRmax 
values for the carotid arteries, aorta, iliac and femoral arteries were also associated 
with serological inflammatory markers (Supplementary Tables S5 and S6, available 
at Rheumatology online). For OA participants, CRP, ESR, and diabetes were not 
associated with the SUVmax values in the arterial segments. The cSUVmax an 
TBRmax values were not associated with any of these values in OA (Supplementary 
Tables S5 and S6, available at Rheumatology online). 
DISCUSSION
The results of this study show that patients with RA have an increased 18F-FDG 
uptake in the wall of several arterial vessels compared to osteoarthritis patients and 
healthy controls. This finding remained significant after adjustment for traditional 
CV risk factors. Furthermore, the 18F-FDG uptake was associated with serological 
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and clinical markers of inflammation such as CRP, ESR and DAS28. Higher levels 
of inflammatory markers were associated with higher FDG uptake in the arteries 
independent of traditional CV risk factors. This indicates that patients with RA 
have increased inflammation in the arterial wall during active disease, which may 
translate into a higher CVD risk. Our results are in line with previous studies in 
which a higher FDG uptake was found in RA in the carotid arteries (24) and the aorta 
(7, 9, 10, 13). However, in these studies, analyses on FDG vessel wall uptake was not 
complete with respect to uptake assessment in all arterial segments, inclusion of a 
control group and/or association with inflammatory markers. The newly diagnosed 
(early) RA group, not yet being treated with DMARDs and/or prednisone, had higher 
CRP, ESR and DAS28, as well as the highest 18F-FDG uptake in all arterial segments. 
In contrast, the established RA group had slightly lower arterial 18F-FDG uptake (in 
SUVmax) compared to early RA patients. These observed lower SUVmax values in 
patients with established RA indicate less inflammation in the arterial wall during 
active disease in comparison with early RA, which is most likely explained by the 
fact that the established RA patients have been treated with DMARDs for a median 
of eight years already since diagnosis. In addition, the early RA group with the 
highest inflammatory burden on 18F-FDG-PET/CT had higher blood pressure, higher 
TC/HDLc ratio and lower HDLc, suggesting that 18F-FDG vessel wall uptake is also 
influenced by traditional CV risk factors during active disease. This finding is also in 
line with previous publications in which the lipid paradox in RA has been described 
extensively. (25-27) 
In our study, RA patients with DM had a significantly higher FDG uptake in the 
arterial wall than RA patients without DM, suggesting an even further increased 
risk in these patients. Insulin is known to alter 18F-FDG uptake in brain and muscle 
but not the heart, even when serum blood glucose levels (which we corrected for 
when calculating SUV) are comparable. (28, 29) This would suggest that, even 
though insulin could influence the availability of FDG in the blood pool, for example 
by increased uptake in muscle tissue, this would only strengthen our results, as 
FDG uptake in the arterial wall of RA patients with DM should then be even higher. 
This association between DM and SUVmax was only observed in RA, but not in the 
OA group, which is in line with other studies that show that DM increases the CVD 
risk in RA patients. (30, 31) In addition, there was a trend for a protective effect 
of statins on arterial inflammation, which is in line with previously published trials 
showing reduced arterial 18F-FDG uptake in participants after using statin therapy. 
(32-38)
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In this study we used the visually detected single-hottest-slice for quantification of 
the 18F-FDG uptake (hotspot method) which is less time-consuming and potentially 
holds the same results as drawing ROIs on all slices of an arterial segment, since 
the SUVmax is calculated using the hottest voxel in the arterial wall. A previous 
study from our group concluded that “the hotspot method is equally sensitive and 
can be used without the risk of missing inflamed lesions”. However, that study 
also concluded that interobserver agreement was not optimal in the segments 
other than the aortic arch and abdominal aorta. In our current study the highest 
interobserver agreement was also found in the aorta, indicating that the results in 
the aorta are possibly more reliable than the results in the other segments. 
Currently there is no consensus about the best way to calculate arterial FDG uptake 
and therefore we have chosen to report four metrics, i.e. SUVmax, SUVmax MDS, 
cSUVmax and TBRmax. For all analyses SUVmax MDS gave comparable results to 
SUVmax, so incorporating information of adjacent slices to the hotspot is probably 
not necessary. We did not find any statistically significant difference in TBRmax, 
a metric where SUVmax is divided by the mean venous blood 18F-FDG uptake to 
correct for the availability of 18F-FDG from the blood. It is known that TBRmax is 
less stable for measuring arterial wall inflammation as its variance is composed 
of both the variance observed in the arterial wall and the variance in the blood 
pool, making TBR less reproducible than SUV (19-21). A new method proposed 
for correction for background activity is subtracting the mean blood SUV from 
SUVmax (cSUVmax), as blood activity adds to arterial wall activity (18-21). However, 
this method only corrects for the partial volume effect and not for differences in 
availability of 18F-FDG from the blood (which is done with TBR). Both cSUVmax and 
TBR have major limitations and therefore (for cross-sectional data) SUVmax might 
be the most appropriate metric.
Several limitations need to be discussed. As mentioned above, the OA patients 
might not have been the right group to compare the RA group with. Recent 
literature suggests that low grade inflammation also exists in OA, and this might 
have led to a less pronounced SUVmax difference between the groups. We did 
determine 18F-FDG uptake in 5 age- and sex-matched healthy individuals to acquire 
some idea about the 18F-FDG uptake in the arterial vessel wall in this group. For 
the aorta the SUVmax values of the healthy controls were lower when compared 
with the RA and OA patients. Unfortunately, due to the low numbers we could not 
perform any statistical analyses to compare the arterial FDG uptake in this group 
to that of the RA or OA patients. Ideally, we would have included a healthy control 
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group with enough statistical power to perform additional analyses.
In conclusion, our study demonstrates that patients with RA have 18F-FDG uptake 
in the arterial wall that is associated with markers of inflammation (i.e. CRP, ESR, 
DAS28), suggesting that it is a direct method for non-invasive visualisation of 
inflammation in arteries. Furthermore, this finding strengthens the notion that high 
inflammatory burden accelerates atherosclerosis and plaque instability, thereby 
increasing the risk of acute CV events. In this light, optimal anti-inflammatory 
therapy is necessary in these patients to reduce CV risk. However, further studies 
are needed to investigate the direct effects of anti-inflammatory therapy on the 
vascular wall as measured by methods such as an 18F-FDG-PET/CT.
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SUPPLEMENTARY MATERIAL
Supplementary Data S1. Interobserver agreement
ICCs were excellent for all arterial segments and VCS (ranging from 0.81 (95%CI 0.58-
0.92) for femoral arteries to 0.96 (95%CI 0.87-0.99) for the aorta; Supplementary 
Table S1, Supplementary Figure S1A). Lower agreement was found for VCI (ICC = 
0.71, 95%CI 0.20-0.92). Scatter and Bland-Altman plots suggest that in the lower 
ranges (SUVmean/max < 1.5) SUV values of observer A were higher, while in the 
higher ranges (SUVmean/max ≥ 1.5) the SUV values of observer B were higher 
(Supplementary Figure S1B+C).  Overall mean difference in SUVmax between the 2 
observers approached zero (0.013; Supplementary Figure S1C).
Supplementary Table S1. Intraclass correlation coefficients 
ICC 95% confidence interval p-value
All arterial segments together 0.87 0.80-0.98 <0.001
Carotid arteries 0.85 0.60-0.93 <0.001
Aorta 0.96 0.87-0.99 <0.001
Iliac arteries 0.88 0.72-0.95 <0.001
Femoral arteries 0.81 0.58-0.92 <0.001
VCS 0.89 0.64-0.97 <0.001
VCI 0.71 0.20-0.92 <0.001
ICC, intraclass correlation coefficients; VCS, superior vena cave; VCI, inferior vena cava. 
Supplementary Figure S1. Intraobserver agreement for SUVmax (arterial segments) or 
SUVmean (VCS and VCI) (n=10). (A) Intraclass correlation coefficients with 95% CI, (B) scatter 
and (C) Bland-Altman plot.
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Supplementary Figure S2. Pattern of FDG uptake. Focal uptake of FDG next to and above a 
calcified (stable) plaque in the abdominal aorta on CT (left) PET/CT overlay (middle) and PET 
(right) images. FDG, Fluorodeoxyglucose.
Supplementary Table S2. Baseline characteristics of early RA and established RA patients
Early RA (n=30) Established RA (n=31)
Demographics 
Age, years 65 ± 9 61 ± 7
Women, no. (%) 17 (56.7) 17 (54.8)
Median inclusion year, no. 2014 2013 
Cardiovascular risk factors
Previous CVD, no. (%) 7 (23.3) 6 (19.4)
Hypertension, no. (%) 17 (56.7) 17 (54.8)
Systolic BP, mmHg 142 ± 21* 127 ± 17*
Diastolic BP, mmHg 85 ± 8* 78 ± 10*
Current smoking, no. (%) 7 (23.3) 8 (25.8)
Pack years 6 (0 – 22) 14 (0 – 30)
DM, no. (%) 5 (16.7) 5 (16.1)
Fasting glucose, mmol/L 5.8 ± 1.0 5.6 ± 1.3
TC/HDLc ratio 4.0 ± 1.6* 3.0 ± 0.9*
TC, mmol/L 4.8 ± 1.2 4.9 ± 1.0
HDLc, mmol/L 1.3 ± 0.3* 1.8 ± 0.8*
LDLc, mmol/L 3.0 ± 1.0 2.7 ± 0.7
Triglycerides, mmol/L 1 (0.9 – 1.6) 0.9 (0.8 – 1.3)
   Waist/hip ratio, cm 0.92 ± 0.08 0.92 ± 0.08
   Body mass index, kg/m2 27 ± 5 28 ± 8
IMT, mm 0.684 ± 0.097 0.675 ± 0.155
AIx, % 29.01 ± 8.65 26.54 ± 9.52




Early RA (n=30) Established RA (n=31)
   Antihypertensive drug 16 (53.3) 13 (41.9)
   Statin 7 (23.3) 9 (29.0)
   Aspirin 5 (16.7) 7 (22.6)
Disease-related factors
   Disease duration, years 0.04 (0.02 – 0.06)* 8 (2 – 14)*
   RF and/or ACPA positive, no. (%) 21 (70.0) 22 (70.9)
   Erosions, no. (%) 5* 16*
   Nodules, no. (%) 2 4
   DAS28, range 0-10 5.0 ± 1.1* 4.4 ± 1.1*
ESR, mm/h 25 (14 – 49)* 18 (7 – 26)*
CRP, mg/L 10 (1 – 30)* 4 (1 – 16)*
RA medications, no. (%)
   NSAID 21 (67.7)* 16 (51.6)*
Coxib 4 (13.3) 2 (6.5)
   Methotrexate 1 (3.3) 26 (83.9)*
   Prednisone 2 (6.7) 12 (38.7)*
   Other DMARD 0 (0) 17 (54.8)*
Continuous variables are presented as mean ± SD or as median (IQR). Categorical and 
dichotomous variables are presented as numbers and/or percentages. * Statistically 
significant difference, IQR = interquartile range, CVD= cardiovascular disease, BP= blood 
pressure, TC= total cholesterol, LDLc= low-density lipoprotein cholesterol, HDLc= high-
density lipoprotein cholesterol, pack years= (packs smoked per day)*(years as a smoker), 
DM= type 2 diabetes mellitus, RA= rheumatoid arthritis, RF= rheumatoid factor, ACPA= anti–
citrullinated protein antibody, DAS28= Disease Activity Score, DMARD= disease-modifying 
antirheumatic drug, cIMT= carotid intima media thickness, AIx= augmentation index, PWV= 
pulse wave velocity, ESR=erythrocyte sedimentation rate, CRP=C-reactive protein, NSAID= 
nonsteroidal anti-inflammatory drug, COXIB= COX-2-selective NSAID. Differences at 
baseline between the groups were analysed using the Student’s t-test, chi square test and 
non-parametric tests.
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Supplementary Table S3. Arterial wall 18F-FDG uptake in RA and OA participants
RA (n=61) OA (n=28) P-value
SUVmax
Carotid arteries 1.51 ± 0.39* 1.26 ± 0.38* <0.01
Aorta 2.11 ± 0.65* 1.73 ± 0.48* <0.01
Iliac arteries 1.75 ± 0.53 1.63 ± 0.40 0.29
Femoral arteries 1.60 ± 0.44 1.43 ± 0.42 0.11
SUVmaxMDS
Carotid arteries 1.39 ± 0.36* 1.18 ± 0.36* 0.01
Aorta 1.91 ± 0.55* 1.59 ± 0.41* <0.01
Iliac arteries 1.56 ± 0.38 1.50 ± 0.38 0.48
Femoral arteries 1.47 ± 0.42 1.32 ± 0.38 0.13
cSUVmax
Carotid arteries 0.70 ± 0.29 0.57 ± 0.30 0.06
Aorta 1.30 ± 0.58* 1.03 ± 0.41* 0.03
Iliac arteries 0.87 ± 0.50 0.86 ± 0.35 0.91
Femoral arteries 0.72 ± 0.42 0.67 ± 0.37 0.57
TBRmax
Carotid arteries 2.25 ± 0.70 1.99 ± 0.51 0.09
Aorta 3.17 ± 1.18 2.76 ± 0.81 0.11
Iliac arteries 2.61 ± 0.90 2.61 ± 0.66 0.99
Femoral arteries 2.39 ± 0.82 2.27 ± 0.54 0.47
RA= rheumatoid arthritis, OA=osteoarthritis, SUVmax=maximum standardized uptake 
value, cSUVmax= corrected SUVmax, TBRmax=maximum tissue to background ratio. Linear 
regression analyses adjusted for age, sex, BMI, hypertension, packyears and TC/HDLc ratio
Supplementary Table S4. Arterial wall 18F-FDG uptake in early RA, established RA and OA 
participants
Early RA (n=30) Established RA 
(n=31)
OA (n=28) P-value for 
trend
SUVmax
Carotid arteries 1.58 ± 0.42* 1.44 ± 0.36* 1.26 ± 0.38* <0.01
Aorta 2.17 ± 0.57* 2.05 ± 0.71* 1.73 ± 0.48* <0.01
Iliac arteries 1.79 ± 0.43 1.71 ± 0.61 1.63 ± 0.40 0.23
Femoral arteries 1.70 ± 0.44* 1.49 ± 0.42* 1.43 ± 0.42* 0.02
SUVmaxMDS
Carotid arteries 1.48 ± 0.39* 1.30 ± 0.31* 1.18 ± 0.36* <0.01
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Early RA (n=30) Established RA 
(n=31)
OA (n=28) P-value for 
trend
Aorta 1.99 ± 0.53* 1.84 ± 0.57* 1.59 ± 0.41* <0.01
Iliac arteries 1.60 ± 0.36 1.52 ± 0.41 1.50 ± 0.38 0.30
Femoral arteries 1.56 ± 0.42* 1.37 ± 0.41* 1.32 ± 0.38* 0.03
cSUVmax
Carotid arteries 0.76 ± 0.31* 0.64 ± 0.27* 0.57 ± 0.30* 0.04
Aorta 1.35 ± 0.52* 1.26 ± 0.63* 1.03 ± 0.41* 0.02
Iliac arteries 0.89 ± 0.36 0.85 ± 0.61 0.86 ± 0.35 0.79
Femoral arteries 0.82 ± 0.46 0.62 ± 0.34 0.67 ± 0.37 0.13
TBRmax
Carotid arteries 2.33 ± 0.67 2.17 ± 0.74 1.99 ± 0.51 0.05
Aorta 3.22 ± 0.98 3.12 ± 1.36 2.75 ± 0.81 0.12
Iliac arteries 2.66 ± 0.76 2.56 ± 1.03 2.61 ± 0.66 0.81
Femoral arteries 2.52 ± 0.78 2.27 ± 0.86 2.27 ± 0.54 0.21
RA= rheumatoid arthritis, OA=osteoarthritis, SUVmax=maximum standardized uptake value, 
cSUVmax= corrected SUVmax, TBRmax=maximum tissue to background ratio
Supplementary Table S5. Association of arterial wall 18F-FDG uptake in cSUVmax with 
inflammatory markers
RA OA
Beta 95% CI p-value Beta 95% CI p-value
Carotid arteries
CRP 0.004 0.000 – 0.008 0.075 0.002 -1.820 – 2.460 0.91
ESR 0.004 0.001 – 0.008 0.02 0.003 -0.007 – 0.013 0.56
DAS28 0.030 -0.039 – 0.099 0.38 n.a. n.a. n.a.
Diabetes 0.091 -0.130 – 0.310 0.40 0.169 -0.410 – 0.750 0.55
Statin -0.023 -0.210 – 0.170 0.81 -0.073 -0.390 – 0.250 0.64
Aorta
CRP 0.008 -0.001 – 0.017 0.072 0.010 -0.054 – 0.075 0.74
ESR 0.013 0.007 – 0.020 <0.01 0.009 -0.005 – 0.023 0.19
DAS28 0.155 0.017 – 0.290 0.03 n.a. n.a. n.a.
Diabetes 0.210 -0.240 – 0.660 0.36 -0.064 -0.930 – 0.810 0.88
Statin 0.022 -0.370 – 0.420 0.91 -0.180 -0.640 – 0.290 0.44
Iliac arteries
CRP 0.018 0.012 – 0.025 <0.01 0.010 -0.036 – 0.055 0.66
ESR 0.007 0.001 – 0.013 0.03 0.004 -0.007 – 0.014 0.47
table continues
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RA OA
Beta 95% CI p-value Beta 95% CI p-value
DAS28 0.058 -0.067 – 0.183 0.35 n.a. n.a. n.a.
Diabetes -0.055 -0.450 – 0.340 0.78 -0.022 -0.640 – 0.590 0.94
Statin -0.036 -0.380 – 0.310 0.83 -0.083 -0.420 – 0.250 0.61
Femoral arteries
CRP 0.006 0.002 – 0.010 <0.01 -0.022 -0.070 – 0.024 0.33
ESR 0.004 0.000 – 0.007 0.04 -0.005 -0.015 – 0.006 0.36
DAS28 0.048 -0.020 – 0.160 0.11 n.a. n.a. n.a.
Diabetes 0.120 -0.096 –  0.326 0.28 0.347 -0.260 – 0.950 0.24
Statin 0.004 -0.184 – 0.192 0.96 0.080 -0.260 – 0.420 0.63
Linear regression analyses adjusted for age, sex, BMI, hypertension, packyears and TC/HDLc 
ratio as appropriate. RA= rheumatoid arthritis, OA=osteoarthritis, cSUVmax=corrected 
maximum standardized uptake value, CRP=C-reactive protein ESR=Erythrocyte sedimentation 
rate, DAS28=,disease activity score 28, PWV=pulse wave velocity.
Supplementary Table S6. Association of arterial wall 18F-FDG uptake in TBRmax with 
inflammatory markers
RA OA
Beta 95% CI p-value Beta 95% CI p-value
Carotid arteries
CRP 0.008 -0.002 – 0.019 0.12 -0.001 -0.080 –0.078 0.980
ESR 0.010 0.001 – 0.019 0.02 0.003 -0.014 – 0.021 0.688
DAS28 0.108 -0.060 – 0.276 0.20 n.a. n.a. n.a.
Diabetes 0.414 -0.106 – 0.934 0.12 0.240 -0.817 – 1.297 0.637
Statin 0.173 -0.293 – 0.640 0.46 -0.089 -0.669 – 0.491 0.751
Aorta
CRP 0.015 -0.003 – 0.033 0.099 0.018 -0.114 – 0.149 0.78
ESR 0.023 0.010 – 0.037 <0.01 0.017 -0.011 – 0.046 0.22
DAS28 0.279 -0.001 – 0.559 0.05 n.a. n.a. n.a.
Diabetes 0.670 -0.216 – 1.557 0.14 -0.282 -2.054 – 1.491 0.74
Statin 0.349 -0.435 – 1.132 0.38 -0.292 -1.253 – 0.668 0.53
Iliac arteries
CRP 0.031 0.019 – 0.043 <0.01 0.026 -0.079 – 0.131 0.61
ESR 0.016 0.005 – 0.027 <0.01 0.011 -0.013 – 0.034 0.34
DAS28 0.178 -0.036 – 0.393 0.10 n.a. n.a. n.a.
Diabetes 0.296 -0.390 – 0.983 0.39 -0.291 -1.710 – 1.127 0.67




Beta 95% CI p-value Beta 95% CI p-value
Femoral arteries
CRP 0.010 -0.001 – 0.021 0.07 -0.021 -0.105 – 0.064 0.61
ESR 0.010 0.001 – 0.019 0.03 -0.003 -0.022 – 0.016 0.74
DAS28 0.168 -0.006 – 0.42 0.06 n.a. n.a. n.a.
Diabetes 0.539 -0.008 – 1.086 0.05 0.360 -0.774 – 1.494 0.51
Statin 0.403 -0.084 – 0.891 0.10 0.095 -0.531 – 0.721 0.75
Linear regression analyses adjusted for age, sex, BMI, hypertension, packyears and TC/
HDLc ratio as appropriate. RA= rheumatoid arthritis, OA=osteoarthritis, TBRmax=maximum 
tissue to background ratio, CRP=C-reactive protein ESR=Erythrocyte sedimentation rate, 
DAS28=,disease activity score 28, PWV=pulse wave velocity. 
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Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular disease 
(CVD), partly due to an increased prevalence of cardiovascular risk factors, but also 
due to chronic systemic inflammation inducing atherosclerotic changes of the 
arterial wall. The aim of this study was to determine whether anti-inflammatory 
therapy for the treatment of RA has favorable effects on arterial wall inflammation 
in RA patients. 
Methods
Arterial wall inflammation before and after 6 months of anti-inflammatory treatment 
was assessed in 49 early and established RA patients using 18F-fluorodeoxyglucose-
positron emission tomography with computed tomography (18F-FDG-PET/
CT). Early RA patients (n=26) were treated with conventional synthetic disease 
modifying anti-rheumatic drugs (in the majority of patients methotrexate) with 
or without corticosteroids, whereas established RA patients (n=23) were treated 
with anti-TNF therapy (adalimumab). Arterial 18F-FDG uptake was quantified as the 
maximum standardized uptake value (SUVmax), maximum tissue-to-blood ratio 
(TBRmax) and the corrected SUVmax (cSUVmax) in the ascending aorta, aortic 
arch, descending aorta, abdominal aorta, carotid, iliac and femoral arteries.
Results
In RA patients, overall SUVmax was over time reduced by 4% (difference -0.06, 
95%CI -0.12- -0.01, p=0.02), with largest reductions in carotid (-8%, p=0.001) and 
femoral arteries (-7%, p=0.005). Blood pool correction with TBRmax showed 
comparable results, while cSUVmax showed substantially larger reductions (overall 
-14%, p=0.01, carotid -31%, p=0.001 and femoral arteries -26%, p=0.002). There was 
no difference in arterial wall inflammation change between early and established 
RA patients (SUVmax difference 0.003, 95%CI -0.11-0.12, p=0.95). There was a 
significant correlation between change in arterial wall inflammation and change in 
serological inflammatory markers (erythrocyte sedimentation rate and C-reactive 
protein).
Conclusion
Arterial wall inflammation in RA patients  is reduced by anti-inflammatory treatment 
and this reduction correlates with reduction of serological inflammatory markers. 
These results suggest that anti-inflammatory treatment of RA may have favorable 
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effects on reducing the risk of cardiovascular events in RA patients.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by 
chronic joint inflammation. RA patients have an increased risk of cardiovascular 
disease (CVD), estimated to be as high as in diabetes mellitus 1, 2. Interestingly, 
this cannot be fully explained by the increased prevalence of traditional CVD risk 
factors in RA 1, 3.
There is accumulating evidence that systemic inflammation accelerates 
atherosclerosis via circulating pro-inflammatory cytokines, activating 
inflammatory cells in atherosclerotic plaques in the arterial wall 3. Previous studies 
have shown that RA patients have an increased prevalence of atherosclerotic 
plaques, faster progression of atherosclerosis and a more rupture-prone plaque 
phenotype than CVD patients without RA 4.
In recent years, it was shown that anti-inflammatory treatment for RA reduces 
cardiovascular risk in RA patients 5-8. In addition, anti-inflammatory treatment 
has favorable effects on the arterial wall by decreasing intima media thickness 
and arterial wall stiffness 9-12. It is therefore hypothesized that anti-inflammatory 
treatment for RA reduces cardiovascular disease risk directly through reducing 
inflammation in the arterial wall. A validated method to measure arterial wall 
inflammation is 18F-fluorodeoxyglucose-positron emission tomography/computed 
tomography (18F-FDG-PET/CT). The 18F-FDG tracer is specifically taken up by 
metabolically active cells, such as inflammatory cells, and both preclinical and 
human studies have shown that 18F-FDG uptake correlates with macrophage 
accumulation in atherosclerotic plaques 13-16.
Previous studies with 18F-FDG-PET/CT, showed that RA patients have increased 
arterial wall inflammation compared to healthy controls and osteoarthritis 
patients, and that arterial wall inflammation is associated with serological markers 
of systemic inflammation in RA patients 17-22. However, to date, only few studies 
have investigated the effects of anti-inflammatory treatment on arterial wall 
inflammation in RA patients 23, 24. This study therefore set out to determine whether 
6 months of anti-inflammatory treatment with conventional synthetic disease 
modifying anti-rheumatic drugs (csDMARDs) or anti-TNF therapy with adalimumab 
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RA patients were recruited from the Rheumatology outpatient clinics of Reade 
and Amsterdam UMC, location VUmc, Amsterdam, the Netherlands, as described 
previously 17. The most important inclusion criteria were age ≥ 50, active disease 
(defined as disease activity score of 28 joints with erythrocyte sedimentation rate 
(DAS28-ESR) ≥ 4) and indication for anti-inflammatory treatment. Patients were 
categorized into two groups: (1) newly diagnosed patients with early RA, not yet 
on DMARD therapy, and starting with methotrexate (MTX) or another csDMARD 
(sulfasalazine or hydroxychloroquine, whether or not combined with short-term 
glucocorticoids), and (2) patients with established RA who were already treated 
with csDMARDs, and started with a biological DMARD (adalimumab) in combination 
to the csDMARDs. The study was approved by the Slotervaartziekenhuis and Reade 
medical ethics committee and a written informed consent form was obtained from 
all participants, according to the principles of the Declaration of Helsinki.
Clinical assessments
RA disease activity was assessed using DAS28, a composite measure that takes 
into account swollen joint count of 28 joints (SJC28), tender joint count of 28 joints 
(TJC28), patient assessment of global health on a visual analogue scale (VAS) 
and erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Additional 
disease-related factors measured included RA medications, IgM-rheumatoid 
factor (IgM-RF), anti-citrullinated protein antibody (ACPA) and European League 
Against Rheumatism (EULAR) DAS28-ESR response criteria. Cardiovascular risk 
factors assessed included cardiovascular disease (CVD) history, CVD medications, 
hypertension, blood pressure, smoking status, pack years, diabetes mellitus (DM), 
fasting glucose, total cholesterol (TC), high density lipoprotein cholesterol (HDLc), 
low density lipoprotein cholesterol (LDLc), triglycerides (TG) and body mass index 
(BMI).
Image acquisition
18F-FDG-PET/CT scans were performed according to established protocols as 
previously described 17, on Gemini TF and Ingenuity TF PET/CT scanners (Philips 
Healthcare; spatial resolution approximately 5 mm 25, 26. Briefly, 18F-FDG was 
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injected intravenously (3.5 MBq/kg, according to international guidelines 27 and 
based on an acquisition time of 2 min/bed position) . After flushing the injection 
device, residual activity in the administration system was measured and the net 
injected dose was determined. A low-dose CT scan (120 kV, 35 mAs; voxel size 
1.17x1.17x4 mm) was performed after a resting period for 90 minutes, followed by 
the total body PET scan with an acquisition time of 2 min/bed position for head 
to groins and 1 min/bed position for groins to toes. PET data were normalized 
and corrected for attenuation, decay, and scatter according to a reconstruction 
method based on international guidelines 27 using a time-of-flight ordered subset 
expectation maximization algorithm as implemented by the vendor (voxel size 
4x4x4). Prior to image analysis, PET images were rebinned to the voxel size of CT 
images, as described in Lensen et al 28. The follow-up PET/CT scan was performed 
on the same scanner as the baseline scan.
Image analysis
18F-FDG-PET/CT images were analyzed using a research software tool developed 
in our hospital. An extensive description of the image analysis is provided in our 
previous paper 17. In summary, for each arterial segment of interest, the axial slice 
with the most intense 18F-FDG uptake was visually determined. Arterial uptake in 
that axial slice (hotspot method 28) was quantified by drawing a region of interest 
(ROI) around the artery and lumen on the CT image. This ROI was transferred to 
the PET image to determine the regional 18F-FDG uptake.  The arterial maximal 
standardized uptake value (SUVmax) was then calculated for each separate ROI 
using the regional 18F-FDG uptake corrected for the net injected 18F-FDG dose 
and lean body mass. Arterial segments of interest were ascending aorta, aortic 
arch, descending aorta, abdominal aorta, carotid, iliac and femoral arteries. Left 
and right measurements of carotid, iliac and femoral arteries were combined using 
the mean. Ascending aorta, aortic arch and descending aorta were combined into 
one thoracic aortic segment using the mean (and also individually reported in 
Supplementary data) and overall arterial wall inflammation was similarly calculated 
by taking the mean of the ten individual segments. In addition, for background 
correction mean blood SUV was determined in the ascending aorta using a 5-slices 
long cylinder VOI with 1 cm diameter placed one slice below the aortic arch. For 
blood pool 18F-FDG uptake correction, two metrics were used: tissue-to-blood 
ratio (TBRmax) was calculated by dividing arterial wall SUVmax by blood SUVmean, 
and corrected SUVmax (cSUVmax) was calculated by subtracting blood SUVmean 
from arterial wall SUVmax. For clarity, in this article we only present SUVmax 
values in the tables, TBRmax and cSUVmax values can be found in main text or 
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Supplementary Files. Image analysis was performed by four independent observers 
(AB, RA, AvS and FU). As reported in our previous paper 17, intraclass correlation 
coefficients (ICCs) for all arterial segments were good to excellent (0.81-0.96).
Statistical analysis
Data are presented as mean ± standard deviation (SD) for normally distributed 
variables, median with interquartile range (IQR) for skewed continuous variables, 
or frequencies for categorical variables. According to protocol, patients who 
discontinued treatment during follow-up were excluded from analysis and additional 
intention to treat analysis was performed. For the primary objective, differences 
in arterial wall inflammation after 6 months of anti-inflammatory treatment in the 
total group of RA patients (early and established RA combined) were assessed with 
paired t-tests.  A sample size calculation was performed, and an estimated sample 
size of approximately 30 patients per group provided >80% power to detect a 
reduction of 10% in TBRmax of arterial wall inflammation with SD=0.30. Differences 
in arterial wall inflammation change between RA groups (early versus established 
RA patients and patients using corticosteroids versus no corticosteroids) were 
assessed with independent t-tests. Differences in RA disease related parameters 
and cardiovascular risk factors after 6 months of treatment were assessed with 
paired t-test, Wilcoxon’s rank test or McNemar’s test for normally distributed, 
skewed distributed continuous and categorical variables, respectively. Spearman’s 
correlation coefficient was used to investigate the correlation of change in 
arterial wall inflammation and RA disease related parameters, or cardiovascular 
risk factors measured at baseline. One outlier with high inflammatory markers at 
baseline (CRP >300 and ESR > 90) was excluded from analyses containing CRP and 
ESR. Data analysis was performed using SPSS version 24. 
RESULTS
Fifty-three out of 61 included RA patients underwent both a baseline 18F-FDG-
PET/CT scan and a second PET scan after 6.3 ± 0.9 months of anti-inflammatory 
treatment. Reasons for not having a follow-up PET scan were alcohol abuse (n=1), 
claustrophobia (n=1), lost-to-follow-up (n=2), did not start with anti-inflammatory 
treatment (n=1), withdrawal of informed consent (n=1) and deceased (n=2). Of 
these patients, 4 (7.5%; 1 early RA and 3 established RA) discontinued treatment 
before the end of the follow-up period, because of treatment failure according to 
the patient and/or rheumatologist (n=3) or toxicity (n=1). See Table 1 for baseline 
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characteristics of the remaining 49 patients who were included in the analyses. 
RA disease activity and response to treatment
RA disease activity was significantly reduced after treatment for both RA groups 
(Table 1). Response to treatment was comparable for both RA groups: of the early 
RA patients, 14 (54%) had a good, 6 (23%) a moderate, and 5 (19%) no EULAR DAS28-
ESR response to csDMARDs (missing n=1, because ESR could not be determined 
in one patient due to measurement failure), and of the established RA patients, 12 
(52%) had a good, 6 (26%) a moderate and 5 (22%) no EULAR DAS28-ESR response 
to adalimumab. 
Effect of treatment on cardiovascular risk factors
At baseline 11 (19%) patients had previous cardiovascular disease, including 
cerebrovascular event (n=5), acute coronary syndrome (n=5), congestive heart 
failure (n=2) and peripheral artery disease (n=1). There were no cardiovascular 
events within the follow-up period. For early RA patients, total cholesterol and 
HDL cholesterol levels statically significantly increased after anti-inflammatory 
treatment, keeping TC/HDLc ratio stable (Table 1). For established RA, all cholesterol 
levels remained stable. There was no statistically significant difference in delta 
total cholesterol nor delta HDL cholesterol between patients using corticosteroids 
and patients not using corticosteroids during any of the visits (not for total RA 
group, nor for early or established RA subgroups; data not shown).  
Table 1. RA-related and cardiovascular disease risk factors before and after 6 months of 
anti-inflammatory treatment
Early RA (n=26) Established RA (n=23)
Baseline 6 months p-value Baseline 6 months p-value
Demographics
   Age, years 64 ± 10 - 60 ± 7 -
   Female, n (%) 16 (62%) - 13 (57%) -
Disease-related factors
Disease duration, 
years 0.04 (0.02-0.07) - 6 (2-14) -
IgM-RF and/or ACPA 
positive, n (%) 18 (69%) - 15 (65%) -
DAS28-ESR, range 
0-10 4.85 ± 1.01 3.09 ± 1.26 
* <0.001 4.28 ± 1.04 2.86 ± 1.32 <0.001
DAS28-CRP, range 
0-10 4.49 ± 0.91 2.76 ±1.01 <0.001 4.08 ± 1.03 2.69 ± 1.21 <0.001
table continues
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Early RA (n=26) Established RA (n=23)
Baseline 6 months p-value Baseline 6 months p-value
ESR, mm/h 23 (12-43) 14 (7-23) * 0.001 17 (6-25) 13 (5-21) 0.04
CRP, mg/L 9 (1-20) 2 (1-5) <0.001 4 (1-16) 1 (1-6) 0.04
RA medications, n (%)
NSAID 17 (65%) 7 (27%) 0.006 12 (52%) 9 (39%) 0.38
Corticosteroids 1 (4%) 12 (46%) 0.002 9 (39%) 6 (26%) 0.25
Methotrexate 0 (0%) 24 (92%) <0.001 21 (91%) 20 (87%) 1.00
Other csDMARD 0 (0%) 4 (15%) 0.13 14 (61%) 9 (39%) 0.06
bDMARD 0 (0%) 0 (0%) 1.00 0 (0%) 23 (100%) <0.001
Cardiovascular risk factors
Current smoking, n (%) 6 (23%) - 5 (22%) -
Pack years 6 (0-16) - 8 (0-31) -
DM, n (%) 4 (15%) - 4 (17%) -
History of CVD, n (%) 5 (19%) 5 (19%) 6 (26%) 6 (26%)
Hypertension, n (%) 15 (58%) 16 (62%) 1.00 14 (61%) 13 (57%) 1.00
Systolic BP, mmHg 140 ± 18 140 ± 19 0.75 127 ± 18 124 ± 15 0.40
Diastolic BP, mmHg 84 ± 7 82 ± 9 0.23 79 ± 11 78 ± 10 0.53
Fasting glucose, 
mmol/L 5.7 ± 1.0 5.8 ± 1.0 0.56 5.6 ± 1.4 5.8 ± 1.9 0.53
TC/HDLc ratio 4.1 ± 1.6 4.1 ± 1.7 0.71 3.1 ± 0.8 3.2 ± 0.9 0.16
TC, mmol/L 4.9 ± 1.2 5.3 ± 1.1 0.023 4.7 ± 1.0 4.8 ± 0.9 0.77
HDLc, mmol/L 1.28 ± 0.37 1.44 ± 0.44 0.013 1.68 ± 0.76 1.63 ± 0.68 0.49
LDLc, mmol/L 3.05 ± 1.05 3.27 ± 1.06 0.13 2.58 ± 0.70 2.69 ± 0.84 0.40
Triglycerides, mmol/L 1.1 (0.9-1.6) 1.2 (0.8-1.7) 0.98 1.0 (0.8-1.5) 1.1 (0.8-1.5) 0.30
Body mass index, kg/
m2 27 ± 4 27 ± 4 0.71 29 ± 8 29 ± 8 0.61
Cardiovascular medications, n (%)
Antihypertensive drug 14 (54%) 13 (50%) 1.00 12 (52%) 12 (52%) 1.00
Statin 6 (23%) 7 (27%) 1.00 8 (35%) 7 (30%) 1.00
Anticoagulants 4 (15%) 5 (19%) 1.00 7 (30%) 7 (30%) 1.00
* ESR missing n=1 because of measurement failure
Effect of treatment on arterial wall inflammation
Arterial wall inflammation was reduced in most arterial segments after 6 months of 
treatment (Figure 1, refer to Supplementary Table 1 for exact values), with largest 
reductions in the carotid (SUVmax -8%, p=0.001) and femoral arteries (SUVmax 
-7%, p=0.005). Combining all arterial segments showed that overall arterial wall 
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inflammation was reduced by 4% (SUVmax difference -0.06, 95%CI -0.12- -0.01, 
p=0.02). Blood pool correction with TBRmax showed comparable results to 
SUVmax, while cSUVmax showed substantially larger reductions after 6 months of 
treatment than SUVmax (carotid: TBRmax -9%, p=0.003; cSUVmax -31%, p=0.001, 
femoral arteries: TBRmax -9%, p=0.004; cSUVmax -26%, p=0.002, overall: 
TBRmax -6%, p=0.03; cSUVmax -14%, p=0.01, Supplementary Table 1). The arterial 
blood SUV was stable over time for all RA patients (SUVmean baseline 0.96 ± 0.17, 
SUVmean follow-up 0.97 ± 0.18, p=0.60), as well as separate for early (SUVmean 
baseline 0.97 ± 0.17, SUVmean follow-up 1.00 ± 0.16, p=0.38) and established RA 
patients (SUVmean baseline 0.95 ± 0.18, SUVmean follow-up 0.94 ± 0.19, p=0.74). 
We did not find a significant difference in arterial wall inflammation change 
between the patients with no response versus moderate/good response according 
to EULAR DAS28-ESR response criteria (SUVmax difference -0.03, 95%CI -0.17-
0.12, p=0.72, TBRmax difference -0.03, 95%CI -0.28-0.22, p=0.79 and cSUVmax 
difference -0.003, 95%CI -0.16-0.15, p=0.97). For the segments that were assessed 
bilaterally (carotid, iliac and femoral arteries), instead of taking the mean, we also 
performed the analyses using (1) the segment (left or right) with the maximum 
18F-FDG uptake, and (2) the segment with the highest 18F-FDG at baseline. Using 
the segment with maximum 18F-FDG uptake showed comparable results as taking 
the mean for all three measures (data not shown). Using the highest segment 
at baseline and following up on this segment resulted in higher reductions of 
arterial wall inflammation (carotid: SUVmax -8%, p=0.001; TBRmax -14%, p<0.001; 
cSUVmax -40%, p<0.001, femoral: SUVmax -7%, p=0.005; TBRmax -15%, p<0.001, 
cSUVmax -38%, p<0.001 and iliac arteries: SUVmax -4%, p=0.20, TBRmax -5%, 
p=0.51, cSUVmax -16%, p=0.21). As can be seen in Figure 1, there was one patient 
with relatively high iliac arterial wall inflammation at follow-up, present in both left 
and right iliac artery (SUVmax left: 2.59, right: 2.42). Sensitivity analysis without 
this patient revealed a significant reduction of arterial wall inflammation in the iliac 
artery over time (SUVmax difference -0.08, 95%CI 0.01-0.16, -5%, p=0.03, TBRmax 
difference -0.11, 95%CI -0.002-0.22, -7%, p=0.05, cSUVmax difference -0.09, 95%CI 
0.007-0.18, -16%, p=0.03). Results from the intention to treat analysis, in which the 
3 patients who discontinued treatment were included, were not different from the 
per protocol analysis (data not shown).
Fasting glucose levels were stable over time (BL: 5.6 ± 1.2 and 6M: 5.8 ± 1.5, p=0.39, 
see Table 1 for early and established RA separately). During 7 out of 100 PET/CT 
scans glucose was >7.5 mmol/L (5 individual patients, 1 patient had glucose >7.5 
during both scans). Mean glucose during the other 93 scans was 5.4 ± 0.8. Sensitivity 
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analysis without the 5 patients with high glucose levels showed comparable results 
as the per protocol analysis (Supplementary Table 2).
Figure 1. Effect of 6 months of anti-inflammatory treatment on arterial wall uptake 
SUVmax: maximum standardized uptake value, BL: baseline, 6M: 6 months. Dots and lines 
represent individual values of each participant and black lines indicate mean change over 
time. Refer to Supplementary Table 1 for exact values.
Table 2. Difference between early and established RA in arterial wall inflammation change 
after 6 months treatment
Segment Δ Arterial wall inflammation Mean difference (95%CI) p-value
Early RA Established RA
ΔSUVmax
 Carotid arteries -0.12 ± 0.23 -0.09 ± 0.19 0.03 (-0.09-0.15) 0.65
 Thoracic aorta -0.04 ± 0.27 0.02 ± 0.32 0.05 (-0.12-0.22) 0.53
 Abdominal aorta -0.04 ± 0.25 -0.10 ± 0.23 -0.07 (0.21-0.07) 0.34
 Illiac arteries -0.04 ± 0.32 -0.08 ± 0.31 -0.05 (-0.23-0.14) 0.62
 Femoral arteries -0.11 ± 0.28 -0.09 ± 0.17 0.01 (-0.13-0.15) 0.85
 Overall -0.07 ± 0.20 -0.06 ± 0.19 0.003 (-0.11-0.12) 0.95
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As shown in Table 2, there was no difference in arterial wall inflammation change 
between early and established RA patients for SUVmax. After blood pool correction, 
there was also no difference between early and established RA (overall: ΔTBRmax 
-0.13 vs. -0.05, p=0.36; ΔcSUVmax -0.10 vs. -0.05, p=0.44, respectively). During the 
second 18F-FDG-PET/CT scan more early RA patients used corticosteroids, while 
for established RA patients, corticosteroid use did not change over time (Table 1). 
RA patients using corticosteroids during one of the 18F-FDG-PET/CT scans (n=21, 
43%) did not have different arterial wall inflammation change than RA patients not 
using corticosteroids (overall ΔSUVmax: -0.07 vs. -0.06, p=0.87; ΔTBRmax -0.05 
vs -0.12, p=0.44; ΔcSUVmax -0.06 vs -0.09, p=0.60, respectively). In subgroup 
analyses separate for early and established RA, no difference between patients 
using corticosteroids and patients not using corticosteroids was found either (data 
not shown).
Correlation between change in arterial wall inflammation and disease 
activity, serological inflammatory markers or cardiovascular risk factors
Change in SUVmax over time significantly correlated with ΔESR and ΔCRP, but not 
with other disease activity parameters change (ΔDAS28, ΔVAS, ΔSJC and ΔTJC; 
Table 3). Results were comparable for TBRmax and cSUVmax (Supplementary Table 
3). Triglycerides significantly correlated with ΔSUVmax, and total cholesterol/HDLc 
ratio and glucose with ΔTBRmax (Supplementary Table 4). There was no correlation 
between the other CVD risk factors at baseline and arterial wall inflammation.
Table 3. Correlation between arterial wall inflammation change and change in disease 
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DISCUSSION
The main finding of this study is that arterial wall inflammation in RA patients is 
reduced after 6 months of anti-inflammatory therapy, as assessed by 18F-FDG-
PET. To our knowledge, this is the largest prospective study so far investigating the 
effect of anti-inflammatory treatment on arterial wall inflammation in RA patients. 
This is also the first study where multiple arterial segments were investigated 
(multi-segment approach), and both early and established RA patients were 
studied at the same time.
Our study confirms previous studies that found a reduction in arterial wall 
inflammation on 18F-FDG-PET/CT of 7 and 17% after 2-8 weeks of inflammatory 
therapy in small cohorts of patients (n=15, n=17) 23, 24, and contributes to a greater 
understanding of arterial wall inflammation in RA patients undergoing anti-
inflammatory treatment. As increased arterial FDG uptake is predictive for future 
cardiovascular events 29-31, our results provide further support for the hypothesis 
that anti-inflammatory treatment does reduce cardiovascular risk in RA patients.
Previous studies have shown that arterial wall inflammation reduced to the level 
of healthy controls after anti-inflammatory treatment 24, and that arterial wall 
inflammation of RA subjects in long-term treatment-induced clinical remission 
was comparable to healthy controls 32. The observed reductions in arterial wall 
inflammation in the present study are comparable to reductions seen with statin 
therapy 33-38, which is known to reduce risk for cardiovascular events with 25-30% 
39, 40. Whether the reduction in 18F-FDG uptake that was found in this study, also 
results in a definite reduction of cardiovascular risk remains to be established in 
future prospective studies assessing cardiovascular events. 
The first aim of this study was to demonstrate that anti-inflammatory treatment 
reduces arterial wall inflammation in RA patients, and secondary we investigated 
whether this was different for early RA patients treated with csDMARDs and 
established RA treated with adalimumab. Apart from the drug-related differences, 
early and established RA are inherently different patient groups with large 
differences in patient characteristics (e.g. disease duration and number of 
previously used anti-inflammatory treatments). Direct comparison of csDMARDs 
and adalimumab is therefore in this study not possible. In addition, our sample 
size calculation was based on comparison of baseline and follow-up arterial wall 
inflammation, and not on the comparison between early and established RA.  The 
point estimates of the difference between the groups suggest that there is no 
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difference between early and established RA, which is in line with the results of 
two previous studies, both investigating one of the patient groups separately 23, 
24. Future research looking deeper into direct comparisons of anti-inflammatory 
treatments and their effect on arterial wall inflammation is needed.
We demonstrated a significant reduction in abdominal aorta, carotid and femoral 
arteries, but not in the thoracic aorta or iliac arteries. Although arterial walls of the 
various segments have different mechanical properties, this does not explain why 
in particular the thoracic aorta or iliac artery would have a different response than 
the other segments. It might, however, be possible that these differences were 
due to a lack of power, because estimates of arterial wall inflammation change 
of these segments were substantially lower than the minimal reduction on which 
the sample size calculation was based (estimates suggesting reduction: -1% to 
-4%, versus power calculation: -10%). In addition, for the iliac artery one outlier 
considerably influenced the results and sensitivity analyses without this patient 
did show a significant reduction in arterial wall inflammation of this segment.
Reductions of serological inflammatory markers (CRP and ESR) correlated 
with arterial wall inflammation reduction after 6 months of anti-inflammatory 
treatment, which supports the hypothesis that systemic inflammation is directly 
linked to increased arterial wall inflammation in RA 1, 3. The reduction in arterial 
wall inflammation was not different for responders and non-responders to anti-
inflammatory treatment, and did not correlate with change in RA disease activity 
markers as DAS28, SJC28, TJC28 and VAS. This suggests that the response to 
treatment of vascular inflammation does not coincide with the response of joint 
inflammation. Future longitudinal PET/CT studies comparing vascular and joint 
inflammation over time might provide new insights on whether the response 
to anti-inflammatory therapy in the arterial wall and joints are indeed separate 
processes or not.
Several aspects regarding the methodology of this study need to be discussed. 
First, theoretically, concomitant corticosteroid use might have affected our results, 
but this is unlikely because arterial wall inflammation after treatment was not 
different for RA patients with and without concomitant corticosteroids. Second, 
observational studies with repeated measurements can be affected by regression-
to-the mean. Since we did not select our patients on high arterial wall inflammation 
on 18F-FDG-PET/CT, we do not think regression-to-the-mean would be a logical 
explanation for our results. Third, quantification of FDG uptake in the vascular wall 
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can be affected by partial-volume effect due to limited spatial resolution of the PET 
scanner, resulting in underestimation of small atherosclerotic lesions (2-3 times 
smaller than spatial resolution 41). The spatial resolution of the clinical PET/CT 
scanners that were used in this study had a resolution of approximately 5 mm, so 
our results reflect arterial wall inflammation of lesions bigger than approximately 
2-2.5 mm.  Finally, we used three metrics to represent arterial wall inflammation, 
because there is currently no consensus on the superiority of blood pool correction 
above SUVmax, nor on the best method for blood pool correction 17, 42-45. An 
important reason to use blood pool correction in the context of our longitudinal 
study, is that the availability of 18F-FDG from the blood pool might change due to 
the anti-inflammatory treatment. We found that blood SUV was stable over time, 
which suggests that in this study both background corrected as well as SUVmax 
values, can be used for quantification of arterial wall inflammation on PET/CT. This 
is further supported by the fact that results were comparable for SUVmax, TBRmax 
and cSUVmax. 
Conclusions
In conclusion, we found that arterial wall inflammation in RA patients is reduced 
after 6 months of anti-inflammatory treatment and this reduction correlates 
with reduction of serological inflammatory markers. These results suggest that 
anti-inflammatory treatment has a favorable effect on cardiovascular risk in RA 
patients. Whether or not this reduction ultimately leads to a significant reduction 
of cardiovascular events remains to be established in future studies.
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Supplementary Table 1. Effect of 6 months of anti-inflammatory treatment on arterial wall 
uptake: per protocol analysis.






Carotid arteries 1.33 ± 0.21 1.23 ± 0.23 -0.10 (-0.16- -0.04) 0.001 -8%
Ascending aorta 1.66 ± 0.35 1.65 ± 0.27 -0.01 (-0.11-0.09) 0.87 -1%
Aortic arch 1.66 ± 0.34 1.64 ± 0.36 -0.02 (-0.13-0.08) 0.66 -1%
Descending aorta 1.71 ± 0.39 1.71 ± 0.29 -0.001 (-0.12-0.12) 0.99 -0.04%
Abdominal aorta 1.70 ± 0.30 1.63 ± 0.29 -0.07 (-0.14-0.001) 0.05 -4%
Iliac arteries 1.52 ± 0.25 1.47 ± 0.27 -0.06 (-0.15-0.03) 0.20 -4%
Femoral arteries 1.39 ± 0.23 1.29 ± 0.20 -0.10 (-0.17- -0.03) 0.005 -7%
Overall 1.52 ± 0.19 1.46 ± 0.19 -0.06 (-0.12- -0.01) 0.02 -4%
TBRmax
Carotid arteries 1.42 ± 0.27 1.29 ± 0.24 -0.13 (-0.22- -0.05) 0.003 -9%
Ascending aorta 1.76 ± 0.34 1.74 ± 0.36 -0.02 (-0.15-0.11) 0.77 -1%
Aortic arch 1.76 ± 0.35 1.72 ± 0.39 -0.04 (-0.16-0.08) 0.46 -2%
Descending aorta 1.81 ± 0.37 1.79 ± 0.35 -0.01 (-0.14-0.12) 0.84 -1%
Abdominal aorta 1.82 ± 0.51 1.71 ± 0.32 -0.11 (-0.26-0.03) 0.12 -6%
Iliac arteries 1.63 ± 0.33 1.54 ± 0.29 -0.09 (-0.20-0.02) 0.11 -6%
Femoral arteries 1.49 ± 0.31 1.35 ± 0.21 -0.13 (-0.22- -0.05) 0.004 -9%
Overall 1.62 ± 0.25 1.53 ± 0.22 -0.09 (-0.18-0.007) 0.03 -6%
cSUVmax
Carotid arteries 0.37 ± 0.22 0.26 ± 0.21 -0.12 (-0.19- -0.05) 0.001 -31%
Ascending aorta 0.70 ± 0.32 0.68 ± 0.25 -0.02 (-0.13-0.08) 0.69 -3%
Aortic arch 0.70 ± 0.31 0.67 ± 0.34 -0.04 (-0.14-0.06) 0.47 -5%
Descending aorta 0.75 ± 0.35 0.74 ± 0.26 -0.01 (-0.12-0.10) 0.81 -2%
Abdominal aorta 0.74 ± 0.32 0.66 ± 0.26 -0.08 (-0.17-0.006) 0.07 -11%
Iliac arteries 0.57 ± 0.25 0.50 ± 0.24 -0.07 (-0.16-0.02) 0.13 -13%
Femoral arteries 0.44 ± 0.24 0.32 ± 0.17 -0.11 (-0.19- -0.05) 0.002 -26%
Overall 0.57 ± 0.17 0.49 ± 0.16 -0.08 (-0.14- -0.02) 0.01 -14%
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Supplementary Table 2. Effect of 6 months of anti-inflammatory treatment on arterial wall 
uptake: sensitivity analysis without patients with glucose > 7.5






Carotid arteries 1.33 ± 0.19 1.25 ± 0.22 -0.08 (-0.15- -0.02) 0.008 -6%
Ascending aorta 1.67 ± 0.35 1.67 ±0.27 -0.004 (-0.11-0.10) 0.94 -0.2%
Aortic arch 1.69 ± 0.35 1.66 ± 0.37 -0.02 (-0.14-0.09) 0.69 -1%
Descending aorta 1.74 ± 0.39 1.73 ± 0.28 -0.002 (-0.13-0.13) 0.98 -0.1%
Abdominal aorta 1.68 ± 0.27 1.61 ± 0.28 -0.07 (-0.13- -0.003) 0.04 -4%
Iliac arteries 1.52 ± 0.25 1.47 ± 0.28 -0.06 (-0.15-0.04) 0.25 -4%
Femoral arteries 1.39 ± 0.24 1.29 ± 0.20 -0.10 (-0.17- -0.03) 0.01 -7%
Overall 1.53 ± 0.18 1.47 ± 0.19 -0.06 (-0.12-0.001) 0.05 -4%
 TBRmax
 Carotid arteries 1.42 ± 0.24 1.31 ± 0.24 -0.11 (-0.19- -0.04) 0.004 -8%
 Ascending aorta 1.78 ± 0.32 1. 771 ± 0.36 -0.01 (-0.14-0.13) 0.90 -0.5%
 Aortic arch 1.80 ± 0.34 1.76 ± 0.39 -0.04 (-0.16-0.08) 0.53 -2%
 Descending aorta 1.84 ± 0.36 1.84 ± 0.33 -0.01 (-0.15-0.13) 0.90 -0.5%
 Abdominal aorta 1.79 ± 0.26 1.71 ± 0.29 -0.09 (-0.19-0.01) 0.08 -5%
 Iliac arteries 1.63 ± 0.28 1.55 ± 0.29 -0.08 (-0.19-0.03) 0.16 -5%
 Femoral arteries 1.49 ± 0.28 1.37 ± 0.21 -0.12 (-0.21- -0.04) 0.006 -8%
 Overall 1.63 ± 0.19 1.55 ± 0.21 -0.08 (-0.15-0.004) 0.04 -5%
cSUVmax
 Carotid arteries 0.38 ± 0.20 0.28 ± 0.20 -0.10 (-0.16- -0.04) 0.002 -26%
 Ascending aorta 0.73 ± 0.32 0.71 ± 025 -0.02 (-0.13-0.09) 0.73 -3%
 Aortic arch 0.74 ± 0.32 0.70 ± 0.34 -0.04 (-0.14-0.07) 0.47 -5%
 Descending aorta 0.79 ± 0.35 0.77 ± 0.24 -0.02 (-0.14-0.10) 0.78 -2%
 Abdominal aorta 0.74 ± 0.23 0.65 ± 0.22 -0.08 (-0.15-0.01) 0.02 -11%
 Iliac arteries 0.57 ± 0.23 0.05 ± 0.25 -0.07 (-0.16- -0.02) 0.13 -12%
 Femoral arteries 0.45 ± 0.23 0.33 ± 0.17 -0.11 (-0.19-0.04) 0.002 -26%
 Overall 0.58 ± 0.14 0.51 ± 0.15 -0.08 (-0.13- -0.02) 0.01 -13%
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Supplementary Table 3. Correlation between arterial wall inflammation change and change 
in disease activity or serological inflammatory markers after anti-inflammatory treatment
ΔTBRmax ΔcSUVmax
Spearman’s r p-value Spearman’s r p-value
ΔDAS28-ESR 0.10 0.49 0.03 0.83
ΔDAS28-CRP 0.07 0.66 -0.02 0.88
ΔESR 0.44 0.002 0.47 0.001
ΔCRP 0.41 0.004 0.46 0.001
ΔVAS -0.10 0.49 -0.11 0.46
ΔSJC 0.14 0.35 0.06 0.69
ΔTJC 0.03 0.82 -0.05 0.72
Supplementary Table 4. Correlation between arterial wall inflammation change and 
cardiovascular risk factors at baseline
ΔSUVmax ΔTBRmax ΔcSUVmax
Spearman’s r p-value Spearman’s r p-value Spearman’s r p-value
Age 0.05 0.73 -0.10 0.48 -0.07 0.64
BMI -0.03 0.86 -0.06 0.68 -0.02 0.87
Packyears -0.10 0.52 0.11 0.44 0.02 0.88
Total cholesterol/
HDLc 
0.03 0.83 -0.28 0.05 -0.19 0.20
Total cholesterol 0.08 0.61 -0.14 0.33 -0.07 0.65
HDLc 0.08 0.66 0.17 0.24 0.16 0.28
LDLc 0.10 0.52 -0.25 0.09 -0.15 0.32
Triglycerides 0.29 0.05 -0.01 0.95 0.12 0.43
Systolic blood 
pressure
0.07 0.66 -0.06 0.68 -0.03 0.84
Diastolic blood 
pressure
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Rheumatoid arthritis (RA) is associated with cardiovascular (CV) morbidity and 
mortality. Interferon regulatory factor 5 (IRF5) gene polymorphysms rs2004640 
and rs4728142 have been associated with autoimmune diseases, but also with 
atherosclerosis. Differences in IRF5 gene expression can lead to the production of 
different interferons and might play a role in the atherogenic process in RA. 
Methods
To investigate the effects of IRF5 gene variants rs2004640 and rs4728142 on 
clinical parameters related to atherosclerosis, such as cIMT (in subgroup n=101), 
and new CV events (in whole cohort n=353). 
Results
For rs2004640, cIMT values at baseline were highest within the group of patients 
carrying the GG-genotype, followed by GT- and TT- genotypes, which was 
statistically significant. Over time patients with the TT-genotype had the highest 
increase in cIMT. For rs4728142 cIMT values were also the highest for patients 
with the GG-genotype at baseline, but the difference between the groups was not 
statistically significant. Over time the highest increase in cIMT was in the patients 
with the AA-genotype. Both rs2004640 ND rs4728142 were not associated with 
new CV events during follow up.
Conclusion
IRF5 alleles are associated with changes in cIMT, but not with new CV events in 
RA. Although these findings implicate a role of the IRF5 transcription pathway 
in atherosclerosis, IRF5 (single nucleotide polymorphisms) SNPs do not appear 
increase the risk of future CV events.
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INTRODUCTION
Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) 
morbidity and mortality (1-3), in part due to the presence of traditional CV risk 
factors (4), but also due to RA-related inflammation that is assumed to accelerated 
atherosclerosis. However, the exact mechanisms behind this phenomenon remains 
unknown. (5, 6) Hence, the search for pathways linking RA to CV disease (CVD) is 
relevant. Interferon regulatory factor 5 (IRF5) gene polymorphisms, also known 
as single nucleotide polymorphisms (SNPs), rs2004640 and rs4728142 have been 
associated with autoimmune diseases, such as systemic lupus erythematosus (SLE) 
(7-10), RA (11-13) and multiple sclerosis (MS) (14), but also with atherosclerosis. (15, 
16) IRF5 is a member of a family of transcription factors that controls inflammatory 
and immune responses through activation of toll like receptors (TLRs). (17) 
Furthermore, IRF5 gene expression is involved in the type I interferon (IFN) pathway, 
leading to the production of different interferons (IFN) involved in the production of 
proinflammatory cytokines. (17) Interferons (IFNs) are a group of cytokines that can 
both inhibit and promote vascular smooth cell proliferation, depending on the type 
of IFN pathway that is activated. (18-22) Both IRF5 rs2004640 and rs4728142 SNPs 
can affect IRF5 gene expression by alternative splicing of the IRF5 gene, causing 
the production of different IFN types and therefore possibly playing a role in the 
atherogenic process in RA. (7, 8)  In this study, we investigated the effects of IRF5 
gene variants on clinical parameters related to atherosclerosis (i.e. carotid intima 
media thickness (cIMT)) and new CV events in RA patients.
PATIENTS AND METHODS
Study population
The CARRE study is a prospective cohort study investigating CVD and its risk 
factors in RA patients. (23) In 2000, a random sample of 353 RA patients registered 
at Reade (former Jan van Breemen Institute) in Amsterdam, the Netherlands, was 
drawn. Patients fulfilled the 1987 American College of Rheumatology classification 
criteria for RA, and were aged between 50 and 75 years. (23, 24) An ultrasound 
study of the carotid artery was performed in 2001 in a randomly selected subgroup 
of 101 patients. The local ethics committee and institutional review boards of the 
VU University Medical Center and Slotervaart Hospital/Reade in Amsterdam, the 
Netherlands, approved the study protocol and all participants gave their written 
informed consent for the study.
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DNA extraction and Genotyping
Total DNA was extracted from EDTA blood from 353 RA patients using Qiagen’s 
DNAeasy blood and tissue kit (Qiagen) according to the manufacturer instructions. 
The IRF5 gene variants rs2004640 and rs4729142 were genotyped using the 
TaqMan SNP Genotyping Assay (Applied Biosystems, CA) according to the 
manufacturers protocol. Allelic discrimination was performed using an ABI Prism 
7900HT sequence Detection system.
Assessment of CV risk factors and RA related factors
CVD history, medical history and medication use was obtained as previously 
described by Peters et al. (25) Total cholesterol (TC), high-density lipoprotein 
cholesterol (HDLc), low-density lipoprotein cholesterol (LDLc), triglycerides (TG), 
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and IgM rheumatoid 
factor (IgM-RF) antibodies were determined as describes previously. (26) TC/
HDLc ratio was calculated by dividing TC with HDLc. Body mass index (BMI) was 
calculated as the ratio of weight and squared height. Hypertension was defined as 
a systolic blood pressure (SBP) over 140 mmHg and/or a diastolic blood pressure 
(DBP) over 90 mmHg and/or the current use of antihypertensive medication. 
Physical examination was performed to determine the Disease Activity Score in 28 
joints (DAS28). (27) Radiographs of hands and feet were obtained to investigate the 
presence of erosions. 
Carotid Intima Media Thickness measurement
cIMT was assessed with Artlab echo tracking system using a 7.5-MHz linear probe, 
connected to a computer equipped with vessel wall movement detection software 
and an acquisition system (Esaote Europe BV). After localization of the common 
carotid artery, cross-sectional measurements were performed 10mm proximal of 
the carotid bifurcation as described previously.(28) 
Assessment of new CV events
As described previously, new CV events were registered according to the 
International Statistical Classification of Diseases and Related Health Problems 9th 
revision (ICD-9 codes, 410.0 – 410.9, 435.9, 436, 443.9 and 798). (29) CV events were 
verified in medical records and included coronary heart disease (i.e. myocardial 
infarction, percutaneous coronary intervention, coronary angiography with 
significant stenosis, stent placement or coronary artery bypass graft), cerebral 
arterial disease (e.g. cerebrovascular accident, transient ischemic attack or 
carotid endarterectomy) or peripheral arterial disease (e.g. ankle brachial pressure 
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index <0.50, peripheral arterial reconstructive surgery or limb amputation). (29) 
Patients were censored after the first CV event or death due to other reasons. The 
patients who were lost to follow up were censored at the date of their last follow 
up visit. The remainder of the patients was censored at study cessation time on 
March 1, 2015. (29)
Statistical analysis
Patients were grouped according to their SNP rs2004640 or rs4728142 allele 
distribution. Differences in demographics, CV- and RA-related factors between 
allele groups and genotypes were analyzed using Students t-test, Chi-square test, 
Mann-Whitney-U test, and ANOVA as appropriate. Logistic regression analyses 
were used to investigate the association between IRF5 genotypes and cIMT in 
the subgroup of 101 patients and Cox proportional hazard models were used 
to investigate the association with new CVD events in the whole cohort of 353 
patients. Longitudinal cIMT data over 3 time points (i.e. baseline, 3 year and 10 year 
measurements) was analyzed using generalized estimation equations (GEE). The 
minor allele was used as the reference group in all analyses. The analyses were 
adjusted for demographic, CV- and RA-related factors on the basis of the literature 
(29) and differences between the groups identified at baseline. Statistical analyses 
were performed with IBM SPSS version 23.0. P values of <0.05 (two tailed) were 
considered statistically significant. 
RESULTS
Patient characteristics
The 353 RA patients from the CARRE cohort were genotyped for IRF5 SNPs 
rs2004640 and rs4728142. Of these 353 patients, cIMT was determined in 101 
patients, which is referred to as the ‘cIMT cohort’. Genotyping failed in eight patients 
of the CARRE cohort, of which one patient was in de cIMT cohort. Both SNPs were 
in Hardy-Weinberg equilibrium. The baseline characteristics and allele frequencies 
of IRF5 rs2004640 and rs4728142 are shown in table 1. 
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Table 1. Baseline characteristics
cIMT cohort (n=101) CARRE cohort (n=353) P
Demographics
Age, years 62 ± 7 63 ± 8 0.62
Female, no. (%) 61 (60.4) 232 (65.7) 0.32
Caucasian, no. (%) 97 (96) 332 (94.1) 0.69
RA characteristics
RA duration, years 8 (5 – 11) 7 (4 – 10) 0.71
DAS28 3.5 ± 1.2 3.9 ± 1.4 0.31
ESR, mm/hr 12 (8 – 27) 18 (9 – 31) 0.03
CRP, mg/l 6 (3 – 15) 7 (3 – 18) 0.22
IgM-RF positive,no. (%) 72 (71.3) 256 (72.5) 0.81
ACPA positive, no (%) 58 (57.4) 187 (53) 0.56
Erosive disease, no. (%) 82 (81.2) 288 (81.6) 0.99
Medication use, no (%)
Antihypertensive 25 (24.8) 94(26.6) 0.69
Statin 11 (10.9) 40 (11.3) 0.90
Salicylic acid 18 (17.8) 56 (15.9) 0.64
Prednisone 13 (12.9) 58 (16.4) 0.49
cDMARDs 88 (87.1) 303 (85.8) 0.74
bDMARDs 11 (10.9) 34 (9.6) 0.71
CV parameters
TC, mmol/L 5.7 ± 1.0 5.8 ± 1.1 0.55
HDLc, mmol/L 1.5 ± 0.5 1.5 ± 0.5 0.53
LDLc, mmol/L 3.6 ± 1.1 3.7 ± 1.0 0.54
TG, mmol/L 1.3 (1.0 – 1.7) 1.5 (1 – 1.8) 0.58
BMI, kg/m2 26 ± 4 27 ± 5 0.28
Pack years 21 (3 – 39) 19 (2 – 36) <0.01
Systolic BP, mmHg 142 ± 18 142 ± 20 0.96
Diastolic BP, mmHg 82 ± 7 81 ± 9 0.28
Diabetes, no. (%) 4 (4) 17 (4.8) 0.71
IMT, mm 0.812 ± 0.131 - n.a.
Previous CVD, no. (%) 15 (14.9) 51 (14.4) 0.91
IRF5 minor allele frequencies
Rs2004640 (G) 0.451                                   0.483 n.a.
Rs4728142 (A) 0.415 0.418                                                     n.a.
DAS28= disease activity score in 28 joints, cIMT= carotid intima media thickness, ESR= 
erythrocyte sedimentation rate, CRP= C-reactive protein, IgM-RF= IgM- rheumatoid factor, 
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ACPA= anti-citrullinated protein antibody, cDMARDs= conventional disease modifying 
antirheumatic drugs, bDMARDs= biologic disease modifying antirheumatic drugs, TC= total 
cholesterol, HDLc= high-density lipoprotein cholesterol, LDLc= low-density lipoprotein 
cholesterol, TG= triglycerides, BMI= body mass index, BP= blood pressure, CVD= cardiovascular 
disease, n.a.= not applicable
Association of the rs2004640 genotype with RA- and CVD-related factors, 
cIMT and new CV events
First, we analysed whether rs2004640 was associated with CV risk factors. No 
significant associations with HDLc, LDLc, SBP, DBP, TC, HDLc, LDLc, TG, BMI, 
smoking or prevalent CV disease were observed (data not shown). Secondly, 
we tested whether IRF5 gene variants were associated with RA-related clinical 
parameters (i.e. RA duration, DAS28, CRP, presence of erosions, presence of RF and/
or ACPA). A higher percentage of patients homozygous for the rs2004640 G-allele 
were positive for RF compared to patients with a GT- or TT-genotype (respectively 
82%, 67% and 70%, p=0.048). No significant associations were observed between 
IRF5 genotypes, and other RA-related characteristics (data not shown). For 
rs2004640, the highest cIMT values at baseline were observed in patients with the 
GG-genotype, followed by the GT- and TT- genotypes (0.874 ± 0.142, 0.806 ± 0.125, 
0.785 ± 0.126). The difference in cIMT between patients carrying the GG- vs. TT-
genotype was significant (p=0.03, figure 1). 
Patients with the TT-genotype were more likely to experience an increase in 
cIMT (median yearly progression in millimeters 0.02 (0.02 – 0.05)) over time when 
compared to the GG-genotype (median yearly progression 0.003 (-0.03 – 0.07) and 
respectively OR 2.84, 95%CI 1.07 – 7.50, p=0.035 and OR 0.26, 95%CI 0.08 – 0.75, p= 
0.013). This was also significant after correction for CV risk factors (age, sex, SBP, 
TC/HDLc-ratio, current smoking and aspirin use) with TT-genotype OR 3.03, 95%CI 
1.06 – 8.65, p=0.038 and GG-genotype OR 0.22, 95%CI 0.07 – 0.69, p=0.01. 
99 of the 353 patients developed a new CV event over a median follow up duration 
of 9 (5 – 11) years. In the crude cox regression analyses rs2004640 genotypes were 
not associated with new CV events (reference GG-genotype, GT-genotype p=0.59 
and TT-genotype p=0.76).
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Association of the rs4728142 genotype with RA- and CVD-related factors, 
cIMT and new CV events
For rs4728142 there were no significant associations with CV risk factors HDLc, 
LDLc, SBP, DBP, TC, HDLc, LDLc, TG, BMI, smoking or prevalent CV disease were 
observed (data not shown). There were no associations between RA-related risk 
factors and rs4728142 (data not shown). No significant differences  were observed 
between cIMT values for the genotypes of rs4728142 (AA 0.775 ± 0.137, AG 0.805 
± 0.129, GG 0.843 ± 0.131, p=0.22, figure 1). For rs4728142, in patients with the GG-
genotype there was a trend for less increase of cIMT (median yearly progression 
0.01 (-0.002 – 0.05) vs. 0.003 (-0.02 – 0.06)) over time (OR 0.43, 95%CI 0.18 – 1.02, 
p=0.057). After correction for traditional risk factors (as described above) there was 
a significant lower increase in cIMT for the GG-genotype with an OR of 0.34, 85%CI 
0.14 – 0.88, p=0.025. For the other genotypes there was no significant increase or 
decrease in cIMT (AA OR 2.02, 95%CI 0.59 – 6.96, p= 0.26, AG OR 1.51, 95%CI 0.68 – 
3.37, p=0.31; after adjustment CV risk factors respectively ORs of 2.85, 95%CI 0.72 
– 11.2, p=0.13 and 1.66, 95%CI 0.69 – 3.99, p= 0.25). The rs4728142 genotypes were 
not associated with the development of new CV events over time in the crude Cox 
regression analyses (reference AA-genotype, AG-genotype p= 0.51, GG-genotype 
p= 0.90).






















In our current study, both IRF5 rs2004640 and rs4728142 GG-genotypes were 
associated with cIMT and patients with the GG-genotype had the highest cIMT 
values at baseline, but the greatest increase in cIMT over time was seen in the 
TT- and AA-genotypes. However, these genotypes were not associated with the 
development of new CV events during follow up. One of the explanations for this 
observation could be the sample size of our study population, which could be too 
small to detect an effect of these SNPs on CVD risk. Another explanation could be 
that IRF5 SNPs might not influence CVD risk directly or that their effect on CVD 
risk is very small. For rs2004640, a previous study described fewer CV events in 
patients with the GG-genotype. (30) In line with this, Malarstig et al. identified IRF5 
mRNA expression in human carotid plaques, including the expression of SNPs 
rs2004640 and rs4728142, but they were not associated with a risk of (unstable) 
coronary artery disease or recurrent CV events in patients who had presented 
with unstable coronary artery disease. (15) In our study, we have also identified an 
association between IRF5 SNPs and surrogate markers of atherosclerotic disease 
(i.e. cIMT), but not with new CVD over a median follow up period of 9 years. This 
is an interesting finding, as IRF5 gene variants are detectible in atherosclerotic 
plaques and may have different effects on the atherosclerotic process, but they do 
not seem to be associated with an increased event risk. IRF5 is a master regulator 
of type I IFN activity and functions as a transcription factor when phosphorylated, 
leading to expression of downstream interferon response genes, including the 
production of type I IFN itself and cytokines such as interleukin-6 (IL-6), tumor 
necrosis factor (TNF), interleukin-12 (IL-12) and interleukin-23 (IL-23). The splicing 
of IRF5 is highly complex and multiple IRF5 isoforms are initiated at each promoter. 
Different isoforms can contain either exon 1a, 1b or 1c, depending on the promoter 
where transcription is initiated. Furthermore, it is known that the IRF5 isoforms 
differ in their ability to transactivate type I IFN genes, i.e. IFNα or IFNβ. (31) IFNβ 
and IFNα, have been described to have both anti- and proatherosclerotic effects 
in several in vitro studies. (21, 22, 32) The rs2004640 IFR5 SNP is located 2bp near 
the intron-exon boundary for exon 1b and creates an exon donor splice site, which 
enables transcription of exon 1b. Specifically the T-allele enables transcription of 
exon 1b, which is associated with higher mRNA levels of IRF5. (7) Thus, the IRF5 
rs2004640 T-allele is likely to enhance the expression of IRF5 and successively 
type I IFNs. In our study, we found a greater increase in cIMT in patient with the TT-
allele, but this was not associated with new CV events during follow up. rs4728142 
is located on the promotor region of IRF5, and has previously been associated with 
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autoimmune disease such as SLE and MS. (7, 14) The exact function of IFNs in the 
development of CVD remains to be elucidated.
Some limitations need to be considered. Our study had a small sample size which 
could have influenced our results as mentioned above, specifically the power to 
detect significant differences between the different IRF5 SNP genotypes. This 
could be one of the reasons for finding an association between cIMT and both IRF5 
SNPs, but not with future CVD.
To our knowledge, this is the first study reporting an association between IRF5 
alleles and cIMT, but not with new CV events in a cohort of RA patients followed for 
a longer period of time. Although, these findings seem to implicate a role of IRF5 
genetics in the development of atherosclerosis, IRF5 gene variants do not appear 
to increase the risk of future CVD events. 
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GENERAL DISCUSSION AND SUMMARY
Scope of this thesis
In this thesis the cardiovascular disease (CVD) risk in inflammatory joint diseases 
(IJD) was investigated, focusing on rheumatoid arthritis (RA) and psoriatic arthritis 
(PsA). We aimed to create awareness of this high CVD risk by investigating the 
magnitude of CVD prevalence in IJD patients over the last decades, also considering 
new treatment modalities such as biological disease modifying antirheumatic 
drugs (bDMARD) and imaging techniques such as 18-fluorodeoxyglucose positron 
emission tomography combined with computed tomography (18F-FDG-PET/
CT). In addition, traditional and novel risk factors for CVD and the effects of anti-
inflammatory therapy on these risk factors were assessed. Lastly, we revised new 
EULAR recommendations for CVD risk management in IJD and proposed ideas for 
future research.
Main findings
An overview of the magnitude of CVD risk in IJD and the factors contributing to this 
risk is provided in chapter 2. Standardized mortality ratios (SMR) are increased in IJD 
compared with the general population, i.e. for RA 1.3 – 2.3, for ankylosing spondylitis 
(AS) 1.6 – 1.9, and for PsA 0.8 – 1.6, and are mainly attributable to atherosclerotic 
events. Traditional CVD risk factors are more prevalent in these patients, which 
is in part a consequence of changes in physical function related to the underlying 
IJD, but also due to inflammation and anti-inflammatory therapy (e.g. lipids). More 
importantly, chronic systemic inflammation itself is an independent CVD risk 
factor. Optimal control of disease activity with conventional, targeted synthetic 
and biological disease-modifying antirheumatic drugs (csDRMARD, tsDMARD and 
bDMARD) decreases this excess risk. Apart from this, subclinical hypothyroidism 
could further enhance CVD risk in RA (chapter 3). The exact mechanism behind 
this phenomenon is not yet elucidated and whether thyroid hormone suppletion 
in these patients decreases CVD risk needs to be further investigated. In chapter 
4, we found that distinct lipoprotein profiles exist in RA patients, due to the 
presence of single nucleotide polymorphisms (SNP) in the IL-32 promotor region 
(i.e. SNP rs4786370). These diversities in lipoproteins could influence CVD risk 
in RA patients. In patients with PsA, we demonstrated that long term therapy 
with etanercept effectively decreases disease activity, but also influences lipid 
levels and lipoproteins (chapter 5). In general lipid levels slightly increased over 
time during treatment with etanercept, but apolipoprotein B/apolipoprotein A1 
(apo B/apo A1) ratio decreased, which could be a reflection of a lower CVD risk. 
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Interestingly, a higher disease activity was associated with a higher high-density 
lipoprotein cholesterol (HDLc) and apo B/apo A1 ratio, which might seem surprising 
as HDLc is considered cardioprotective. However, the relationship between lipids 
and CVD risk is not linear in IJD. Inflammation can adversely influence the protein 
composition of lipoproteins and the reverse cholesterol transport capacity of 
HDLc. Therefore, a raise in HDLc does not necessarily translate into a favorable 
lipid and CVD risk profile in patients with high disease activity. The composition 
and reverse cholesterol transport ability of HDLc rather than its level determine 
its function. Thus, an increase in lipids during anti-inflammatory therapy should 
be considered as a normalization of lipid levels and a reflection of effective anti-
inflammatory therapy, without increasing CVD risk. 
In chapter 6, we demonstrated that CVD risk in RA has not decreased in the last 
decades. RA patients from the CARRE cohort developed more CVD events during a 
median follow up duration of 11 years when compared with type 2 diabetes patients 
and the general population from the Hoorn Study. Furthermore, RA patients with 
diabetes or insulin resistance had the highest hazard rate (HR) for developing new 
CVD, followed by patients with RA but without diabetes and patients with only 
diabetes type 2. This increased hazard was independent of traditional CVD risk 
factors for RA patients, underscoring the importance of lowering disease activity 
in these patients. Clinicians and patients should be aware of this higher CVD risk in 
IJD compared with the general population and act accordingly. In light of this, we 
devised new EULAR recommendations for CVD risk management in IJD in chapter 
7. 
We investigated novel factors and imaging modalities associated with CVD risk in RA 
in chapters 8, 9, 10, 11 and 12. In chapter 8, we investigated the role of noncanonical 
NF-κB pathway in neovascularization of plaques as a measure of plaque instability. 
The noncanonical NF-κB pathway has a role in the activation of epithelial cells 
(EC) and pathological angiogenesis, through NF-κB inducing kinase (NIK) and 
CXCL12 expression, in the context of chronic inflammation and cancer, but this 
is not observed in healthy tissues. In our study, NIK+EC were present in lesions of 
coronary and carotid arteries in patients with chronic inflammatory diseases (CID). 
In plaques with greater than 40% stenosis NIK+ vessel density was increased in 
patients with CID, with a higher content of immune cells compared to controls. This 
was observed for all lesions, but was more pronounced as the stenosis increased 
and in atheromatous (unstable and/or ruptured) plaques. NIK+EC was associated 
with an unstable plaque profile, underscoring the important role of inflammation 
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in the development of CVD in patients with inflammatory diseases. Targeting 
noncanonical NF-κB signaling in EC may hold therapeutic potential for patients and 
should thus be further investigated. 
As inflammation is an important feature of IJD and independently associated 
with CVD risk, we performed 18F-FDG-PET/CT scans as a measure of arterial wall 
inflammation in patients with RA and compared them with osteoarthritis patients 
and healthy controls in chapter 9. Arterial wall inflammation was highest in early 
RA patients, wo were still DMARD naive, followed by established RA patients who 
were treated with csDMARDs. Osteoarthritis patients and healthy controls had the 
lowest FDG uptake in the arterial wall. This observation persisted after adjustment 
for traditional CVD risk factors. A higher level of clinical disease activity and 
circulating inflammatory markers was associated with higher arterial FDG uptake, 
which may support a role of arterial wall inflammation in the pathogenesis of 
vascular complications in RA. Furthermore, in the era of personalized medicine 
and tapering of bDMARDs in patients with remission or low disease activity, 
18F-FDG-PET/CT could be a valuable tool in assessing whether tapering would be 
potentially harmful in patients with high arterial inflammation. In chapter 10, we 
demonstrated that arterial wall inflammation is reduced in RA patients after anti-
inflammatory therapy, possibly translating into a decreased CVD risk. In chapter 
11, we investigated the interferon regulatory factor 5 (IRF5) gene polymorphisms 
rs2004640 and rs4728142 and their association with new CVD events. Interferons 
(IFNs) are a group of cytokines that can both inhibit and promote vascular smooth 
muscle cell proliferation, depending on the type of IFN pathway that is activated. 
Genome wide association studies (GWAS) on components of the IFN signaling 
cascade revealed an association between IRF5 and autoimmune diseases such as 
systemic lupus erythematosus (SLE), RA and multiple sclerosis (MS), but also with 
atherosclerosis. In our study, the IRF5 SNPs were associated with carotid intima 
media thickness (cIMT), but not with the development of new CV events during a 
median follow up of 9 years. Altogether, the IRF5 transcription pathway may have a 
role in atherosclerosis, but it did not increase the risk for future CVD. 
Implications for daily clinical practice
CVD risk is high in IJD, accounting for the majority of deaths in these patients. There 
is accumulating literature supporting both the role of traditional CVD risk factors 
as well as the independent role of inflammation in the development of CVD in IJD. In 
this thesis, we underscored the crucial part that inflammation plays in accelerating 
atherosclerosis by influencing plaque morphology (i.e. unstable and rupture prone) 
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in patients with chronic inflammatory diseases. Furthermore, RA patients with the 
highest disease activity had the highest arterial wall inflammation visualized by 
18F-FDG-PET/CT as a presumable early marker of cardiovascular complications. 
More importantly, we found that the hazard for developing CVD in RA was still high 
in the past decade and even higher than in type 2 diabetes patients, despite new 
treatment strategies. 
Altogether, we still fail to prevent excessive CVD morbidity and mortality in IJD. 
It is important for clinicians and patients to be aware of this high CVD risk. CVD 
prevention programs should be developed focusing on life style education 
emphasizing the importance of smoking cessation, diet recommendations and 
exercise specifically designed for IJD patients. In addition, CVD assessment 
should be performed according to national guidelines and risk factors such as 
hypertension and hyperlipidemia should be treated accordingly. Furthermore, 
clinicians should assess the presence of thyroid disease in these patients and if 
necessary, treatment should be started according to existing guidelines. Apart 
from this, and taking into account the current EULAR recommendations for CVD 
risk management in IJD, the underlying disease should be treated optimally and 
swiftly. Previous studies have shown deleterious effects of cumulative disease 
activity burden and disease flares on CVD risk in RA.
 
Limitations and future research
Several limitations need to be considered when reading this thesis. All research 
questions have been investigated in prospective cohort studies with patients 
recruited from outpatient clinics and hospitals in the Netherlands and may not be 
generalizable to other countries and populations. In addition, some studies had a 
small sample size making the results less conclusive. This is why we have described 
some of the study results as explorative. Those findings should be confirmed in 
studies with a larger sample size. Furthermore, it would have been of additional 
value to investigate CVD risk factors and risk profile in IJD patients with a different 
ethnicity and in males vs. females. However, this was not possible in with our 
patient cohorts due to lack of power. Also, studies investigating the effects of an 
intervention, such as thyroxine replacement therapy or DMARD therapy, on RA flares, 
patient well-being, CVD risk and risk factors would have implications for clinical 
practice and are relevant. Although the role of inflammation in the development of 
CVD is evident, the exact pathways and mechanisms underlying this phenomenon 
are not clear. Research should focus on areas such as gene expression profiles, 
SNPs, new biomarkers as well as the possibility of targeting these pathways 
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with existing and/or new medications. Identifying IJD-specific biomarkers could 
aid in improving CVD risk stratification in these patients. Currently, there are no 
IJD-specific CVD risk prediction models available with a superior predictive value 
above existing general population algorithms. It is unclear whether IJD tailored 
CVD risk algorithms would perform better than IJD adjusted general population 
algorithms. Another interesting area is that of lipidomics. Inflammation influences 
lipid subfractions and routine tests are not reliably during periods of high disease 
activity. There are some reports that apolipoprotein measurements could be 
more accurate in predicting CVD. However, their clinical value above existing lipid 
measurements is not well studied. Moreover, these markers are not part of routine 
practice and expensive. In the era of personalized medicine and tapering of DMARD 
therapy, imaging studies could improve the selection of patients that would be 
more likely to experience adverse effects, mainly of cardiovascular origin. Finally, 
it is less well studied whether currently applied CVD risk management programs 
are cost-effective in IJD and in some areas, such as physical activity, there is a lack 
of programs suitable for IJD patients.
Conclusion
Atherosclerosis is an inflammatory process, which is further enhanced by the 
chronic inflammation inherent to IJD. This has implications for health care 
professionals, especially rheumatologists and cardiologists, but IJD patients 
should also be aware of their increased CVD risk and take timely precautions. 
Acknowledging this high risk is an important step preceding the implementation of 
strategies for prediction, prevention and management of CVD in IJD. There lies an 
evidence gap which needs to be filled in the future and general practice guidelines 
need to be developed to reduce CVD risk in these patients. 
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NEDERLANDSE SAMENVATTING
Patiënten met chronische systemische inflammatoire gewrichtsaandoeningen, 
zoals reumatoïde artritis (RA) en spondylartropathieën (SpA, o.a. de ziekte 
van Bechterew ofwel ankyloserende spondylitis (AS) en artritis psoriatica), 
hebben een verhoogd risico op het ontwikkelen van hart- en vaatziekten. In dit 
proefschrift is onderzoek gedaan naar de omvang van het cardiovasculair risico 
bij de bovengenoemde patiëntengroepen. Tevens is onderzoek gedaan naar 
nieuwe modaliteiten voor het in beeld brengen van vaatwandontsteking met 
een 18-fluorodeoxyglucose positron emissie tomografie/computed tomografie 
(18F-FDG-PET/CT) scan en is het effect van ontstekingsremmende medicijnen op 
de vaatwandinflammatie onderzocht. Hiernaast zijn traditionale risicofactoren en 
nieuwe biomarkers voor hart- en vaatziekten en het effect van anti-inflammatoire 
therapie op deze factoren onderzocht. Tenslotte zijn nieuwe EULAR-aanbevelingen 
voor cardiovasculair risicomanagement geformuleerd voor patiënten met 
inflammatoire gewrichtsaandoeningen. 
Bevindingen
In hoofdstuk 2 wordt een overzicht gegeven van de omvang van het cardiovasculair 
risico en de factoren die bijdragen aan dit risico bij patiënten met een inflammatoire 
gewrichtsaandoeningen. De verhoogde kans op sterfte in patiënten met RA 
en SpA is voornamelijk toe te schrijven aan hart- en vaatziekten. Traditionele 
risicofactoren voor hart- en vaatziekten zijn vaker aanwezig bij patiënten met een 
chronische inflammatoire gewrichtsaandoening, deels door veranderingen in het 
fysiek functioneren als gevolg van de onderliggende ziekte, maar ook door de 
beïnvloeding van deze factoren door inflammatie en anti-inflammatoire therapie. 
Ook blijkt chronische systemische inflammatie zèlf een onafhankelijke risicofactor 
voor hart- en vaatziekten te zijn. Optimale verlaging van ziekteactiviteit met 
ontstekingsremmende medicijnen, zoals conventionele, targeted synthetic en 
biological disease-modifying antirheumatic drugs (csDMARD, tsDMARD, bDMARD), 
verlaagt dit risico. Tevens lijkt subklinische hypothyreoïdie geassocieerd te zijn met 
een verdere toename van het cardiovasculair risico in patiënten met reumatoïde 
artritis (hoofdstuk 3). Het exacte mechanisme achter dit fenomeen is nog niet 
opgehelderd. Of het medicamenteus suppleren van schildklierhormoon bij deze 
patiënten het cardiovasculair risico verlaagt moet nog verder worden onderzocht. 
In hoofdstuk 4 beschrijven wij de aanwezigheid van verschillende lipoproteïne 
profielen bij RA-patiënten als gevolg van de aanwezigheid van polymorfismen in de 
IL-32 promotor regio, ook wel bekend als ‘single nucleotide polymorphisms (SNP)’. 
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Deze verschillen in lipoproteïnen kunnen het cardiovasculair risico bij RA-patiënten 
(in gunstige of ongunstige zin) beïnvloeden. In hoofdstuk 5 wordt bij patiënten met 
PsA, die langdurig behandeld worden met het ontstekingsremmende medicijn 
‘etanercept’, naast een effectieve verlaging van ziekteactiviteit een gunstig effect 
op lipiden en lipoproteïnen gevonden. Hoewel er een milde stijging van lipiden werd 
gevonden, daalde de apolipoproteine B/apolipoproteine A1 (apo B/apo A1) ratio, wat 
mogelijk een reflectie is van een lager cardiovasculair risico. Ook was een hogere 
ziekteactiviteit geassocieerd met een hoger HDL-cholesterol (HDLc), terwijl het 
cardiovasculair risico wel verhoogd was. Dit lijkt verassend, omdat HDLc bekend 
staat als beschermend tegen hart- en vaatziekten, echter de relatie tussen lipiden 
en het risico op hart-en vaatziekten is niet lineair voor patiënten met chronische 
inflammatoire gewrichtsziekten. Inflammatie kan een negatieve invloed hebben 
op de compositie en functie van lipiden en lipoproteïnen. Hierdoor betekent 
een stijging in HDLc niet altijd een gunstiger cardiovasculair risicoprofiel voor 
patiënten met een hoge ziekteactiviteit. Dit vonden wij ook in onze studie, waarin 
deze patiënten een hoog apo B/apo A1 ratio hadden als reflectie van een hoger 
cardiovasculair risico. De compositie van het HDLc molecuul en het vermogen om 
het teveel aan cholesterol vanuit weefsels terug te transporteren naar de lever, 
en niet de hoogte van de HDLc waarde gemeten in het bloed, is bepalend voor 
het effect die HDLc heeft op het cardiovasculair risico. Een stijging van lipiden 
gedurende anti-inflammatoire therapie (na het bereiken van lage ziekteactiviteit) 
dient te worden beschouwd als een normalisate van lipiden en een reflectie van 
effectieve anti-inflammatoire therapie, zonder dat het cardiovasculair risico 
hierdoor toeneemt.
In hoofdstuk 6 hebben we aangetoond dat het cardiovasculair risico in RA-
patiënten niet is gedaald de afgelopen decennia. RA-patiënten van het CARRE-
cohort ontwikkelden vaker hart- en vaatziekten gedurende een mediane follow up 
duur van 11 jaar in vergelijking met patiënten met diabetes type 2 en de algemene 
bevolking. Tevens hadden RA-patiënten met diabetes of insuline resistentie het 
hoogste risico om hart- en vaatziekten te ontwikkelen, gevolgd door patiënten met 
RA zonder diabetes en patiënten met alleen diabetes type 2. Dit verhoogde risico 
was onafhankelijk van traditionele risicofactoren voor hart- en vaatziekten en 
benadrukt het belang van het verlagen van ziekteactiviteit in deze patiëntengroep. 
Clinici en patiënten dienen zich bewust te zijn van dit hoge cardiovasculaire 
risico bij patiënten met inflammatoire gewrichtsziekten in vergelijking tot de 
algemene bevolking. Om deze reden hebben we nieuwe EULAR-aanbevelingen 
voor cardiovasculair risicomanagement in inflammatoire gewrichtsziekten 
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geformuleerd in hoofdstuk 7. 
Hiernaast hebben we onderzoek gedaan naar nieuwe factoren en beeldvormende 
technieken geassocieerd met hart- en vaatziekten in RA in hoofdstukken 8,9, 10 en 
11. 
In hoofdstuk 8 hebben we onderzocht wat de rol van noncanonical NF-κB is 
bij de neovascularisatie van atherosclerotische plaques als maat voor plaque 
instabiliteit. Noncanonical NF-κB speelt een rol bij activatie van epitheliale 
cellen en pathologische angiogenese bij chronische inflammatie en kanker door 
expressie van NF-κB inducing kinase (NIK) and CXCL12. Deze NIK-expressie wordt 
in de literatuur niet geobserveerd in gezonde weefsels. In onze studie waren NIK 
positieve epitheliale cellen aanwezig in atherosclerotische plaques afkomstig 
uit de krans- en halsslagaders van patiënten met chronische inflammatoire 
aandoeningen. In de plaques met meer dan 40% vernauwing waren meer NIK 
positieve vaten aanwezig, met ook een hoger aantal aanwezige immuuncellen 
in vergelijking met controles. Dit was het meest uitgesproken in de ernstiger 
vernauwde instabiele of geruptureerde plaques, met andere woorden, NIK positieve 
epitheliale cellen waren geassocieerd met een instabiel plaque profiel en dus een 
verhoogd cardiovasculair risico. Deze resultaten bevestigen dat inflammatie een 
additioneel cardiovasculair risico verhogend effect heeft bij patiënten met een 
chronische inflammatoire aandoening. Therapie gericht op noncanonical NF-κB 
zou een potentiele nieuwe behandelstrategie kunnen zijn voor deze patiënten, maar 
dient eerst verder te worden onderzocht. Gezien de belangrijke rol van inflammatie 
bij de ontwikkeling van hart- en vaatziekten bij patiënten met inflammatoire 
gewrichtsziekten hebben we onderzocht of we met een 18F-FDG-PET/CT scan de 
hoeveelheid ontsteking in de slagaders van patiënten met RA kunnen meten. De 
bij RA gemeten vaatwandontsteking hebben we vergeleken met patiënten met 
artrose en met gezonde controles. Deze resultaten beschrijven we in hoofdstuk 9. 
Patiënten met vroege RA, dus een net gediagnosticeerde RA die nog niet behandeld 
is met ontstekingsremmende medicijnen, ofwel DMARDs, hadden de hoogste 
inflammatie in de slagaders, gevolgd door patiënten met gevorderde RA (behandeld 
met csDMARDs). Bij de artrose patiënten en gezonde controles was de gemeten 
FDG opname in de slagaderen, als maat voor ontsteking, het laagst. Een hogere 
ziekteactiviteit en circulerende inflammatoire markers waren geassocieerd met 
hogere arteriële FDG opname, hoogstwaarschijnlijk wijzend op een belangrijke rol 
van inflammatie in de pathogenese van vasculaire complicaties in RA. In hoofdstuk 
10 beschrijven we dat de ontsteking in de slagaderwand van patiënten met RA lager 
wordt na behandeling met ontstekingsremmende medicijnen, mogelijk wijzend op 
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een verlaging van het cardiovasculair risico. Tegenwoordig worden DMARDs (met 
name biologicals) waar mogelijk afgebouwd en gestaakt bij patiënten met een 
lage ziekteactiviteit of remissie van ziekte. De 18F-FDG-PET/CT zou een waardevol 
hulpmiddel kunnen zijn voor het identificeren van patiënten waarbij dit op 
cardiovasculair gebied potentieel schadelijk zou kunnen zijn vanwege persisterend 
verhoogde arteriële inflammatie ondanks behandeling. In hoofdstuk 11 hebben we 
onderzoek gedaan naar de interferon regulatory factor 5 (IRF5) gen polymorfismen 
rs2004640 en rs4728142 en onderzocht of deze polymorfismen geassocieerd 
zijn met het optreden van hart- en vaatziekten. Genoom brede associatie studies 
(GWAS) van de componenten van de IFN signaling cascade hebben laten zien dat 
er een associatie bestaat tussen IRF5 en autoimmuunziekten zoals systemische 
lupus erythematodes (SLE), RA en multipel sclerose (MS). Interferonen (IFNs) 
zijn een groep cytokinen die de proliferatie van vasculair gladspierweefsel zowel 
kunnen remmen als simuleren afhankelijk van het type IFN die is geactiveerd. Met 
name IFN beta is bekend om antiproliferatieve en dus beschermende effecten, die 
mogelijk ook bescherming bieden tegen het optreden van hart- en vaatziekten. 
In onze studie was het TT-genotype van rs2004640 geassocieerd met een 
lager cardiovasculair risico in RA na correctie voor confounders. Dit werd niet 
geobserveerd voor rs4728142. 
Implicaties voor de dagelijkse klinische praktijk
Patiënten met een chronische inflammatoire gewrichtsaandoening hebben een 
verhoogd risico op het ontwikkelen van hart- en vaatziekten, met als uitkomst 
een verhoogd sterfterisico. Steeds vaker wordt in de wetenschappelijke literatuur 
de belangrijke rol van zowel de aanwezigheid van traditionele risicofactoren voor 
hart- en vaatziekten alsook langdurige blootstelling aan systemische ontsteking 
hierbij beschreven. In dit proefschrift bevestigen wij de essentiële rol van 
inflammatie in het versnellen van aderverkalking bij patiënten met inflammatoire 
gewrichtsziekten. Inflammatie beïnvloedt plaque morfologie en veroorzaakt een 
instabiele plaque profiel, met een ongunstiger cardiovasculair risicoprofiel. Dit zien 
we ook terug op 18F-FDG-PET/CT-scans, waarop slagaderen van RA-patiënten met 
de hoogste ziekteactiviteit ook de hoogste inflammatie vertonen. Aangenomen 
wordt dat dit een vroege marker van toekomstige cardiovasculaire complicaties 
kan zijn. Even belangrijk is dat het verhoogd risico op hart- en vaatziekten in deze 
patiëntengroep onveranderd is gebleven in de afgelopen decennia, waarbij dit risico 
zelf hoger is dan bij patiënten met diabetes type 2. Er is nog veel winst te behalen 
in het voorkomen van overmatige cardiovasculaire comorbiditeit en sterfte in deze 
patiëntenpopulatie. 
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Belangrijk is dat clinici en patiënten zich bewust zijn van dit verhoogd 
cardiovasculair risico. Preventieprogramma’s met een focus op leefstijleducatie, 
nadruk op stoppen met roken en sportieve activiteiten ontwikkeld voor patiënten 
met een inflammatoire gewrichtsaandoening zijn essentieel. Hiernaast wordt 
cardiovasculair risicomanagement volgens huidige richtlijnen aanbevolen, waarbij 
adequate behandeling van risicofactoren zoals hypertensie en hyperlipidemie 
cruciaal is. Ook is het aanbevolen om de aanwezigheid van schildklieraandoeningen 
te onderzoeken, en te behandelen volgens bestaande protocollen waar noodzakelijk. 
De huidige EULAR-aanbevelingen voor cardiovasculair risicomanagement in acht 
nemend is het optimaal en snel behandelen van de onderliggende ziekte van 
fundamenteel belang ter preventie van hart- en vaatziekten. Voorgaande studies 
hebben aangetoond dat zowel een hoge cumulatieve ziektelast als opvlamming van 
ziekte ongunstige effecten hebben op het cardiovasculair risico. 
Limitaties en toekomstperspectieven
Bij het lezen van dit proefschrift dient rekening te worden gehouden met een 
aantal (mogelijke) beperkingen van de bovengenoemde studies. Een groot 
gedeelte van de studies betreft prospectief cohortonderzoek met patiënten 
gerekruteerd uit Nederlandse ziekenhuizen en klinieken. Deze resultaten kunnen 
mogelijk niet geëxtrapoleerd worden naar andere landen en populaties. Verder 
hadden enkele studies een klein aantal deelnemers, waardoor de bevindingen 
mogelijk minder overtuigend zijn. Deze resultaten zijn om die reden als exploratief 
en hypothesevormend beschouwd en dienen opnieuw te worden onderzocht en 
bevestigd in studies met een groter aantal deelnemers. In de bovenbeschreven 
studies hadden we graag de genderverschillen in cardiovasculaire risicofactoren en 
risicoprofiel bij patiënten met inflammatoire gewrichtsziekten willen onderzoeken, 
alsook verschillen tussen patiënten met een andere etniciteit. Helaas was dit niet 
mogelijk vanwege een te kleine studiepopulatie en dus te weinig ‘power’ om de 
bovenstaande vragen te kunnen beantwoorden. Ook waren interventiestudies, 
waarin het effect van bijvoorbeeld thyroxine suppletie of therapie met 
ontstekingsremmende medicijnen op het cardiovasculair risico (en risico factoren) 
en kwaliteit van leven wordt onderzocht, van meerwaarde geweest voor de dagelijkse 
klinische praktijk. Hoewel de rol van inflammatie bij de ontwikkeling van hart- en 
vaatziekten evident is, zijn de exacte mechanismen die hieraan ten grondslag liggen 
nog niet voldoende opgehelderd. Toekomstig onderzoek zou zich moeten richten op 
zowel basaal als translationeel onderzoek op het gebied van genexpressieprofielen, 
SNPs en nieuwe biomarkers. Meer kennis over deze ‘pathways’ kan mogelijk leiden 
tot nieuwe behandelstrategieën in de toekomst. Tevens kan het identificeren van 
Chapter 12. General discussion and summary
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inflammatoire gewrichtsziekte-specifieke markers bijdragen aan het verbeteren 
van cardiovasculaire risicopredictiemodellen en een accuratere stratificatie van 
patiënten in de juiste risicogroep bewerkstelligen. Ook is onderzoek op het gebied 
van ‘lipidomics’ mogelijk bijdragend aan de cardiovasculaire risico inschatting 
bij patiënten met een inflammatoire gewrichtsziekte. Uit de literatuur blijkt dat 
inflammatie lipidensubfracties kan beïnvloeden. De gebruikelijke lipiden, zoals 
totaal cholesterol, HDLc en LDLc, die worden gemeten voor het berekenen 
van het cardiovasculair risico, zijn bij een hoge ziekteactiviteit onbetrouwbaar 
gebleken voor het inschatten van het cardiovasculair risico bij patiënten met een 
inflammatoire gewrichtsziekte. Enkele studies suggereren dat apolipoproteïnen 
accurater zijn, echter zijn deze markers geen onderdeel van de routine bepalingen 
en duurder dan de gebruikelijke testen. Tevens is de klinische meerwaarde boven 
de gebruikelijke testen niet goed bestudeerd.
In het tijdperk van ‘personalized medicine’ wordt het afbouwen en stoppen 
van DMARD-therapie bij remissie of lage ziekteactiviteit een onderdeel van de 
dagelijkse klinische praktijk. Beeldvormende technieken zouden een hulpmiddel 
kunnen zijn voor het selecteren van hiervoor geschikte patiënten. Bij patiënten 
met meer inflammatie of resterende arteriële inflammatie, die meer kans hebben 
op het ontwikkelen van cardiovasculaire comorbiditeit, zou het helemaal stoppen 
van een DMARD achterwege gelaten moeten worden indien studies dit bevestigen. 
Als laatste is het onduidelijk of de huidige cardiovasculaire risicomanagement 
programma’s kosteneffectief zijn en is op sommige gebieden zoals sport en 
voeding een gebrek aan onderzoek naar passende programma’s voor patiënten 
met inflammatoire gewrichtsziekten. 
Conclusie
Atherosclerose is een inflammatoir proces dat wordt versterkt door de chronische 
systemische ontsteking inherent aan inflammatoire gewrichtsziekten. Het 
erkennen van het verhoogd cardiovasculair risico in deze patiëntengroep is 
een belangrijke stap, waarna de implementatie van strategieën voor predictie, 
preventie en management van hart- en vaatziekten bij patiënten met inflammatoire 
gewrichtsziekten moet worden geoptimaliseerd. Zowel clinici als patiënten spelen 
een belangrijke rol in deze bewustwording en het tijdig nemen van preventieve 
maatregelen. Verder onderzoek ter opvulling van de huidige ‘knowledge gap’ en 
de ontwikkeling van passende richtlijnen voor de algemene klinische praktijk zijn 
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